

별첨 2

배제문헌

문헌배제사유

1. 동물연구 또는 전임상시험
2. 원저가 아닌 연구(중설, letter, comment 등)
3. 한국어나 영어로 출판되지 않은 문헌
4. 동료심사된 학술지에 게재되지 않은 문헌
5. 사전에 정의한 연구대상자에 대한 연구가 아닌 문헌
6. 사전에 정의된 증재법에 대한 연구가 아닌 문헌
7. 사전에 정의한 연구결과가 하나 이상 보고되지 않은 문헌
8. 2004년 이전에 발표된 문헌
9. 원문 확보가 불가능한 문헌

연번	서지정보	배제 사유
1	Abe Y, Kimura N, Takahashi R, Gotou M, Mizukami K, Uchida H, et al. Relationship between cytokine levels in the cerebrospinal fluid and 11C-Pittsburgh compound B retention in patients with mild cognitive impairment. <i>Geriatrics & gerontology international</i> . 2017;17(11):1907-13.	7
2	Abner EL, Jicha GA, Shaw LM, Trojanowski JQ, Goetzl EJ. Plasma neuronal exosomal levels of Alzheimer's disease biomarkers in normal aging. <i>Annals of Clinical and Translational Neurology</i> . 2016;3(5):399-403.	7
3	Abramowski D, Wiederhold KH, Furrer U, Jatou AL, Neuenschwander A, Runser MJ, et al. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition. <i>Journal of Pharmacology and Experimental Therapeutics</i> . 2008;327(2):411-24.	1
4	Abu-Rumeileh S, Steinacker P, Polisch B, Mammana A, Bartoletti-Stella A, Oeckl P, et al. CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia. <i>Alzheimer's Research and Therapy</i> . 2019;12 (1) (no pagination)(2).	7
5	Abu-Rumeileh, S., S. Capellari, M. Stanzani-Maserati, B. Polisch, P. Martinelli, P. Caroppo, et al. The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias. <i>Alzheimer's Research and Therapy</i> , 2018. 10 (1) (no pagination)(3).	7
6	Abuyaman O, Nexø E. The soluble transcobalamin receptor (sCD320) is present in cerebrospinal fluid and correlates to dementia-related biomarkers tau proteins and amyloid-beta. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> . 2015;75(6):514-8.	7
7	Agah E, Saleh F, Sanjari Moghaddam H, Saghazadeh A, Tafakhori A, Rezaei N. CSF and blood biomarkers in amyotrophic lateral sclerosis: Protocol for a systematic review and meta-analysis. <i>Systematic Reviews</i> . 2018;7 (1) (no pagination)(237).	2

연번	서지정보	배제 사유
8	Ahman HB, Giedraitis V, Cedervall Y, Lennhed B, Berglund L, McKee K, et al. Dual-Task Performance and Neurodegeneration: Correlations Between Timed Up-and-Go Dual-Task Test Outcomes and Alzheimer's Disease Cerebrospinal Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> . 2019;71(s1):S75-S83.	7
9	Aizawa Y, Fukatsu R, Takamaru Y, Tsuzuki K, Chiba H, Kobayashi K, et al. Amino-terminus truncated apolipoprotein E is the major species in amyloid deposits in Alzheimer's disease-affected brains: A possible role for apolipoprotein E in Alzheimer's disease. <i>Brain Research</i> . 1997;768(1-2):208-14.	7
10	Akhtar RS, Mano T. High serum neurofilament light chain predicts a worse fate in early parkinsonism. <i>Neurology</i> . 2019;92(13):595-6.	2
11	Alam J, Blackburn K, Prins N, Scheltens P. Reverse-SD: ongoing phase-2b study of neflamapimod designed in accordance with emerging scientific and regulatory concepts of early Alzheimer's disease (AD). <i>Journal of prevention of alzheimer's disease</i> . 2018;5(1):S50-S1.	4
12	Albertini V, Benussi L, Paterlini A, Glionna M, Prestia A, Bocchio-Chiavetto L, et al. Distinct cerebrospinal fluid amyloid-beta peptide signatures in cognitive decline associated with Alzheimer's disease and schizophrenia. <i>Electrophoresis</i> . 2012;33(24):3738-44.	7
13	Alcolea D, Pegueroles J, Munoz L, Camacho V, Lopez-Mora D, Fernandez-Leon A, et al. Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse. <i>Annals of Clinical and Translational Neurology</i> . 2019;6(9):1815-24.	7
14	Alexopoulos P, Gunther F, Popp J, Jessen F, Peters O, Wolf S, et al. Plasma homocysteine and cerebrospinal fluid neurodegeneration biomarkers in mild cognitive impairment and dementia. <i>Journal of the American Geriatrics Society</i> . 2009;57(4):737-9.	2
15	Alexopoulos P, Guo LH, Tsolakidou A, Kratzer M, Grimmer T, Westerteicher C, et al. Interrelations between CSF soluble AbetaPPbeta, amyloid-beta 1-42, SORL1, and tau levels in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> . 2012;28(3):543-52.	7
16	Alexopoulos P, Sirinian C. Cerebrospinal fluid biomarkers of preclinical Alzheimer's disease. <i>Neuromethods</i> . 2018;137:93-106.	2
17	Alexopoulos P, Thierjung N, Economou P, Werle L, Buhl F, Kagerbauer S, et al. Plasma levels of soluble AbetaPPbeta as a biomarker for Alzheimer's disease with dementia. <i>Journal of Alzheimer's Disease</i> . 2019;69(1):83-90.	7
18	Allali G, Kern I, Laidet M, Armand S, Assal F. Parkinsonism is a Phenotypical Signature of Amyloidopathy in Patients with Gait Disorders. <i>Journal of Alzheimer's Disease</i> . 2018;63(4):1373-81.	5
19	Almdahl IS, Lauridsen C, Selnes P, Kalheim LF, Coello C, Gajdzik B, et al. Cerebrospinal Fluid Levels of Amyloid Beta 1-43 Mirror 1-42 in Relation to Imaging Biomarkers of Alzheimer's Disease. <i>Frontiers in aging neuroscience</i> . 2017;9:9.	7
20	Almeida RP, Schultz SA, Austin BP, Boots EA, Dowling NM, Gleason CE, et al. Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease. <i>JAMA Neurology</i> . 2015;72(6):699-706.	7
21	Aluise CD, Sowell RA, Butterfield DA. Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease. <i>Biochimica et Biophysica Acta - Molecular Basis of Disease</i> . 2008;1782(10):549-58.	2
22	Alvarez I, Aguilar M, Gonzalez JM, Ysamat M, Lorenzo-Bosquet C, Alonso A, et al. Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia. <i>Journal of Alzheimer's Disease</i> . 2018;61(1):135-43.	7
23	Alves G, Bronnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: The Norwegian ParkWest study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> . 2010;81(10):1080-6.	7
24	Alves G, Lange J, Blennow K, Zetterberg H, Andreasson U, Forland MG, et al. CSF Abeta42 predicts early-onset dementia in Parkinson disease. <i>Neurology</i> . 2014;82(20):1784-90.	7
25	Andersson M, Zetterberg H, Minthon L, Blennow K, Londos E. The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia. <i>International Journal of Geriatric Psychiatry</i> . 2011;26(1):100-5.	7

연번	서지정보	배제 사유
26	Andreassen N, Blennow K. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. <i>Clinical Neurology and Neurosurgery</i> . 2005;107(3):165-73.	2
27	Andreasson U, Blennow K, Zetterberg H. Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> . 2016;3:98-102.	2
28	Andreasson U, Vanmechelen E, Shaw LM, Zetterberg H, Vanderstichele H. Analytical aspects of molecular Alzheimers disease biomarkers. <i>Biomarkers in Medicine</i> . 2012;6(4):377-89.	2
29	Antonell A, Fortea J, Rami L, Bosch B, Balasa M, Sanchez-Valle R, et al. Different profiles of Alzheimer's disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints. <i>Journal of Neural Transmission</i> . 2011;118(2):259-62.	7
30	Antonell A, Mansilla A, Rami L, Llado A, Iranzo A, Olives J, et al. Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> . 2014;42(3):901-8.	7
31	Aquilani R, Costa A, Maestri R, Ramusino MC, Pierobon A, Dossena M, et al. Mini nutritional assessment may identify a dual pattern of perturbed plasma amino acids in patients with alzheimer's disease: A window to metabolic and physical rehabilitation? <i>Nutrients</i> . 2020;12(6):1-18.	6
32	Araki W, Araki YM, Mizusawa H. Potential value of soluble APP- α and APP- β in CSF as biomarkers of dementia disorders: Unresolved issues and perspectives. <i>Neurology and Clinical Neuroscience</i> . 2018;6(4):89-93.	2
33	Arenaza-Urquijo EM, Molinuevo JL, Sala-Llloch R, Sole-Padullés C, Balasa M, Bosch B, et al. Cognitive reserve proxies relate to gray matter loss in cognitively healthy elderly with abnormal cerebrospinal fluid amyloid-beta levels. <i>Journal of Alzheimer's Disease</i> . 2013;35(4):715-26.	7
34	Artuso V, Benussi L, Ghidoni R, Bachiller SM, Fusco F, Curtolo S, et al. Asymptomatic carriers of presenilin-1 E318G variant show no cerebrospinal fluid biochemical signs suggestive of alzheimer's disease in a family with late-onset dementia. <i>Current Alzheimer Research</i> . 2019;16(1):1-7.	7
35	Ashton NJ, Hye A, Rajkumar AP, Leuz A, Snowden S, Suarez-Calvet M, et al. An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. <i>Nature Reviews Neurology</i> . 2020;16(5):265-84.	2
36	Ashton NJ, Ide M, Zetterberg H, Blennow K. Salivary Biomarkers for Alzheimer's Disease and Related Disorders. <i>Neurology and Therapy</i> . 2019;8(Supplement 2):83-94.	2
37	Ashton NJ, Scholl M, Heurling K, Gkanatsiou E, Portelius E, Hoglund K, et al. Update on biomarkers for amyloid pathology in Alzheimer's disease. <i>Biomarkers in Medicine</i> . 2018;12(7):799-812.	2
38	Ashton NJ, Suarez-Calvet M, Heslegrave A, Hye A, Razquin C, Pastor P, et al. Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. <i>Alzheimer's Research and Therapy</i> . 2019;11 (1) (no pagination)(94).	6
39	Babic Leko M, Nikolac Perkovic M, Klepac N, Strac DS, Borovecki F, Pivac N, et al. IL-1beta, IL-6, IL-10, and TNFalpha Single Nucleotide Polymorphisms in Human Influence the Susceptibility to Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> . 2020;75(3):1029-47.	7
40	Babic Leko M, Nikolac Perkovic M, Klepac N, Svob Strac D, Borovecki F, Pivac N, et al. Relationships of Cerebrospinal Fluid Alzheimer's Disease Biomarkers and COMT, DBH, and MAOB Single Nucleotide Polymorphisms. <i>Journal of Alzheimer's Disease</i> . 2020;73(1):135-45.	7
41	Babic Leko M, Willumsen N, Nikolac Perkovic M, Klepac N, Borovecki F, Hof PR, et al. Association of MAPT haplotype-tagging polymorphisms with cerebrospinal fluid biomarkers of Alzheimer's disease: A preliminary study in a Croatian cohort. <i>Brain and Behavior</i> . 2018;8 (11) (no pagination)(e01128).	7
42	Babic M, Strac DS, Muck-Seler D, Pivac N, Stanic G, Hof PR, et al. Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease. <i>Croatian Medical Journal</i> . 2014;55(4):347-65.	2
43	Babic M, Vogrinc Z, Diana A, Klepac N, Borovecki F, Hof PR, et al. Comparison of two commercial enzyme-linked immunosorbent assays for cerebrospinal fluid measurement of amyloid β_{1-42} and total tau. <i>Translational Neuroscience</i> . 2013;4(2):234-40.	7

연번	서지정보	배제 사유
44	Bach JP, Gold M, Mengel D, Hattesoehl A, Lubbe D, Schmid S, et al. Measuring Compounds in Exhaled Air to Detect Alzheimer's Disease and Parkinson's Disease. PLoS ONE [Electronic Resource]. 2015;10(7):e0132227.	7
45	Bagnato S, Andriolo M, Boccagni C, Galardi G. Prolonged changes in amyloid-beta metabolism after a severe traumatic brain injury. NeuroReport. 2017;28(5):250-2.	7
46	Bagyinszky E, Youn YC, An SSA, Kim S. Diagnostic methods and biomarkers for alzheimer's disease. Toxicology and Environmental Health Sciences. 2014;6(3):133-47.	2
47	Bai L, Song N, Yu J, Tan L, Shen Y, Xie J, et al. Elevated plasma levels of soluble TNFRs and TACE activity in Alzheimer's disease patients of Northern Han Chinese descent. Current Alzheimer Research. 2013;10(1):57-62.	7
48	Baiardi S, Abu-Rumeileh S, Rossi M, Zenesini C, Bartoletti-Stella A, Polischi B, et al. Antemortem CSF Abeta42/Abeta40 ratio predicts Alzheimer's disease pathology better than Abeta42 in rapidly progressive dementias. Annals of Clinical and Translational Neurology. 2019;6(2):263-73.	7
49	Baldacci F, Daniele S, Piccarducci R, Giampietri L, Pietrobono D, Giorgi FS, et al. Potential Diagnostic Value of Red Blood Cells alpha-Synuclein Heteroaggregates in Alzheimer's Disease. Molecular Neurobiology. 2019;56(9):6451-9.	6
50	Barkovits K, Helling S, Marcus K. MS-based methods for biomarkers of Parkinson's disease: What is the future? Bioanalysis. 2015;7(2):149-51.	2
51	Barrero Hernandez FJ. Biomarkers for the diagnosis of alzheimer's disease. Recent Advances in Alzheimer Research. 2019;3:67-82.	2
52	Barten DM, Cadelina GW, Hoque N, DeCarr LB, Guss VL, Yang L, et al. Tau transgenic mice as models for cerebrospinal fluid tau biomarkers. Journal of Alzheimer's Disease. 2011;24 Suppl 2:127-41.	1
53	Barthelemy NR, Bateman RJ, Hirtz C, Marin P, Becher F, Sato C, et al. Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification. Alzheimer's Research and Therapy. 2020;12 (1) (no pagination)(26).	7
54	Barthelemy NR, Gabelle A, Hirtz C, Fenaille F, Sergeant N, Schraen-Maschke S, et al. Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies. Journal of Alzheimer's Disease. 2016;51(4):1033-43.	7
55	Barthelemy NR, Li Y, Joseph-Mathurin N, Gordon BA, Benzinger TLS, Fagan AM, et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. Nature Medicine. 2020;26(3):398-407.	6
56	Bartos A, Cechova L, Svarcova J, Ricny J, Ripova D. Cerebrospinal fluid triplet in the diagnosis of Alzheimer-Fischer disease. [Czech]. Ceska a Slovenska Neurologie a Neurochirurgie. 2012;75(5):587-94.	3
57	Bartos A, Fialova L, Svarcova J. Lower Serum Antibodies Against Tau Protein and Heavy Neurofilament in Alzheimer's Disease. Journal of Alzheimer's Disease. 2018;64(3):751-60.	7
58	Bateman RJ, Barthelemy NR, Horie K. Another step forward in blood-based diagnostics for Alzheimer's disease. Nature Medicine. 2020;26(3):314-6.	2
59	Bateman RJ, Blennow K, Doody R, Hendrix S, Lovestone S, Salloway S, et al. Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report. Journal of Prevention of Alzheimer's Disease. 2019;6(3):169-73.	2
60	Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, et al. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Annals of Neurology. 2009;66(1):48-54.	7
61	Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology. 2007;68(9):666-9.	7
62	Bates KA, Verdile G, Li QX, Ames D, Hudson P, Masters CL, et al. Clearance mechanisms of Alzheimer's amyloid-B peptide: Implications for therapeutic design and diagnostic tests. Molecular Psychiatry. 2009;14(5):469-86.	2

연번	서지정보	배제 사유
63	Baumann TP, Duyar H, Sollberger M, Kuhle J, Regeniter A, Gomez-Mancilla B, et al. CSF-tau and CSF-Aβeta(1-42) in posterior cortical atrophy. <i>Dementia & Geriatric Cognitive Disorders</i> . 2010;29(6):530-3.	7
64	Begcevic I, Tsolaki M, Brinc D, Brown M, Martinez-Morillo E, Lazarou I, et al. Neuronal pentraxin receptor-1 is a new cerebrospinal fluid biomarker of Alzheimer's disease progression. <i>F1000Research</i> . 2018;7 (no pagination)(1012).	7
65	Benedict C, Blennow K, Zetterberg H, Cedernaes J. Effects of acute sleep loss on diurnal plasma dynamics of CNS health biomarkers in young men. <i>Neurology</i> . 2020;94(11):e1181-e9.	6
66	Benedictus MR, Goos JD, Binnewijzend MA, Muller M, Barkhof F, Scheltens P, et al. Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer's disease. <i>Neurobiology of Aging</i> . 2013;34(11):2488-94.	7
67	Bennet AM, Reynolds CA, Eriksson UK, Hong MG, Blennow K, Gatz M, et al. Genetic association of sequence variants near AGER/NOTCH4 and dementia. <i>Journal of Alzheimer's Disease</i> . 2011;24(3):475-84.	7
68	Benussi A, Grassi M, Palluzzi F, Koch G, Di Lazzaro V, Nardone R, et al. Classification Accuracy of Transcranial Magnetic Stimulation for the Diagnosis of Neurodegenerative Dementias. <i>Annals of Neurology</i> . 2020;87(3):394-404.	6
69	Benvenuto A, Giusiano B, Koric L, Gueriot C, Didic M, Felician O, et al. Imaging Biomarkers of Neurodegeneration in Alzheimer's Disease: Distinct Contributions of Cortical MRI Atrophy and FDG-PET Hypometabolism. <i>Journal of Alzheimer's Disease</i> . 2018;65(4):1147-57.	6
70	Berenguer RG, Monge Argiles JA, Ruiz CM, Paya JS, Blanco Canto MA, Santana CL. Alzheimer disease cerebrospinal fluid biomarkers predict cognitive decline in healthy elderly over 2 years. <i>Alzheimer Disease and Associated Disorders</i> . 2014;28(3):234-8.	7
71	Bergamaschini L, Parnetti L, Pareyson D, Canziani S, Cugno M, Agostoni A. Activation of the contact system in cerebrospinal fluid of patients with Alzheimer disease. <i>Alzheimer Disease & Associated Disorders</i> . 1998;12(2):102-8.	7
72	Berge G, Lauridsen C, Sando SB, Holder DJ, Moller I, Aasly JO, et al. Effect of tween-20 on core biomarkers measured in cerebrospinal fluid from patients with Alzheimer's disease, mild cognitive impairment, or healthy control individuals. <i>Journal of Alzheimer's Disease</i> . 2015;49(2):493-502.	7
73	Berge G, Sando SB, Albrektsen G, Lauridsen C, Moller I, Grontvedt GR, et al. Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer's disease, mild cognitive impairment, or healthy controls: A two year follow-up study. <i>BMC Neurology</i> . 2016;16 (1) (no pagination)(180).	7
74	Berger M, McDonagh D, Mathew J, Newman M, James M. The effect of propofol versus isoflurane anesthesia on human csf markers of alzheimer's disease-preliminary results of a randomized controlled trial. <i>Anesthesia and analgesia</i> . 2013;116.	7
75	Berriault DR, Diamandis EP, Portelius E, Perret-Liaudet A, Salloway S. Biomarkers, assays, and therapies for Alzheimer disease. <i>Clinical Chemistry</i> . 2015;61(7):903-8.	2
76	Best JD, Jay MT, Otu F, Ma J, Nadin A, Ellis S, et al. Quantitative measurement of changes in amyloid-β(40) in the rat brain and cerebrospinal fluid following treatment with the γ-secretase inhibitor LY-411575 [N ² -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N ¹ -[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl] -L-alaninamide]. <i>Journal of Pharmacology and Experimental Therapeutics</i> . 2005;313(2):902-8.	1
77	Bibl M, Esselmann H, Lewczuk P, Trenkwalder C, Otto M, Kornhuber J, et al. Combined analysis of CSF Tau, A 42, A 142 and A 1 40 ox in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. <i>International Journal of Alzheimer's Disease</i> . 2010;(no pagination)(761571).	7
78	Bibl M, Esselmann H, Otto M, Lewczuk P, Cepek L, Ruther E, et al. Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloid beta peptides. <i>Electrophoresis</i> . 2004;25(17):2912-8.	7
79	Bibl M, Esselmann H, Wiltfang J. Neurochemical biomarkers in Alzheimer's disease and related disorders. <i>Therapeutic Advances in Neurological Disorders</i> . 2012;5(6):335-48.	2

연번	서지정보	배제 사유
80	Bibl M, Lewczuk P, Esselmann H, Mollenhauer B, Klafki HW, Welge V, et al. CSF amyloid-beta 1-38 and 1-42 in FTD and AD: Biomarker performance critically depends on the detergent accessible fraction. <i>Proteomics - Clinical Applications</i> . 2008;2(10-11):1548-56.	7
81	Bibl M, Mollenhauer B, Esselmann H, Schneider M, Lewczuk P, Welge V, et al. Cerebrospinal fluid neurochemical phenotypes in vascular dementias: Original data and mini-review. <i>Dementia and Geriatric Cognitive Disorders</i> . 2008;25(3):256-65.	7
82	Bibl M, Mollenhauer B, Lewczuk P, Esselmann H, Wolf S, Otto M, et al. Cerebrospinal fluid tau, p-tau 181 and amyloid-beta38/40/42 in frontotemporal dementias and primary progressive aphasia. <i>Dementia & Geriatric Cognitive Disorders</i> . 2011;31(1):37-44.	7
83	Bibl M, Mollenhauer B, Wolf S, Esselmann H, Lewczuk P, Kornhuber J, et al. Reduced CSF carboxyterminally truncated Abeta peptides in frontotemporal lobe degenerations. <i>Journal of Neural Transmission</i> . 2007;114(5):621-8.	7
84	Biere AL, Ostaszewski B, Zhao H, Gillespie S, Younkin SG, Selkoe DJ. Co-expression of beta-amyloid precursor protein (betaAPP) and apolipoprotein E in cell culture: analysis of betaAPP processing. <i>Neurobiology of disease</i> . 1995;2(3):177-87.	7
85	Biscetti L, Salvadori N, Farotti L, Cataldi S, Eusebi P, Paciotti S, et al. The added value of Abeta42/Abeta40 in the CSF signature for routine diagnostics of Alzheimer's disease. <i>Clinica Chimica Acta</i> . 2019;494:71-3.	7
86	Bittner T, Zetterberg H, Teunissen CE, Ostlund RE, Militello M, Andreasson U, et al. Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of beta-amyloid (1-42) in human cerebrospinal fluid. <i>Alzheimer's and Dementia</i> . 2016;12(5):517-26.	7
87	Bjerke M, Andreasson U, Rolstad S, Nordlund A, Lind K, Zetterberg H, et al. Subcortical vascular dementia biomarker pattern in mild cognitive impairment. <i>Dementia and Geriatric Cognitive Disorders</i> . 2009;28(4):348-56.	7
88	Bjerke M, Portelius E, Minthon L, Wallin A, Anckarster H, Anckarster R, et al. Confounding factors influencing amyloid beta concentration in cerebrospinal fluid. <i>International Journal of Alzheimer's Disease</i> . 2010;(no pagination)(986310).	7
89	Bjerke M, Zetterberg H, Edman A, Blennow K, Wallin A, Andreasson U. Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> . 2011;27(3):665-76.	7
90	Bjornstal O, Rogers K, Zhang W, Delhay R, Malone M, Unger S, et al. The impact of decreased bead count to determine concentrations of amyloid beta1-42, total-tau, and phosphorylated-tau181 in human cerebrospinal fluid using xMAP technology. <i>Journal of Pharmaceutical Sciences</i> . 2011;100(11):4655-63.	7
91	Blennow K, Biscetti L, Eusebi P, Parnetti L. Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice. <i>Movement Disorders</i> . 2016;31(6):836-47.	2
92	Blennow K, Chen C, Cicognola C, Wildsmith KR, Manser PT, Bohorquez SMS, et al. Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology. <i>Brain</i> . 2020;143(2):650-60.	7
93	Blennow K, De Meyer G, Hansson O, Minthon L, Wallin A, Zetterberg H, et al. Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment. <i>Journal of Nutrition, Health & Aging</i> . 2009;13(3):205-8.	6
94	Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leon MJ, Hampel H. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. <i>Alzheimer's & Dementia</i> . 2015;11(1):58-69.	2
95	Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. <i>Nature Reviews Neurology</i> . 2010;6(3):131-44.	2
96	Blennow K, Hampel H, Zetterberg H. Biomarkers in amyloid-beta immunotherapy trials in Alzheimer's disease. <i>Neuropsychopharmacology</i> . 2014;39(1):189-201.	7

연번	서지정보	배제 사유
97	Blennow K, Nikolcheva T, Lasser RA, Dukart J, Rabe C, Volz D, et al. Gantenerumab treatment reduces biomarkers of neuronal and synaptic degeneration in Alzheimer's disease. <i>Alzheimer's & dementia</i> . 2016;12(7):P198.	4
98	Blennow K, Shaw LM, Stomrud E, Mattsson N, Toledo JB, Buck K, et al. Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Abeta(1-42), pTau and tTau CSF immunoassays. <i>Scientific Reports</i> . 2019;9(1):19024.	7
99	Blennow K, Zetterberg H, Minthon L, Lannfelt L, Strid S, Annas P, et al. Longitudinal stability of CSF biomarkers in Alzheimer's disease. <i>Neuroscience Letters</i> . 2007;419(1):18-22.	7
100	Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate alzheimer disease. <i>Archives of Neurology</i> . 2012;69(8):1002-10.	7
101	Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: current status and prospects for the future. <i>Journal of Internal Medicine</i> . 2018;284(6):643-63.	2
102	Blennow K, Zetterberg H. Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings. <i>Progress in Molecular Biology and Translational Science</i> . 2019;168:3-23.	2
103	Blennow K, Zetterberg H. The Past and the Future of Alzheimer's Disease Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> . 2018;62(3):1125-40.	2
104	Blennow K, Zetterberg H. Understanding biomarkers of neurodegeneration: Ultrasensitive detection techniques pave the way for mechanistic understanding. <i>Nature Medicine</i> . 2015;21(3):217-9.	2
105	Blennow K. A Review of Fluid Biomarkers for Alzheimer's Disease: Moving from CSF to Blood. <i>Neurology and Therapy</i> . 2017;6(Supplement 1):15-24.	2
106	Blennow K. CSF biomarkers for Alzheimer's disease: Use in early diagnosis and evaluation of drug treatment. <i>Expert Review of Molecular Diagnostics</i> . 2005;5(5):661-72.	2
107	Blennow K. Dementia in 2010: Paving the way for Alzheimer disease drug development. <i>Nature Reviews Neurology</i> . 2011;7(2):65-6.	2
108	Blom ES, Giedraitis V, Zetterberg H, Fukumoto H, Blennow K, Hyman BT, et al. Rapid progression from mild cognitive impairment to alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the Apoe epsilon4/epsilon4 genotype. <i>Dementia and Geriatric Cognitive Disorders</i> . 2009;27(5):458-64.	7
109	Bogstedt A, Groves M, Tan K, Narwal R, McFarlane M, Hoglund K. Development of Immunoassays for the Quantitative Assessment of Amyloid-beta in the Presence of Therapeutic Antibody: Application to Pre-Clinical Studies. <i>Journal of Alzheimer's Disease</i> . 2015;46(4):1091-101.	7
110	Bonelli RM, Aschoff A, Niederwieser G, Heuberger C, Jirikowski G. Cerebrospinal fluid tissue transglutaminase as a biochemical marker for Alzheimer's disease. <i>Neurobiology of Disease</i> . 2002;11(1):106-10.	7
111	Borger M, Funke S, Bahr M, Grus F, Lingor P. Biomarker sources for Parkinson's disease: Time to shed tears? <i>Basal Ganglia</i> . 2015;5(2-3):63-9.	2
112	Borroni B, Benussi A, Archetti S, Galimberti D, Parnetti L, Nacmias B, et al. Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia. <i>Amyotrophic Lateral sclerosis & Frontotemporal Degeneration</i> . 2015;16(1-2):86-91.	6
113	Bouji M, Lecomte A, Gamez C, Blazy K, Villegier AS. Impact of Cerebral Radiofrequency Exposures on Oxidative Stress and Corticosterone in a Rat Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> . 2020;73(2):467-76.	1
114	Boulo S, Kuhlmann J, Andreasson U, Brix B, Venkataraman I, Herbst V, et al. First amyloid beta1-42 certified reference material for re-calibrating commercial immunoassays. <i>Alzheimer's and Dementia</i> . 2020.	7
115	Bourbouli M, Rentzos M, Bougea A, Zouvelou V, Constantinides VC, Zaganas I, et al. Cerebrospinal Fluid TAR DNA-Binding Protein 43 Combined with Tau Proteins as a Candidate Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Spectrum Disorders. <i>Dementia and Geriatric Cognitive Disorders</i> . 2017;44(3-4):144-52.	7

연번	서지정보	배제 사유
116	Bousiges O, Cretin B, Lavaux T, Philippi N, Jung B, Hezard S, et al. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Abeta42, and Abeta40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> . 2016;51(4):1069-83.	7
117	Bouwman FH, van der Flier WM, Scheltens P. Can lumbar puncture help to identify patients with incipient Alzheimer's disease? <i>Nature Clinical Practice Neurology</i> . 2006;2(10):530-1.	7
118	Bouwman FH, Van Der Flier WM, Schoonenboom NSM, Van Elk EJ, Kok A, Scheltens P, et al. Usefulness of longitudinal measurements of beta-amyloid1-42 in cerebrospinal fluid of patients with various cognitive and neurologic disorders [3]. <i>Clinical Chemistry</i> . 2006;52(8):1604-6.	2
119	Bradley-Whitman MA, Abner E, Lynn BC, Lovell MA. A Novel Plasma Based Biomarker of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> . 2015;47(3):761-71.	7
120	Brady LS, Potter WZ. Proteomic biomarkers for brain disorders: technical considerations and challenges. <i>Neuropsychopharmacology</i> . 2014;39(1):252.	2
121	Bram JMF, Talib LL, Joaquim HPG, Carvalho CL, Gattaz WF, Forlenza OV. Alzheimer's disease-related biomarkers in aging adults with down syndrome: Systematic review. <i>Current Psychiatry Research and Reviews</i> . 2019;15(1):49-57.	2
122	Brettschneider S, Morgenthaler NG, Teipel SJ, Fischer-Schulz C, Burger K, Dodel R, et al. Decreased serum amyloid beta(1-42) autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid beta(1-42) peptide. <i>Biological Psychiatry</i> . 2005;57(7):813-6.	6
123	Briani C, Ruggero S, Naccarato M, Cagnin A, Ricchieri GL, Pasqui L, et al. Combined analysis of CSF betaA42 peptide and tau protein and serum antibodies to glycosaminoglycans in Alzheimer's disease: preliminary data. <i>Journal of Neural Transmission</i> . 2002;109(3):393-8.	7
124	Brinkmalm G, Brinkmalm A, Bourgeois P, Persson R, Hansson O, Portelius E, et al. Soluble amyloid precursor protein alpha and beta in CSF in Alzheimer's disease. <i>Brain Research</i> . 2013;1513:117-26.	7
125	Bros P, Delatour V, Vialaret J, Lalere B, Barthelemy N, Gabelle A, et al. Quantitative detection of amyloid-beta peptides by mass spectrometry: State of the art and clinical applications. <i>Clinical Chemistry and Laboratory Medicine</i> . 2015;53(10):1483-93.	2
126	Brown AM, Tummo DM, Rhodes KJ, Hofmann JR, Jacobsen JS, Sonnenberg-Reines J. Selective aggregation of endogenous beta-amyloid peptide and soluble amyloid precursor protein in cerebrospinal fluid by zinc. <i>Journal of Neurochemistry</i> . 1997;69(3):1204-12.	7
127	Brown RC, Han Z, Cascio C, Papadopoulos V. Oxidative stress-mediated DHEA formation in Alzheimer's disease pathology. <i>Neurobiology of Aging</i> . 2003;24(1):57-65.	7
128	Bruggink KA, Jongbloed W, Biemans EA, Veerhuis R, Claassen JA, Kuiperij HB, et al. Amyloid-beta oligomer detection by ELISA in cerebrospinal fluid and brain tissue. <i>Analytical Biochemistry</i> . 2013;433(2):112-20.	7
129	Bruggink KA, Kuiperij HB, Gloerich J, Otte-Holler I, Rozemuller AJ, Claassen JA, et al. Dickkopf-related protein 3 is a potential Abeta-associated protein in Alzheimer's Disease. <i>Journal of Neurochemistry</i> . 2015;134(6):1152-62.	7
130	Buchhave P, Janciauskiene S, Zetterberg H, Blennow K, Minthon L, Hansson O. Elevated plasma levels of soluble CD40 in incipient Alzheimer's disease. <i>Neuroscience Letters</i> . 2009;450(1):56-9.	7
131	Buckley RF, Mormino EC, Chhatwal J, Schultz AP, Rabin JS, Rentz DM, et al. Associations between baseline amyloid, sex, and APOE on subsequent tau accumulation in cerebrospinal fluid. <i>Neurobiology of Aging</i> . 2019;78:178-85.	7
132	Burkhard PE, Fournier R, Mermillod B, Krause KH, Bouras C, Irminger I. Cerebrospinal fluid tau and Abeta42 concentrations in healthy subjects: Delineation of reference intervals and their limitations. <i>Clinical Chemistry and Laboratory Medicine</i> . 2004;42(4):396-407.	2
133	Cacabelos R, Franco-Maside A, Alvarez XA. Interleukin-1 in Alzheimer's disease and multi-infarct dementia: neuropsychological correlations. <i>Methods & Findings in Experimental & Clinical Pharmacology</i> . 1991;13(10):703-8.	7
134	Calcagno A, Atzori C, Romito A, Vai D, Audagnotto S, Stella ML, et al. Blood brain barrier impairment is associated with cerebrospinal fluid markers of neuronal damage in HIV-positive patients. <i>Journal of NeuroVirology</i> . 2016;22(1):88-92.	7

연번	서지정보	배제 사유
135	Calcagno A, Romito A, Atzori C, Ghisetti V, Cardellino C, Audagnotto S, et al. Blood Brain Barrier Impairment in HIV-Positive Naive and Effectively Treated Patients: Immune Activation Versus Astrocytosis. <i>Journal of Neuroimmune Pharmacology</i> . 2017;12(1):187-93.	7
136	Canuet L, Pusil S, Lopez ME, Bajo R, Pineda-Pardo JA, Cuesta P, et al. Network disruption and cerebrospinal fluid amyloid-beta and phospho-tau levels in mild cognitive impairment. <i>Journal of Neuroscience</i> . 2015;35(28):10325-30.	7
137	Carapelle E, Mundi C, Cassano T, Avolio C. Interaction between cognitive reserve and biomarkers in alzheimer disease. <i>International Journal of Molecular Sciences</i> . 2020;21(17):1-12.	2
138	Carmona P, Molina M, Toledano A. Blood-based biomarkers of alzheimer's disease: Diagnostic algorithms and new technologies. <i>Current Alzheimer Research</i> . 2016;13(4):450-64.	2
139	Carraro M, Ferrari C, Latorraca S, Mazzeo S, Bessi V, Lucidi G, et al. Cerebrospinal fluid biomarkers for dementia: A case of post-lumbar puncture epidural hematoma. <i>Clinical Neurology and Neurosurgery</i> . 2020;190 (no pagination)(105638).	7
140	Carrillo MC, Blennow K, Soares H, Lewczuk P, Mattsson N, Oberoi P, et al. Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium. <i>Alzheimer's and Dementia</i> . 2013;9(2):137-40.	1
141	Carro E, Trejo JL, Spuch C, Bohl D, Heard JM, Torres-Aleman I. Blockade of the insulin-like growth factor I receptor in the choroid plexus originates Alzheimer's-like neuropathology in rodents: new cues into the human disease? <i>Neurobiology of Aging</i> . 2006;27(11):1618-31.	7
142	Casaleto KB, Elahi FM, Bettcher BM, Neuhaus J, Bendlin BB, Asthana S, et al. Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers. <i>Neurology</i> . 2017;89(17):1782-8.	7
143	Casoli T, Paolini S, Fabbietti P, Fattoretti P, Paciaroni L, Fabi K, et al. Cerebrospinal fluid biomarkers and cognitive status in differential diagnosis of frontotemporal dementia and Alzheimer's disease. <i>Journal of International Medical Research</i> . 2019;47(10):4968-80.	6
144	Catak M, Zedde M, Malik R, Janowitz D, Soric V, Seegerer A, et al. Decreased CSF levels of s-amyloid in patients with cortical superficial siderosis. <i>Frontiers in Neurology</i> . 2019;10 (APR) (no pagination)(439).	7
145	Catalan-Garcia M, Garcia-Garcia FJ, Moreno-Lozano PJ, Alcarraz-Vizan G, Tort-Merino A, Milisenda JC, et al. Mitochondrial dysfunction: A common hallmark underlying comorbidity between sIBM and other degenerative and age-related diseases. <i>Journal of Clinical Medicine</i> . 2020;9 (5) (no pagination)(1446).	6
146	Celebi O, Uzdogan A, Oguz KK, Has AC, Dolgun A, Cakmakli GY, et al. Default mode network connectivity is linked to cognitive functioning and CSF Aβ1-42 levels in Alzheimer's disease. <i>Archives of Gerontology and Geriatrics</i> . 2016;62:125-32.	7
147	Chakrabarti A, Chatterjee A, Sengupta MB, Chattopadhyay P, Mukhopadhyay D. Altered levels of amyloid precursor protein intracellular domain-interacting proteins in Alzheimer disease. <i>Alzheimer Disease & Associated Disorders</i> . 2014;28(3):283-90.	7
148	Chan HN, Xu D, Ho SL, He D, Wong MS, Li HW. Highly sensitive quantification of Alzheimer's disease biomarkers by aptamer-assisted amplification. <i>Theranostics</i> . 2019;9(10):2939-49.	7
149	Chatterjee M, Del Campo M, Morrema THJ, de Waal M, van der Flier WM, Hoozemans JJM, et al. Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer's disease. <i>Alzheimer's Research & Therapy</i> . 2018;10(1):52.	7
150	Chatterjee P, Gupta VB, Fagan AM, Jasielec MS, Xiong C, Sohrabi HR, et al. Decreased platelet APP isoform ratios in autosomal dominant Alzheimer's disease: baseline data from a DIAN cohort subset. <i>Current Alzheimer Research</i> . 2015;12(2):157-64.	6
151	Chen CC, Engelborghs S, Dewaele S, Le Bastard N, Martin JJ, Vanhooren V, et al. Altered serum glycomics in Alzheimer disease: a potential blood biomarker? <i>Rejuvenation Research</i> . 2010;13(4):439-44.	7
152	Chen J, Wang A, Liu L. Blood-based amyloid and tau biomarker tests for alzheimer's disease. <i>Neuroscience and Biomedical Engineering</i> . 2016;4(1):4-13.	7

연번	서지정보	배제 사유
153	Chen S, Zheng Y, Xiao J, Lin S, Chen D, Li S. FGF2 shows therapeutic effects in Alzheimer's disease animal model via suppressing PI3K/Akt mediated ER stress. <i>International Journal of Clinical and Experimental Medicine</i> . 2016;9(2):2130-8.	1
154	Chen Z, Mengel D, Keshavan A, Rissman RA, Billinton A, Perkinton M, et al. Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease. <i>Alzheimer's and Dementia</i> . 2019;15(3):487-96.	6
155	Chen-Plotkin AS. Unbiased approaches to biomarker discovery in neurodegenerative diseases. <i>Neuron</i> . 2014;84(3):594-607.	2
156	Chiaravallotti A, Barbagallo G, Ricci M, Martorana A, Ursini F, Sannino P, et al. Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study. <i>Brain Research</i> . 2018;1678:116-22.	7
157	Chiasserini D, Biscetti L, Eusebi P, Salvadori N, Frattini G, Simoni S, et al. Differential role of CSF fatty acid binding protein 3, alpha-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia. <i>Alzheimer's Research and Therapy</i> . 2017;9 (1) (no pagination)(52).	7
158	Choi YS, Hou S, Choe LH, Lee KH. Targeted human cerebrospinal fluid proteomics for the validation of multiple Alzheimer's disease biomarker candidates. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> . 2013;930:129-35.	7
159	Choi-Miura NH, Ihara Y, Fukuchi K, Takeda M, Nakano Y, Tobe T, et al. SP-40,40 is a constituent of Alzheimer's amyloid. <i>Acta Neuropathologica</i> . 1992;83(3):260-4.	7
160	Chong JK, Miller BE, Ghanbari HA. Detection of amyloid beta protein precursor immunoreactivity in normal and Alzheimer's disease cerebrospinal fluid. <i>Life Sciences</i> . 1990;47(13):1163-71.	7
161	Cicognola C, Brinkmalm G, Wahlgren J, Portelius E, Gobom J, Cullen NC, et al. Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's disease. <i>Acta Neuropathologica</i> . 2019;137(2):279-96.	7
162	Cicognola C, Chiasserini D, Eusebi P, Andreasson U, Vanderstichele H, Zetterberg H, et al. No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSF. <i>Molecular Neurodegeneration</i> . 2016;11 (1) (no pagination)(65).	7
163	Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. <i>Journal of Neuroscience</i> . 2003;23(26):8844-53.	1
164	Clark CM, Pratico D, Shaw LM, Leight S, Xie SX, Gu A, et al. Commentary on "Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease." Biochemical biomarkers of late-life dementia. <i>Alzheimer's and Dementia</i> . 2006;2(4):287-93.	2
165	Clarke EE, Shearman MS. Quantitation of amyloid-beta peptides in biological milieu using a novel homogeneous time-resolved fluorescence (HTRF) assay. <i>Journal of Neuroscience Methods</i> . 2000;102(1):61-8.	2
166	Clarke MTM, Brinkmalm A, Foiani MS, Woollacott IOC, Heller C, Heslegrave A, et al. CSF synaptic protein concentrations are raised in those with atypical Alzheimer's disease but not frontotemporal dementia. <i>Alzheimer's Research and Therapy</i> . 2019;11 (1) (no pagination)(105).	7
167	Coart E, Barrado LG, Duits FH, Scheltens P, Van Der Flier WM, Teunissen CE, et al. Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> . 2015;46(4):889-99.	7
168	Colciaghi F, Borroni B, Pastorino L, Marcello E, Zimmermann M, Cattabeni F, et al. [alpha]-Secretase ADAM10 as well as [alpha]APPs is reduced in platelets and CSF of Alzheimer disease patients. <i>Molecular Medicine</i> . 2002;8(2):67-74.	7
169	Compta Y, Buongiorno M, Bargallo N, Valdeoriola F, Munoz E, Tolosa E, et al. White matter hyperintensities, cerebrospinal amyloid-beta and dementia in Parkinson's disease. <i>Journal of the Neurological Sciences</i> . 2016;367:284-90.	7
170	Compta Y, Ezquerro M, Munoz E, Tolosa E, Valdeoriola F, Rios J, et al. High cerebrospinal tau levels are associated with the rs242557 tau gene variant and low cerebrospinal beta-amyloid in Parkinson disease. <i>Neuroscience Letters</i> . 2011;487(2):169-73.	7
171	Compta Y, Ibarretxe-Bilbao N, Pereira JB, Junque C, Bargallo N, Tolosa E, et al. Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia. <i>Parkinsonism and Related Disorders</i> . 2012;18(8):941-7.	7

연번	서지정보	배제 사유
172	Compta Y, Marti MJ, Ibarretxe-Bilbao N, Junque C, Valldeoriola F, Munoz E, et al. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. <i>Movement Disorders</i> . 2009;24(15):2203-10.	7
173	Constantinides VC, Paraskevas GP, Efthymiopoulou E, Stefanis L, Kapaki E. Clinical, neuropsychological and imaging characteristics of Alzheimer's disease patients presenting as corticobasal syndrome. <i>Journal of the Neurological Sciences</i> . 2019;398:142-7.	7
174	Conti E, Gregori M, Radice I, Da Re F, Grana D, Re F, et al. Multifunctional liposomes interact with Abeta in human biological fluids: Therapeutic implications for Alzheimer's disease. <i>Neurochemistry International</i> . 2017;108:60-5.	7
175	Contu L, Carare RO, Hawkes CA. Knockout of apolipoprotein A-I decreases parenchymal and vascular beta-amyloid pathology in the Tg2576 mouse model of Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> . 2019;45(7):698-714.	1
176	Coppi, E., L. Ferrari, R. Santangelo, F. Caso, P. Pinto, G. Passerini, et al. Further evidence about the crucial role of CSF biomarkers in diagnosis of posterior cortical atrophy. <i>Neurological Sciences</i> , 2014. 35(5): p. 785-787.	7
177	Coskuner O, Murray IV. Adenosine triphosphate (ATP) reduces amyloid-beta protein misfolding in vitro. <i>Journal of Alzheimer's Disease</i> . 2014;41(2):561-74.	1
178	Costa M, Ortiz AM, Horrillo R, Perez A, Boada M, Ruiz A, et al. Modifications in albumin molecular profile in a phase 2 study based on therapeutic plasma exchange and 5% albumin replacement in Alzheimer's disease. <i>Alzheimer's & dementia</i> . 2016;12(7):P633-P4.	4
179	Counts SE, He B, Prout JG, Michalski B, Farotti L, Fahnestock M, et al. Cerebrospinal fluid proNGF: A putative biomarker for early alzheimer's disease. <i>Current Alzheimer Research</i> . 2016;13(7):800-8.	7
180	Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, et al. Intranasal insulin therapy for Alzheimer disease and amnesic mild cognitive impairment: a pilot clinical trial. <i>Archives of neurology</i> . 2012;69(1):29-38.	7
181	Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, et al. Multiplexed immunoassay panel identifies novel CSF biomarkers for alzheimer's disease diagnosis and prognosis. <i>PLoS ONE</i> . 2011;6 (4) (no pagination)(e18850).	7
182	Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, et al. YKL-40: A novel prognostic fluid biomarker for preclinical Alzheimer's disease. <i>Biological Psychiatry</i> . 2010;68(10):903-12.	7
183	Cseh EK, Veres G, Danics K, Szalardy L, Nanasi N, Klivenyi P, et al. Additional value of tau protein measurement in the diagnosis of Creutzfeldt-Jakob disease. <i>Ideggyogyaszati Szemle</i> . 2019;72(1-2):39-47.	5
184	Cuchillo-Ibanez I, Lopez-Font I, Boix-Amoros A, Brinkmalm G, Blennow K, Molinuevo JL, et al. Heteromers of amyloid precursor protein in cerebrospinal fluid. <i>Molecular Neurodegeneration</i> . 2015;10:2.	7
185	Cullen VC, Fredenburg RA, Evans C, Conliffe PR, Solomon ME. Development and advanced validation of an optimized method for the quantitation of A β ₄₂ in human cerebrospinal fluid. <i>AAPS Journal</i> . 2012;14(3):510-8.	7
186	Cummings J, Blennow K, Johnson K, Keeley M, Bateman RJ, Molinuevo JL, et al. Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force. <i>Journal of Prevention of Alzheimer's Disease</i> . 2019;6(3):157-63.	6
187	Cutler P, Brown F, Camilleri P, Carpenter D, George A, Gray C, et al. The recognition of haemoglobin by antibodies raised for the immunoassay of beta-amyloid. <i>FEBS Letters</i> . 1997;412(2):341-5.	7
188	Cysique LA, Hewitt T, Croitoru-Lamourey J, Taddei K, Martins RN, Chew CS, et al. APOE epsilon4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study. <i>BMC Neurology</i> . 2015;15:51.	7
189	d'Abramo C, Acker CM, Jimenez HT, Davies P. Tau Passive Immunotherapy in Mutant P301L Mice: Antibody Affinity versus Specificity. <i>PLoS ONE</i> . 2013;8 (4) (no pagination)(e62402).	1
190	Dalmau J. A box of chocolates. <i>Neurology: Neuroimmunology and NeuroInflammation</i> . 2016;3 (3) (no pagination)(e234).	2

연번	서지정보	배제 사유
191	D'Anna L, Abu-Rumeileh S, Fabris M, Pistis C, Baldi A, Sanvilli N, et al. Serum Interleukin-10 Levels Correlate with Cerebrospinal Fluid Amyloid Beta Deposition in Alzheimer Disease Patients. <i>Neurodegenerative Diseases</i> . 2017;17(4-5):227-34.	7
192	Darreh-Shori T, Hosseini SM, Nordberg A. Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors. <i>Journal of Alzheimer's Disease</i> . 2014;39(2):423-40.	7
193	Davidsson P, Sjogren M. The use of proteomics in biomarker discovery in neurodegenerative diseases. <i>Disease Markers</i> . 2005;21(2):81-92.	2
194	Davinelli S, Intrieri M, Russo C, Di Costanzo A, Zella D, Bosco P, et al. The "Alzheimer's disease signature": Potential perspectives for novel biomarkers. <i>Immunity and Ageing</i> . 2011;8 (no pagination)(7).	2
195	Dayon L, Nunez Galindo A, Wojcik J, Cominetti O, Corthesy J, Oikonomidi A, et al. Alzheimer disease pathology and the cerebrospinal fluid proteome. <i>Alzheimer's Research and Therapy</i> . 2018;10 (1) (no pagination)(66).	7
196	Dayon L, Wojcik J, Nunez Galindo A, Corthesy J, Cominetti O, Oikonomidi A, et al. Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults. <i>Journal of Alzheimer's Disease</i> . 2017;60(4):1641-52.	7
197	de Almeida SM, Ribeiro CE, Rotta I, Letendre S, Potter M, Tang B, et al. Blood amyloid-beta protein isoforms are affected by HIV-1 in a subtype-dependent pattern. <i>Journal of NeuroVirology</i> . 2020;26(1):3-13.	7
198	de Almeida SM, Ribeiro CE, Rotta I, Piovesan M, Tang B, Vaida F, et al. Biomarkers of neuronal injury and amyloid metabolism in the cerebrospinal fluid of patients infected with HIV-1 subtypes B and C. <i>Journal of NeuroVirology</i> . 2018;24(1):28-40.	7
199	de Almeida SM, Tang B, Ribeiro CE, Rotta I, Vaida F, Piovesan M, et al. Neprilysin in the Cerebrospinal Fluid and Serum of Patients Infected With HIV1-Subtypes C and B. <i>Journal of acquired immune deficiency syndromes (1999)</i> . 2018;78(2):248-56.	7
200	De Jong D, Jansen RWMM, Kremer BPH, Verbeek MM. Potential pitfalls in the analysis of CSF biomarkers in Alzheimer's disease and vascular dementia [2]. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> . 2007;62(8):924-5.	2
201	de la Escosura-Muniz A, Plichta Z, Horak D, Merkoci A. Alzheimer's disease biomarkers detection in human samples by efficient capturing through porous magnetic microspheres and labelling with electrocatalytic gold nanoparticles. <i>Biosensors and Bioelectronics</i> . 2015;67:162-9.	7
202	De La Monte SM, Tong M, Daiello LA, Ott BR. Early-Stage Alzheimer's Disease Is Associated with Simultaneous Systemic and Central Nervous System Dysregulation of Insulin-Linked Metabolic Pathways. <i>Journal of Alzheimer's Disease</i> . 2019;68(2):657-68.	6
203	De la Monte, S.M. and J.R. Wands. The AD7c-NTP neuronal thread protein biomarker for detecting Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2001. 3(3): p. 345-353.	7
204	de Leon MJ, Pirraglia E, Osorio RS, Glodzik L, Saint-Louis L, Kim HJ, et al. The nonlinear relationship between cerebrospinal fluid A β 42 and tau in preclinical Alzheimer's disease. <i>PLoS ONE</i> . 2018;13 (2) (no pagination)(e0191240).	7
205	de Leon MJ, Segal S, Tarshish CY, DeSanti S, Zinkowski R, Mehta PD, et al. Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment. <i>Neuroscience Letters</i> . 2002;333(3):183-6.	7
206	De Riva V, Galloni E, Marcon M, Di Dionisio L, Deluca C, Meligrana L, et al. Analysis of combined CSF biomarkers in AD diagnosis. <i>Clinical Laboratory</i> . 2014;60(4):629-34.	7
207	de Souza LC, Corlier F, Habert MO, Uspenskaya O, Maroy R, Lamari F, et al. Similar amyloid-beta burden in posterior cortical atrophy and Alzheimer's disease. <i>Brain</i> . 2011;134(Pt 7):2036-43.	7
208	De Vos A, Jacobs D, Struyfs H, Fransen E, Andersson K, Portelius E, et al. C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease. <i>Alzheimer's & Dementia</i> . 2015;11(12):1461-9.	7
209	Dean R, Siemers E, Carlson C, Estergard W, Sundell K, Henley D, et al. Effects of solanezumab versus placebo administration on biomarkers in people with mild-to-moderate Alzheimer's disease: results from two phase III clinical trials. <i>Alzheimer's & dementia</i> . 2013;9(4 SUPPL. 1):P283.	4

연번	서지정보	배제 사유
210	Dean RA, Shaw LM. Use of cerebrospinal fluid biomarkers for diagnosis of incipient Alzheimer disease in patients with mild cognitive impairment. <i>Clinical Chemistry</i> . 2010;56(1):7-9.	2
211	Decourt B, Gonzales A, Beach TG, Malek-Ahmadi M, Walker A, Sue L, et al. BACE1 levels by APOE genotype in non-demented and Alzheimer's post-mortem brains. <i>Current Alzheimer Research</i> . 2013;10(3):309-15.	7
212	Degerman Gunnarsson M, Lindau M, Wall A, Blennow K, Darreh-Shori T, Basu S, et al. Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: An exploratory study. <i>Dementia & Geriatric Cognitive Disorders</i> . 2010;29(3):204-12.	7
213	Dehghani C, Frost S, Jayasena R, Masters CL, Kanagasingam Y. Ocular biomarkers of Alzheimer's disease: The role of anterior eye and potential future directions. <i>Investigative Ophthalmology and Visual Science</i> . 2018;59(8):3554-63.	2
214	Dehlin M, Bjersing J, Erlandsson M, Andreassen N, Zetterberg H, Mannerkorpi K, et al. Cerebrospinal Flt3 ligand correlates to tau protein levels in primary Sjogren's syndrome. <i>Scandinavian Journal of Rheumatology</i> . 2013;42(5):394-9.	7
215	Del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH, et al. Recommendations to standardize preanalytical confounding factors in Alzheimers and Parkinsons disease cerebrospinal fluid biomarkers: An update. <i>Biomarkers in Medicine</i> . 2012;6(4):419-30.	2
216	Del Campo Milan M, Zuroff L, Jimenez CR, Scheltens P, Teunissen CE. Can agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease? <i>Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring</i> . 2015;1(1):75-80.	7
217	Delaby C, Gabelle A, Blum D, Schraen-Maschke S, Moulinier A, Boulanghien J, et al. Central nervous system and peripheral inflammatory processes in Alzheimer's disease: Biomarker profiling approach. <i>Frontiers in Neurology</i> . 2015;6 (Aug) (no pagination)(181).	7
218	Delaby C, Gabelle A, Meynier P, Loubiere V, Vialaret J, Tiers L, et al. Development and validation of dried matrix spot sampling for the quantitative determination of amyloid beta peptides in cerebrospinal fluid. <i>Clinical Chemistry and Laboratory Medicine</i> . 2014;52(5):649-55.	7
219	Demeritte T, Nellore BP, Kanchanapally R, Sinha SS, Pramanik A, Chavva SR, et al. Hybrid Graphene Oxide Based Plasmonic-Magnetic Multifunctional Nanoplatfrom for Selective Separation and Label-Free Identification of Alzheimer's Disease Biomarkers. <i>Acs Applied Materials & Interfaces</i> . 2015;7(24):13693-700.	7
220	Demirtas M, Falcon C, Tucholka A, Gispert JD, Molinuevo JL, Deco G. A whole-brain computational modeling approach to explain the alterations in resting-state functional connectivity during progression of Alzheimer's disease. <i>NeuroImage: Clinical</i> . 2017;16:343-54.	7
221	Deng F, Miller J. A review on protein markers of exosome from different bio-resources and the antibodies used for characterization. <i>Journal of Histotechnology</i> . 2019;42(4):226-39.	2
222	Desideri G, Gentile R, Antonosante A, Benedetti E, Grassi D, Cristiano L, et al. Uric Acid Amplifies Abeta Amyloid Effects Involved in the Cognitive Dysfunction/Dementia: Evidences From an Experimental Model In Vitro. <i>Journal of Cellular Physiology</i> . 2017;232(5):1069-78.	1
223	Di Battista ME, Dell'Acqua C, Baroni L, Fenoglio C, Galimberti D, Gallucci M. Frontotemporal dementia misdiagnosed for post-treatment lyme disease syndrome or vice versa? A treviso dementia (TREDEM) registry case report. <i>Journal of Alzheimer's Disease</i> . 2018;66(2):445-51.	7
224	Di Domenico F, Pupo G, Giraldo E, Badia MC, Monllor P, Lloret A, et al. Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients. <i>Free Radical Biology and Medicine</i> . 2016;91:1-9.	7
225	Diamandis EP, Yousef GM, Petraki C, Soosaipillai AR. Human kallikrein 6 as a biomarker of alzheimer's disease. <i>Clinical Biochemistry</i> . 2000;33(8):663-7.	7
226	Diehl-Wiesenecker E, von Armin CA, Dupuis L, Muller HP, Ludolph AC, Kassubek J. Adipose Tissue Distribution in Patients with Alzheimer's Disease: A Whole Body MRI Case-Control Study. <i>Journal of Alzheimer's Disease</i> . 2015;48(3):825-32.	7
227	Dietrich MO, Spuch C, Antequera D, Rodal I, de Yebenes JG, Molina JA, et al. Megalin mediates the transport of leptin across the blood-CSF barrier. <i>Neurobiology of Aging</i> . 2008;29(6):902-12.	7
228	Doecke JD, Rembach A, Villemagne VL, Varghese S, Rainey-Smith S, Sarros S, et al. Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms. <i>Journal of Alzheimer's Disease</i> . 2018;61(1):169-83.	7

연번	서지정보	배제 사유
229	Doecke JD, Ward L, Burnham SC, Villemagne VL, Li QX, Collins S, et al. Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging. <i>Alzheimer's Research and Therapy</i> . 2020;12 (1) (no pagination)(36).	7
230	Dorey A, Tholance Y, Vighetto A, Perret-Liaudet A, Lachman I, Krolak-Salmon P, et al. Association of cerebrospinal fluid prion protein levels and the distinction between Alzheimer disease and Creutzfeldt-Jakob disease. <i>JAMA Neurology</i> . 2015;72(3):267-75.	7
231	Dorothee G, Bottlaender M, Moukari E, De Souza LC, Maroy R, Corlier F, et al. Distinct patterns of anti-amyloid-beta antibodies in typical and atypical Alzheimer disease. <i>Archives of Neurology</i> . 2012;69(9):1181-5.	7
232	Du J, Murphy RM. Characterization of the interaction of beta-Amyloid with Transthyretin monomers and tetramers. <i>Biochemistry</i> . 2010;49(38):8276-89.	7
233	Du Pasquier RA, Jilek S, Kalubi M, Yerly S, Fux CA, Gutmann C, et al. Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy. <i>AIDS (london, england)</i> . 2013;27(2):203-10.	7
234	Du Y, Dodel R, Hampel H, Buerger K, Lin S, Eastwood B, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. <i>Neurology</i> . 2001;57(5):801-5.	7
235	Duits FH, Hernandez-Guillamon M, Montaner J, Goos JD, Montanola A, Wattjes MP, et al. Matrix Metalloproteinases in Alzheimer's Disease and Concurrent Cerebral Microbleeds. <i>Journal of Alzheimer's Disease</i> . 2015;48(3):711-20.	7
236	Dumurgier J, Laplanche JL, Mouton-Liger F, Lapalus P, Indart S, Prevot M, et al. The screening of Alzheimer's patients with CSF biomarkers, modulates the distribution of APOE genotype: impact on clinical trials. <i>Journal of Neurology</i> . 2014;261(6):1187-95.	7
237	Duron E, Vidal JS, Grouselle D, Gabelle A, Lehmann S, Pasquier F, et al. Somatostatin and neuropeptide Y in cerebrospinal fluid: Correlations with amyloid peptides Abeta1-42 and tau proteins in elderly patients with mild cognitive impairment. <i>Frontiers in Aging Neuroscience</i> . 2018;10 (OCT) (no pagination)(297).	7
238	Dursun E, Alayiloglu M, Bilgic B, Hanagasi H, Gurvit H, Emre M, et al. Amyloid Beta Adsorption Problem with Transfer Plates in Amyloid Beta 1-42 IVD Kits. <i>Journal of Molecular Neuroscience</i> . 2019;67(4):534-9.	7
239	Eckerstrom C, Andreasson U, Olsson E, Rolstad S, Blennow K, Zetterberg H, et al. Combination of hippocampal volume and cerebrospinal fluid biomarkers improves predictive value in mild cognitive impairment. <i>Dementia & Geriatric Cognitive Disorders</i> . 2010;29(4):294-300.	7
240	Efficacy and safety results of reverse-SD, phase-2b clinical study of the selective p38a kinase inhibitor neflamapimod in early-stage Alzheimer's disease (AD). <i>Journal of prevention of alzheimer's disease</i> . 2019;6:S9-S10.	4
241	El Mouedden M, Haseldonckx M, Mackie C, Meert T, Mercken M. Method for the determination of the levels of beta-amyloid peptide in the CSF sampled from freely moving rats. <i>Journal of Pharmacological and Toxicological Methods</i> . 2005;52(2):229-33.	1
242	El Mouedden M, Vandermeeren M, Meert T, Mercken M. Development of a specific ELISA for the quantitative study of amino-terminally truncated beta-amyloid peptides. <i>Journal of Neuroscience Methods</i> . 2005;145(1-2):97-105.	7
243	El Mouedden M, Vandermeeren M, Meert T, Mercken M. Reduction of Abeta levels in the Sprague Dawley rat after oral administration of the functional gamma-secretase inhibitor, DAPT: A novel non-transgenic model for Abeta production inhibitors. <i>Current Pharmaceutical Design</i> . 2006;12(6):671-6.	2
244	Eliassen CF, Reinvang I, Selnes P, Grambaite R, Fladby T, Hessen E. Biomarkers in subtypes of mild cognitive impairment and subjective cognitive decline. <i>Brain and Behavior</i> . 2017;7 (9) (no pagination)(e00776).	7
245	Elibol B, Beker M, Terzioglu-Usak S, Dalli T, Kilic U. Thymoquinone administration ameliorates Alzheimer's disease-like phenotype by promoting cell survival in the hippocampus of amyloid beta ₁₋₄₂ infused rat model. <i>Phytomedicine</i> . 2020;79 (no pagination)(153324).	1
246	Elliott DA, Halliday GM, Garner B. Apolipoprotein-E forms dimers in human frontal cortex and hippocampus. <i>BMC Neuroscience</i> . 2010;11:23.	7

연번	서지정보	배제 사유
247	Ellis TA, Li J, Leblond D, Waring JF. The relationship between different assays for detection and quantification of amyloid beta 42 in human cerebrospinal fluid. <i>International Journal of Alzheimer's Disease</i> . 2012;(no pagination)(984746).	7
248	Ellis, K.A., S.R. Rainey-Smith, A. Rembach, S.L. Macaulay, and V.L. Villemagne. Enabling a multidisciplinary approach to the study of ageing and Alzheimer's disease: An update from the Australian Imaging Biomarkers and Lifestyle (AIBL) study. <i>International Review of Psychiatry</i> , 2013. 25(6): p. 699-710.	7
249	Elobeid A, Laurell K, Cesarini KG, Alafuzoff I. Correlations between mini-mental state examination score, cerebrospinal fluid biomarkers, and pathology observed in brain biopsies of patients with normal-pressure hydrocephalus. <i>Journal of Neuropathology & Experimental Neurology</i> . 2015;74(5):470-9.	7
250	Endres K, Fahrenholz F, Lotz J, Hiemke C, Teipel S, Lieb K, et al. Increased CSF APPs-a levels in patients with Alzheimer disease treated with acitretin. <i>Neurology</i> . 2014;83(21):1930-5.	7
251	Engelborghs S, Le Bastard N. The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia. <i>Journal of the Neurological Sciences</i> . 2012;322(1-2):197-9.	7
252	Engelborghs S, Maertens K, Vloeberghs E, Aerts T, Somers N, Marien P, et al. Neuropsychological and behavioural correlates of CSF biomarkers in dementia. <i>Neurochemistry International</i> . 2006;48(4):286-95.	7
253	Engelborghs S, Sleegers K, Cras P, Brouwers N, Serneels S, De Leenheir E, et al. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease. <i>Brain</i> . 2007;130(9):2320-6.	7
254	Erickson CM, Schultz SA, Oh JM, Darst BF, Ma Y, Norton D, et al. KLOTHO heterozygosity attenuates APOE4-related amyloid burden in preclinical AD. <i>Neurology</i> . 2019;92(16):E1878-E89.	7
255	Erickson D. Doomsday diagnostic? <i>Scientific American</i> . 1992;267(2):120.	2
256	Eruysal E, Ravdin L, Kamel H, Iadecola C, Ishii M. Plasma lipocalin-2 levels in the preclinical stage of Alzheimer's disease. <i>Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring</i> . 2019;11:646-53.	7
257	Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, Holtzman DM, et al. Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls. <i>Annals of Neurology</i> . 2013;73(1):104-19.	7
258	Eutr SE. A 52-week, multi-center, randomized, double-blind, placebo-controlled, time-lagged, parallel group study in patients with mild to moderate Alzheimer's Disease (AD) to investigate the safety, tolerability and Abeta-specific antibody response following three subcutaneous injections of CAD106. http://www.who.int/trialssearch/Trial2.aspx?TrialID=EUCTR2005-000048-10-SE . 2005.	4
259	Evered L, Silbert B, Scott DA, Ames D, Maruff P, Blennow K. Cerebrospinal Fluid Biomarker for Alzheimer Disease Predicts Postoperative Cognitive Dysfunction. <i>Anesthesiology</i> . 2016;124(2):353-61.	7
260	Fagan AM, Christopher E, Taylor JW, Parsadanian M, Spinner M, Watson M, et al. ApoA1 deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis. <i>American Journal of Pathology</i> . 2004;165(4):1413-22.	1
261	Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. <i>Annals of Neurology</i> . 2006;59(3):512-9.	1
262	Fagan AM, Shaw LM, Xiong C, Vanderstichele H, Mintun MA, Trojanowski JQ, et al. Comparison of analytical platforms for cerebrospinal fluid measures of beta-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. <i>Archives of Neurology</i> . 2011;68(9):1137-44.	7
263	Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TL, et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. <i>Science Translational Medicine</i> . 2014;6(226):226ra30.	7

연번	서지정보	배제 사유
264	Fahnestock M. Brain-derived neurotrophic factor: The link between amyloid-beta and memory loss. <i>Future Neurology</i> . 2011;6(5):627-39.	2
265	Falcon C, Tucholka A, Monte-Rubio GC, Cacciaglia R, Operto G, Rami L, et al. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets. <i>NeuroImage Clinical</i> . 2018;19:190-201.	7
266	Fania C, Arosio B, Capitanio D, Torretta E, Gussago C, Ferri E, et al. Protein signature in cerebrospinal fluid and serum of Alzheimer's disease patients: The case of apolipoprotein A-1 proteoforms. <i>PLoS ONE [Electronic Resource]</i> . 2017;12(6):e0179280.	7
267	Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. <i>Alzheimer's & Dementia</i> . 2012;8(4):261-71.	7
268	Farlow M, Ghetti B, Benson MD, Farrow JS, van Nostrand WE, Wagner SL. Low cerebrospinal-fluid concentrations of soluble amyloid beta-protein precursor in hereditary Alzheimer's disease. <i>Lancet</i> . 1992;340(8817):453-4.	7
269	Fazeli PL, Moore DJ, Franklin DR, Umlauf A, Collier AC, Marra CM, et al. Lower CSF Abeta is associated with HAND in HIV-infected adults with a family History of Dementia. <i>Current HIV Research</i> . 2016;14(4):324-30.	7
270	Federico A, Formichi P, Parnetti L, Radi E, Cevenini G, Dotti MT. CSF biomarkers profile in CADASIL-A model of pure vascular dementia: Usefulness in differential diagnosis in the dementia disorder. <i>International Journal of Alzheimer's Disease</i> . 2010;(no pagination)(959257).	7
271	Fei M, Jianghua W, Rujuan M, Wei Z, Qian W. The relationship of plasma Abeta levels to dementia in aging individuals with mild cognitive impairment. <i>Journal of the Neurological Sciences</i> . 2011;305(1-2):92-6.	7
272	Feinkohl I, Schipke CG, Kruppa J, Menne F, Winterer G, Pischon T, et al. Plasma Amyloid Concentration in Alzheimer's Disease: Performance of a High-Throughput Amyloid Assay in Distinguishing Alzheimer's Disease Cases from Controls. <i>Journal of Alzheimer's Disease</i> . 2020;74(4):1285-94.	6
273	Fereshtehnejad SM, Zeighami Y, Dagher A, Postuma RB. Clinical criteria for subtyping Parkinson's disease: Biomarkers and longitudinal progression. <i>Brain</i> . 2017;140(7):1959-76.	2
274	Figurski MJ, Waligorska T, Toledo J, Vanderstichele H, Korecka M, Lee VM, et al. Improved protocol for measurement of plasma beta-amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients. <i>Alzheimer's & Dementia</i> . 2012;8(4):250-60.	7
275	Fiorini M, Bongianini M, Benedetti MD, Monaco S, Zanusso G. Reappraisal of Abeta40 and Abeta42 Peptides Measurements in Cerebrospinal Fluid of Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> . 2018;66(1):219-27.	7
276	Fitzgerald DJ, Maggio JE, Esler WP, Stimson ER, Jennings JM, Ghilardi JR, et al. Zinc and Alzheimer's disease. <i>Science</i> . 1995;268(5219):1920-3.	7
277	Foiani MS, Cicognola C, Ermann N, Woolacott IOC, Heller C, Heslegrave AJ, et al. Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: An elusive quest. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> . 2019;90(7):740-6.	7
278	Forlenza OV, Diniz BS, Teixeira AL, Radanovic M, Talib LL, Rocha NP, et al. Lower Cerebrospinal Fluid Concentration of Brain-Derived Neurotrophic Factor Predicts Progression from Mild Cognitive Impairment to Alzheimer's Disease. <i>NeuroMolecular Medicine</i> . 2015;17(3):326-32.	7
279	Forlenza OV, Diniz BS, Teixeira AL, Stella F, Gattaz W. Mild cognitive impairment (part 2): Biological markers for diagnosis and prediction of dementia in Alzheimer's disease. <i>Revista Brasileira de Psiquiatria</i> . 2013;35(3):284-94.	2
280	Formichi P, Battisti C, Radi E, Federico A. Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease. <i>Journal of Cellular Physiology</i> . 2006;208(1):39-46.	2
281	Formichi P, Parnetti L, Radi E, Cevenini G, Dotti MT, Federico A. CSF levels of beta-amyloid 1-42, tau and phosphorylated tau protein in CADASIL. <i>European Journal of Neurology</i> . 2008;15(11):1252-5.	7
282	Forsberg A, Almkvist O, Engler H, Wall A, Langstrom B, Nordberg A. High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. <i>Current Alzheimer Research</i> . 2010;7(1):56-66.	7

연번	서지정보	배제 사유
283	Fortea J, Llado A, Bosch B, Antonell A, Oliva R, Molinuevo JL, et al. Cerebrospinal fluid biomarkers in Alzheimer's disease families with PSEN1 mutations. <i>Neurodegenerative Diseases</i> . 2011;8(4):202-7.	7
284	Fortea J, Sala-Llloch R, Bartres-Faz D, Llado A, Sole-Padullés C, Bosch B, et al. Cognitively preserved subjects with transitional cerebrospinal fluid s-amyloid 1-42 values have thicker cortex in Alzheimer's disease vulnerable areas. <i>Biological Psychiatry</i> . 2011;70(2):183-90.	7
285	Foucault-Fruchard L, Delaye JB, Morange V, Beaufils E, Duwicquet C, Quadrio I, et al. An automated alert system based on the p-Tau/Tau ratio to quickly inform health professionals upon a suspected case of sporadic Creutzfeldt-Jakob disease. <i>Journal of the Neurological Sciences</i> . 2020;415 (no pagination)(116971).	5
286	Fourier A, Portelius E, Zetterberg H, Blennow K, Quadrio I, Perret-Liaudet A. Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability. <i>Clinica Chimica Acta</i> . 2015;449:9-15.	2
287	Fradinger EA, Bitan G. En route to early diagnosis of Alzheimer's disease - Are we there yet? <i>Trends in Biotechnology</i> . 2005;23(11):531-3.	2
288	Frank RA, Galasko D, Hampel H, Hardy J, De Leon MJ, Mehta PD, et al. Biological markers for therapeutic trials in Alzheimer's disease: Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. <i>Neurobiology of Aging</i> . 2003;24(4):521-36.	2
289	Frankfort SV, Tulner LR, van Campen JPCM, Verbeek MM, Jansen RWM, Beijnen JH. Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: A review of recent literature. <i>Current Clinical Pharmacology</i> . 2008;3(2):123-31.	2
290	Franz G, Beer R, Kampfl A, Engelhardt K, Schmutzhard E, Ulmer H, et al. Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury. <i>Neurology</i> . 2003;60(9):1457-61.	5
291	Freeman GB, Lin JC, Pons J, Raha NM. 39-week toxicity and toxicokinetic study of ponzemab (PF-04360365) in cynomolgus monkeys with 12-week recovery period. <i>Journal of Alzheimer's Disease</i> . 2012;28(3):531-41.	1
292	Freeman SH, Raju S, Hyman BT, Frosch MP, Irizarry MC. Plasma Abeta levels do not reflect brain Abeta levels. <i>Journal of Neuropathology & Experimental Neurology</i> . 2007;66(4):264-71.	6
293	Frigerio CS, Lau P, Salta E, Tournoy J, Bossers K, Vandenberghe R, et al. Reduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease. <i>Neurology</i> . 2013;81(24):2103-6.	7
294	Frisoni GB, Galluzzi S, Signorini M, Garibotto V, Paghera B, Binetti G, et al. Preliminary evidence of validity of the revised criteria for Alzheimer disease diagnosis: report of 2 cases. <i>Alzheimer Disease & Associated Disorders</i> . 2010;24(1):108-14.	7
295	Fritsch SK, Langer F, Kaeser SA, Maia LF, Portelius E, Pinotsi D, et al. Highly potent soluble amyloid-beta seeds in human Alzheimer brain but not cerebrospinal fluid. <i>Brain</i> . 2014;137(11):2909-15.	7
296	Fronek K, Lange P, Spreer A, Eiffert H, Nau R. Bacterial contamination and the transport vial material affect cerebrospinal fluid concentrations of beta-Amyloid and Tau protein as determined by enzyme immunoassay. <i>Dementia & Geriatric Cognitive Disorders</i> . 2011;32(2):126-34.	7
297	Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, et al. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. <i>Journal of Neuroscience</i> . 2005;25(11):2803-10.	1
298	Fu XJ. Determination of tau protein and beta-amyloid 42 in cerebrospinal fluid of cognitive handicap patients with cerebral infarction and diabetes mellitus. [Chinese]. <i>Chinese Journal of Clinical Rehabilitation</i> . 2005;9(9):92-4.	3
299	Fukumoto H, Tokuda T, Kasai T, Ishigami N, Hidaka H, Kondo M, et al. High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. <i>FASEB Journal</i> . 2010;24(8):2716-26.	7
300	Fukuyama R, Mizuno T, Mori S, Nakajima K, Fushiki S, Yanagisawa K. Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer's disease patients. <i>European Neurology</i> . 2000;43(3):155-60.	7

연번	서지정보	배제 사유
301	Fuller SJ, Storey E, Li QX, Smith AI, Beyreuther K, Masters CL. Intracellular production of beta A4 amyloid of Alzheimer's disease: modulation by phosphoramidon and lack of coupling to the secretion of the amyloid precursor protein. <i>Biochemistry</i> . 1995;34(25):8091-8.	7
302	Funke SA, Birkmann E, Willbold D. Detection of amyloid-beta aggregates in body fluids: A suitable method for early diagnosis of Alzheimer's disease? <i>Current Alzheimer Research</i> . 2009;6(3):285-9.	2
303	Funke SA, Willbold D. Quantitation of amyloid-beta oligomers in human body fluids for alzheimer's disease: Early diagnosis or therapy monitoring? <i>Alzheimer's Disease Research Journal</i> . 2011;4(3):315-34.	2
304	Funke SA. Detection of soluble amyloid-beta oligomers and insoluble high-molecular-weight particles in CSF: Development of methods with potential for diagnosis and therapy monitoring of Alzheimer's disease. <i>International Journal of Alzheimer's Disease</i> . 2011;(no pagination)(151645).	2
305	Gabelle A, Jaussent I, Hirtz C, Navucet S, Grasselli C, Lehmann S, et al. CSF orexin-a/hypocretin-1 changes in the alzheimer disease process. Alzheimer's and dementia Conference: alzheimer's association international conference 2016 Canada Conference start: 20160722 Conference end: 20160728. 2016;12(7 Supplement):P476.	4
306	Gabelle A, Roche S, Geny C, Bennys K, Labauge P, Tholance Y, et al. Correlations between soluble alpha/beta forms of amyloid precursor protein and Abeta38, 40, and 42 in human cerebrospinal fluid. <i>Brain Research</i> . 2010;1357:175-83.	7
307	Gabelle A, Roche S, Geny C, Bennys K, Labauge P, Tholance Y, et al. Decreased sAbetaPPbeta, Abeta38, and Abeta40 cerebrospinal fluid levels in frontotemporal dementia. <i>Journal of Alzheimer's Disease</i> . 2011;26(3):553-63.	5
308	Gabelle A, Roche S, Lehmann S. CSF biomarkers: Proteomics investigations and clinical applications in neurodegenerative disorders. [French]. <i>Revue Neurologique</i> . 2009;165(3):213-22.	2
309	Gagni P, Sola L, Cretich M, Chiari M. Development of a high-sensitivity immunoassay for amyloid-beta 1-42 using a silicon microarray platform. <i>Biosensors & Bioelectronics</i> . 2013;47:490-5.	7
310	Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. <i>Archives of Neurology</i> . 1998;55(7):937-45.	8
311	Galasko D. Biological markers and the treatment of Alzheimer's disease. <i>Journal of Molecular Neuroscience</i> . 2001;17(2):119-25.	2
312	Galasko D. Cerebrospinal fluid biomarkers in Alzheimer disease: A fractional improvement? <i>Archives of Neurology</i> . 2003;60(9):1195-6.	2
313	Galasko D. Cerebrospinal fluid opens a window on Alzheimer disease. <i>Archives of Neurology</i> . 1999;56(6):655-6.	2
314	Galasko D. Expanding the repertoire of biomarkers for Alzheimer's disease: Targeted and non-targeted approaches. <i>Frontiers in Neurology</i> . 2015;6 (DEC) (no pagination)(256).	2
315	Galasko DR, Graff-Radford N, May S, Hendrix S, Cottrell BA, Sagi SA, et al. Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. <i>Alzheimer disease and associated disorders</i> . 2007;21(4):292-9.	7
316	Galeano P, Leal MC, Ferrari CC, Dalmasso MC, Martino Adami PV, Farias MI, et al. Chronic Hippocampal Expression of Notch Intracellular Domain Induces Vascular Thickening, Reduces Glucose Availability, and Exacerbates Spatial Memory Deficits in a Rat Model of Early Alzheimer. <i>Molecular Neurobiology</i> . 2018;55(11):8637-50.	1
317	Gallozzi S, Marcus K, Barkovits K. Amyloid-beta as a biomarker for Alzheimer's disease: Quantification methods in body fluids. <i>Expert Review of Proteomics</i> . 2015;12(4):343-54.	2
318	Gandbhir O, Sundaram P. Pre-Clinical Safety and Efficacy Evaluation of Amytrap, a Novel Therapeutic to Treat Alzheimers Disease. <i>Journal of Alzheimer's Disease Reports</i> . 2019;3(1):77-94.	6
319	Gandy S, Simon AJ, Steele JW, Lublin AL, Lah JJ, Walker LC, et al. Days to criterion as an indicator of toxicity associated with human alzheimer amyloid-beta oligomers. <i>Annals of Neurology</i> . 2010;68(2):220-30.	7

연번	서지정보	배제 사유
320	Gaozva Z, Antosova A, Kristofikova Z, Bartos A, Ricny J, Cechova L, et al. Attenuated antiaggregation effects of magnetite nanoparticles in cerebrospinal fluid of people with Alzheimer's disease. <i>Molecular BioSystems</i> . 2010;6(11):2200-5.	7
321	Garcia Barrado L, Coart E, Vanderstichele HMJ, Burzykowski T. Transferring Cut-off Values between Assays for Cerebrospinal Fluid Alzheimer's Disease Biomarkers. <i>Journal of Alzheimer's Disease</i> . 2015;49(1):187-99.	7
322	Garcia-Ayllon MS, Silveyra MX, Andreasen N, Brimijoin S, Blennow K, Saez-Valero J. Cerebrospinal fluid acetylcholinesterase changes after treatment with donepezil in patients with Alzheimer's disease. <i>Journal of Neurochemistry</i> . 2007;101(6):1701-11.	7
323	Gatson JW, Warren V, Abdelfattah K, Wolf S, Hynan LS, Moore C, et al. Detection of beta-amyloid oligomers as a predictor of neurological outcome after brain injury: Laboratory investigation. <i>Journal of Neurosurgery</i> . 2013;118(6):1336-42.	6
324	Gawinecka J, Schmitz M, Zerr I. Biomarkers in cerebrospinal fluid. <i>Neuromethods</i> . 2017;129:229-52.	2
325	Gelfanova V, Higgs RE, Dean RA, Holtzman DM, Farlow MR, Siemers ER, et al. Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry. <i>Briefings in Functional Genomics and Proteomics</i> . 2007;6(2):149-58.	7
326	Ghiso J, Tagliavini F, Timmers WF, Frangione B. Alzheimer's disease amyloid precursor protein is present in senile plaques and cerebrospinal fluid: immunohistochemical and biochemical characterization. <i>Biochemical & Biophysical Research Communications</i> . 1989;163(1):430-7.	7
327	Giedraitis V, Sundelof J, Irizarry MC, Garevik N, Hyman BT, Wahlund LO, et al. The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. <i>Neuroscience Letters</i> . 2007;427(3):127-31.	7
328	Gil-Bea FJ, Solas M, Solomon A, Mugueta C, Winblad B, Kivipelto M, et al. Insulin levels are decreased in the cerebrospinal fluid of women with prodromal Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> . 2010;22(2):405-13.	7
329	Gille B, Dedeene L, Stoops E, Demeyer L, Francois C, Lefever S, et al. Automation on an Open-Access Platform of Alzheimer's Disease Biomarker Immunoassays. <i>SLAS Technology</i> . 2018;23(2):188-97.	7
330	Gil-Navarro S, Llado A, Rami L, Castellvi M, Bosch B, Bargallo N, et al. Neuroimaging and biochemical markers in the three variants of primary progressive aphasia. <i>Dementia and Geriatric Cognitive Disorders</i> . 2013;35(1-2):106-17.	7
331	Giovannoni G, Nath A. Editorial: After the storm: Neurofilament levels as a surrogate endpoint for neuroaxonal damage. <i>Neurology</i> . 2011;76(14):1200-1.	2
332	Giuffrida ML, Tomasello MF, Pandini G, Caraci F, Battaglia G, Busceti C, et al. Monomeric s-amyloid interacts with type-1 insulin-like growth factor receptors to provide energy supply to neurons. <i>Frontiers in Cellular Neuroscience</i> . 2015;9 (AUGUST) (no pagination)(297).	1
333	Gleerup HS, Hasselbalch SG, Simonsen AH. Biomarkers for Alzheimer's disease in saliva: A systematic review. <i>Disease Markers</i> . 2019;2019 (no pagination)(4761054).	2
334	Glosova L, Hort J, Bojar M, Skoda D. Assessment of total tau protein, phospho-tau and beta amyloid in cerebrospinal fluid: The first experience of our laboratory. [Czech]. <i>Klinicka Biochemie a Metabolismus</i> . 2004;12(2):113-6.	3
335	Goldhardt O, Warnhoff I, Yakushev I, Begcevic I, Forstl H, Magdolen V, et al. Kallikrein-related peptidases 6 and 10 are elevated in cerebrospinal fluid of patients with Alzheimer's disease and associated with CSF-TAU and FDG-PET. <i>Translational Neurodegeneration</i> . 2019;8 (1) (no pagination)(25).	7
336	Gomez Tortosa E, Gonzalo I, Fanjul S, Cantarero S, Cuadrado N, Garcia Yebenes J, et al. Tau protein and beta-amyloid levels in dementia with Lewy bodies compared to Alzheimer's disease. [Spanish]. <i>Mapfre Medicina</i> . 2003;14(2):118-24.	3
337	Gomez-Tortosa E, Gonzalo I, Fanjul S, Sainz MJ, Cantarero S, Cemillan C, et al. Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease. <i>Archives of Neurology</i> . 2003;60(9):1218-22.	7
338	Goncalves I, Quintela T, Baltazar G, Almeida MR, Saraiva MJ, Santos CR. Transthyretin interacts with metallothionein 2. <i>Biochemistry</i> . 2008;47(8):2244-51.	1

연번	서지정보	배제 사유
339	Gonzales A, Decourt B, Walker A, Condjella R, Nural H, Sabbagh MN. Development of a specific ELISA to measure BACE1 levels in human tissues. <i>Journal of Neuroscience Methods</i> . 2011;202(1):70-6.	7
340	Gonzalez-Sanchez M, Jimenez J, Narvaez A, Antequera D, Llamas-Velasco S, Martin AHS, et al. Kynurenic acid levels are increased in the CSF of Alzheimer's disease patients. <i>Biomolecules</i> . 2020;10 (4) (no pagination)(571).	6
341	Goossens J, Bjerke M, Struyfs H, Niemantsverdriet E, Somers C, Van Den Bossche T, et al. No added diagnostic value of non-phosphorylated tau fraction (p-tau _{rel}) in CSF as a biomarker for differential dementia diagnosis. <i>Alzheimer's Research and Therapy</i> . 2017;9 (1) (no pagination)(49).	7
342	Gourmaud S, Paquet C, Dumurgier J, Pace C, Bouras C, Gray F, et al. Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: Links to cognitive decline. <i>Journal of Psychiatry and Neuroscience</i> . 2015;40(3):151-61.	7
343	Grant MKO, Handoko M, Rozga M, Brinkmalm G, Portelius E, Blennow K, et al. Human cerebrospinal fluid 6E10-immunoreactive protein species contain amyloid precursor protein fragments. <i>PLoS ONE [Electronic Resource]</i> . 2019;14(2):e0212815.	7
344	Gravina SA, Ho L, Eckman CB, Long KE, Otvos L, Jr., Younkin LH, et al. Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). <i>Journal of Biological Chemistry</i> . 1995;270(13):7013-6.	7
345	Gu H, Robison G, Hong L, Barrea R, Wei X, Farlow MR, et al. Increased beta-amyloid deposition in Tg-SWDI transgenic mouse brain following in vivo lead exposure. <i>Toxicology Letters</i> . 2012;213(2):211-9.	1
346	Gu H, Zhong Z, Jiang W, Du E, Dodel R, Farlow MR, et al. The role of choroid plexus in IVIG-induced beta-amyloid clearance. <i>Neuroscience</i> . 2014;270:168-76.	7
347	Guntert A, Campbell J, Saleem M, O'Brien DP, Thompson AJ, Byers HL, et al. Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> . 2010;21(2):585-96.	7
348	Guo HZ, Liang LP, Qu CQ. Sensitivity and specificity of proteins in cerebrospinal fluid for diagnosis of Alzheimer's disease. <i>Chinese Journal of Clinical Rehabilitation</i> . 2004;8(10):1982-3.	9
349	Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. <i>Nature Reviews Molecular Cell Biology</i> . 2007;8(2):101-12.	2
350	Hall A, Mattila J, Koikkalainen J, Lotjonen J, Wolz R, Scheltens P, et al. Predicting progression from cognitive impairment to alzheimer's disease with the disease state index. <i>Current Alzheimer Research</i> . 2015;12(1):69-79.	7
351	Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ. Total and phosphorylated tau protein as biological markers of Alzheimer's disease. <i>Experimental Gerontology</i> . 2010;45(1):30-40.	2
352	Hampel H, Goernitz A, Buerger K. Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein. <i>Brain Research Bulletin</i> . 2003;61(3):243-53.	2
353	Hampel H, O'Bryant SE, Molinuevo JL, Zetterberg H, Masters CL, Lista S, et al. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. <i>Nature Reviews Neurology</i> . 2018;14(11):639-52.	2
354	Hampel H, Shen Y. Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease. <i>Scandinavian Journal of Clinical & Laboratory Investigation</i> . 2009;69(1):8-12.	2
355	Han X, Fagan AM, Cheng H, Morris JC, Xiong C, Holtzman DM. Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. <i>Annals of Neurology</i> . 2003;54(1):115-9.	7
356	Hanes J, Kovac A, Kvartsberg H, Kontseikova E, Fialova L, Katina S, et al. Evaluation of a novel immunoassay to detect p-Tau Thr127 in the CSF to distinguish Alzheimer disease from other dementias. <i>Neurology</i> . 2020;24.	7
357	Hanisch K, Soininen H, Alafuzoff I, Hoffmann R. Analysis of human tau in cerebrospinal fluid. <i>Journal of Proteome Research</i> . 2010;9(3):1476-82.	7

연번	서지정보	배제 사유
358	Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, et al. CSF biomarkers of Alzheimer's disease concord with amyloid-beta PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. <i>Alzheimer's and Dementia</i> . 2018;14(11):1470-81.	7
359	Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, et al. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. <i>Neurobiology of Aging</i> . 2010;31(3):357-67.	7
360	Hanzel CE, Iulita MF, Eyjolfsson H, Hjorth E, Schultzberg M, Eriksdotter M, et al. Analysis of matrix metallo-proteases and the plasminogen system in mild cognitive impairment and Alzheimer's disease cerebrospinal fluid. <i>Journal of Alzheimer's Disease</i> . 2014;40(3):667-78.	7
361	Harari O, Cruchaga C, Kauwe JS, Ainscough BJ, Bales K, Pickering EH, et al. Phosphorylated tau-Abeta42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid. <i>Biological Psychiatry</i> . 2014;75(9):723-31.	7
362	Hardy J. CSF biomarking for diagnosis and treatment assessment in neurodegeneration. <i>Journal of Neurochemistry</i> . 2012;123(3):339-41.	2
363	Harigaya Y, Shoji M, Yamaguchi H, Hirai S, Takatama M. A study of beta protein precursor using antiserum against a synthetic peptide (1-28). <i>Progress in Clinical & Biological Research</i> . 1989;317:945-52.	7
364	Harr SD, Uhlir L, Hollister R, Hyman BT, Mendez AJ. Brain expression of apolipoproteins E, J, and A-I in Alzheimer's disease. <i>Journal of Neurochemistry</i> . 1996;66(6):2429-35.	7
365	Hartl D, Gu W, Mayhaus M, Pichler S, Schöpe J, Wagenpfeil S, et al. Amyloid-beta Protein Precursor Cleavage Products in Postmortem Ventricular Cerebrospinal Fluid of Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> . 2015;47(2):365-72.	7
366	Hata S, Omori C, Kimura A, Saito H, Kimura N, Gupta V, et al. Decrease in p3-Alc-beta37 and p3-Alc-beta40, products of Alc-beta generated by gamma-secretase cleavages, in aged monkeys and patients with Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> . 2019;5:740-50.	7
367	Hata S, Taniguchi M, Piao Y, Ikeuchi T, Fagan AM, Holtzman DM, et al. Multiple gamma-secretase product peptides are coordinately increased in concentration in the cerebrospinal fluid of a subpopulation of sporadic Alzheimer's disease subjects. <i>Molecular Neurodegeneration</i> . 2012;7 (1) (no pagination)(16).	7
368	Hayes CD, Dey D, Palavicini JP, Wang H, Araki W, Lakshmana MK. Chronic cladribine administration increases amyloid beta peptide generation and plaque burden in mice. <i>PLoS ONE [Electronic Resource]</i> . 2012;7(10):e45841.	1
369	He B, Chao Y, Tan EL, Li P. The application of aptasensors for the aging diseases diagnosis. <i>Current Immunology Reviews</i> . 2017;13(2):144-52.	2
370	He XF, Liu DX, Zhang Q, Liang FY, Dai GY, Zeng JS, et al. Voluntary exercise promotes glymphatic clearance of amyloid beta and reduces the activation of astrocytes and microglia in aged mice. <i>Frontiers in Molecular Neuroscience</i> . 2017;10 (no pagination)(144).	1
371	He Y, Sun SH, Chen RW, Guo YJ, He XW, Huang L, et al. Effects of epitopes combination and adjuvants on immune responses to anti-Alzheimer disease DNA vaccines in mice. <i>Alzheimer Disease and Associated Disorders</i> . 2005;19(4):171-7.	1
372	Head E, Barrett EG, Murphy MP, Das P, Nistor M, Sarsoza F, et al. Immunization with fibrillar Abeta(1-42) in young and aged canines: Antibody generation and characteristics, and effects on CSF and brain Abeta. <i>Vaccine</i> . 2006;24(15):2824-34.	1
373	Henjum K, Almdahl IS, Arskog V, Minthon L, Hansson O, Fladby T, et al. Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> . 2016;8 (1) (no pagination)(182).	7
374	Henjum K, Quist-Paulsen E, Zetterberg H, Blennow K, Nilsson LMG, Watne LO. CSF sTREM2 in delirium - Relation to Alzheimer's disease CSF biomarkers Abeta42, t-tau and p-tau 11 Medical and Health Sciences 1109 Neurosciences 11 Medical and Health Sciences 1103 Clinical Sciences. <i>Journal of Neuroinflammation</i> . 2018;15 (1) (no pagination)(304).	7

연번	서지정보	배제 사유
375	Henriksson T, Barbour RM, Braa S, Ward P, Fritz LC, Johnson-Wood K, et al. Analysis and quantitation of the beta-amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients with a monoclonal antibody-based immunoassay. <i>Journal of Neurochemistry</i> . 1991;56(3):1037-42.	7
376	Herbert MK, Aerts MB, Kuiperij HB, Claassen JAHR, Spies PE, Esselink RAJ, et al. Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias. <i>Alzheimer's and Dementia</i> . 2014;10(4):448-55.	7
377	Herbert MK, Kuiperij HB, Verbeek MM. Optimisation of the quantification of glutamine synthetase and myelin basic protein in cerebrospinal fluid by a combined acidification and neutralisation protocol. <i>Journal of Immunological Methods</i> . 2012;381(1-2):1-8.	7
378	Hermann DM, Keyvani K, Van De Nes J, Weimar C, Wiltfang J, Nitsch RM, et al. Clinical/scientific notes. <i>Neurology</i> . 2011;77(5):503-5.	2
379	Herskovits AZ, Locascio JJ, Peskind ER, Li G, Hyman BT. A Luminex assay detects amyloid beta oligomers in Alzheimer's disease cerebrospinal fluid. <i>PLoS ONE [Electronic Resource]</i> . 2013;8(7):e67898.	7
380	Herukka SK, Helisalmi S, Hallikainen M, Tervo S, Soininen H, Pirttilä T. CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI. <i>Neurobiology of Aging</i> . 2007;28(4):507-14.	7
381	Heslegrave A, Heywood W, Paterson R, Magdalinou N, Svensson J, Johansson P, et al. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. <i>Molecular Neurodegeneration</i> . 2016;11:3.	7
382	Heywood WE, Galimberti D, Bliss E, Sirka E, Paterson RW, Magdalinou NK, et al. Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. <i>Molecular Neurodegeneration</i> . 2015;10 (1) (no pagination)(64).	7
383	Higuchi M, Iwata N, Matsuba Y, Takano J, Suemoto T, Maeda J, et al. Mechanistic involvement of the calpain-calpastatin system in Alzheimer neuropathology. <i>FASEB Journal</i> . 2012;26(3):1204-17.	7
384	Hock C, Golombowski S, Muller-Spahn F, Naser W, Beyreuther K, Monning U, et al. Cerebrospinal fluid levels of amyloid precursor protein and amyloid beta-peptide in Alzheimer's disease and major depression - Inverse correlation with dementia severity. <i>European Neurology</i> . 1998;39(2):111-8.	7
385	Hock C, Maddalena A, Raschig A, Müller-Spahn F, Eschweiler G, Hager K, et al. Treatment with the selective muscarinic m1 agonist talsadine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. <i>Amyloid</i> . 2003;10(1):1-6.	7
386	Hoglund K, Wallin A, Blennow K. Effect of statins on beta-amyloid metabolism in humans: Potential importance for the development of senile plaques in Alzheimer's disease. <i>Acta Neurologica Scandinavica</i> . 2006;114(SUPPL. 185):87-92.	2
387	Hol EM, van Dijk R, Gerez L, Sluijs JA, Hobo B, Tonk MT, et al. Frameshifted beta-amyloid precursor protein (APP+1) is a secretory protein, and the level of APP+1 in cerebrospinal fluid is linked to Alzheimer pathology. <i>Journal of Biological Chemistry</i> . 2003;278(41):39637-43.	7
388	Holmberg B, Johnels B, Blennow K, Rosengren L. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. <i>Movement disorders : official journal of the Movement Disorder Society</i> . 2003;18(2):186-90.	7
389	Holttä M, Hansson O, Andreasson U, Hertze J, Minthon L, Nagga K, et al. Evaluating Amyloid-beta Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer's Disease. <i>PLoS ONE</i> . 2013;8 (6) (no pagination)(e66381).	7
390	Holttä M, Minthon L, Hansson O, Holmen-Larsson J, Pike I, Ward M, et al. An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of alzheimer's disease. <i>Journal of Proteome Research</i> . 2015;14(2):654-63.	7
391	Hong S, Quintero-Monzon O, Ostaszewski BL, Podlisny DR, Cavanaugh WT, Yang T, et al. Dynamic analysis of amyloid beta-protein in behaving mice reveals opposing changes in ISF versus parenchymal Abeta during age-related plaque formation. <i>Journal of Neuroscience</i> . 2011;31(44):15861-9.	1

연번	서지정보	배제 사유
392	Horak D, Hlidakova H, Hiraoui M, Taverna M, Proks V, Mazl Chanova E, et al. Monodisperse carboxyl-functionalized poly(ethylene glycol)-coated magnetic poly(glycidyl methacrylate) microspheres: Application to the immunocapture of beta-amyloid peptides. <i>Macromolecular Bioscience</i> . 2014;14(11):1590-9.	7
393	Hort J, Bartos A, Pirttila T, Scheltens P. Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe. <i>European Journal of Neurology</i> . 2010;17(1):90-6.	7
394	Hort J, Valis M, Waberzinek G, Talab R, Glossova L, Bojar M, et al. Proportion of tau protein to phosphorylated tau protein CSF levels in differential diagnosis of dementia. [German]. <i>Nervenarzt</i> . 2008;79(8):891-8.	3
395	Horvath I, Jia X, Johansson P, Wang C, Moskalenko R, Steinau A, et al. Pro-inflammatory S100A9 Protein as a Robust Biomarker Differentiating Early Stages of Cognitive Impairment in Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> . 2016;7(1):34-9.	7
396	Hov KR, Bolstad N, Idland AV, Zetterberg H, Blennow K, Chaudhry FA, et al. Cerebrospinal fluid S100B and Alzheimer's disease biomarkers in hip fracture patients with delirium. <i>Dementia and Geriatric Cognitive Disorders Extra</i> . 2017;7(3):374-85.	7
397	Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, et al. Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. <i>Acta Neuropathologica</i> . 2010;120(3):385-99.	2
398	Huang X, Huang K, Li Z, Bai D, Hao Y, Wu Q, et al. Electroacupuncture improves cognitive deficits and insulin resistance in an OLETF rat model of Al/D-gal induced aging model via the PI3K/Akt signaling pathway. <i>Brain Research</i> . 2020;1740 (no pagination)(146834).	1
399	Huang Y, Potter R, Sigurdson W, Santacruz A, Shih S, Ju YE, et al. Effects of age and amyloid deposition on Abeta dynamics in the human central nervous system. <i>Archives of Neurology</i> . 2012;69(1):51-8.	7
400	Hulstaert F, Blennow K, Ivanioiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. <i>Neurology</i> . 1999;52(8):1555-62.	8
401	Humpel C. Identifying and validating biomarkers for Alzheimer's disease. <i>Trends in Biotechnology</i> . 2011;29(1):26-32.	2
402	Huttenrauch M, Ogorek I, Klafki H, Otto M, Stadelmann C, Weggen S, et al. Glycoprotein NMB: a novel Alzheimer's disease associated marker expressed in a subset of activated microglia. <i>Acta Neuropathologica Communications</i> . 2018;6(1):108.	7
403	Huttunen HJ, Havas D, Peach C, Barren C, Duller S, Xia W, et al. The acyl-coenzyme A: cholesterol acyltransferase inhibitor CI-1011 reverses diffuse brain amyloid pathology in aged amyloid precursor protein transgenic mice. <i>Journal of Neuropathology & Experimental Neurology</i> . 2010;69(8):777-88.	1
404	Iannuzzi F, Sirabella R, Canu N, Maier TJ, Annunziato L, Matrone C. Fyn tyrosine kinase elicits amyloid precursor protein Tyr682 phosphorylation in neurons from Alzheimer's disease patients. <i>Cells</i> . 2020;9(8):1-21.	1
405	Ibach B, Haen E, Marienhagen J, Hajak G. Clioquinol treatment in familiar early onset of Alzheimer's disease: A case report. <i>Pharmacopsychiatry</i> . 2005;38(4):178-9.	7
406	Ikeda M, Yonemura K, Kakuda S, Tashiro Y, Fujita Y, Takai E, et al. Cerebrospinal fluid levels of phosphorylated tau and Abeta1-38/Abeta1-40/Abeta1-42 in Alzheimer's disease with PS1 mutations. <i>Amyloid</i> . 2013;20(2):107-12.	7
407	Ikeuchi T, Hirayama S, Miida T, Fukamachi I, Tokutake T, Ebinuma H, et al. Increased levels of soluble LR11 in cerebrospinal fluid of patients with alzheimer disease. <i>Dementia and Geriatric Cognitive Disorders</i> . 2010;30(1):28-32.	7
408	Inekci D, Henriksen K, Linemann T, Karsdal MA, Habib A, Bisgaard C, et al. Serum Fragments of Tau for the Differential Diagnosis of Alzheimer's Disease. <i>Current Alzheimer Research</i> . 2015;12(9):829-36.	7
409	Ingelsson M, Jesneck J, Irizarry MC, Hyman BT, Rebeck GW. Lack of association of the cholesterol 24-hydroxylase (CYP46) intron 2 polymorphism with Alzheimer's disease. <i>Neuroscience Letters</i> . 2004;367(2):228-31.	7

연번	서지정보	배제 사유
410	Ilores-Marcal LM, Viel TA, Buck HS, Nunes VA, Gozzo AJ, Cruz-Silva I, et al. Bradykinin release and inactivation in brain of rats submitted to an experimental model of Alzheimer's disease. <i>Peptides</i> . 2006;27(12):3363-9.	1
411	Iqbal K, Flory M, Khatoon S, Soininen H, Pirttilä T, Lehtovirta M, et al. Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. <i>Annals of Neurology</i> . 2005;58(5):748-57.	7
412	Irie K. New diagnostic method for Alzheimer's disease based on the toxic conformation theory of amyloid beta. <i>Bioscience, Biotechnology & Biochemistry</i> . 2020;84(1):1-16.	7
413	Irizarry MC, Deng A, Lleo A, Berezovska O, Von Arnim CA, Martin-Rehrmann M, et al. Apolipoprotein E modulates gamma-secretase cleavage of the amyloid precursor protein. <i>Journal of Neurochemistry</i> . 2004;90(5):1132-43.	7
414	Irvine GB, El-Agnaf OM, Shankar GM, Walsh DM. Protein aggregation in the brain: The molecular basis for Alzheimer's and Parkinson's diseases. <i>Molecular Medicine</i> . 2008;14(7-8):451-64.	2
415	Irwin DJ, Fedler J, Coffey CS, Caspell-Garcia C, Kang JH, Simuni T, et al. Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease. <i>Annals of Neurology</i> . 2020;88(3):574-87.	7
416	Ishii M, Kamel H, Iadecola C. Retinol Binding Protein 4 Levels Are Not Altered in Preclinical Alzheimer's Disease and Not Associated with Cognitive Decline or Incident Dementia. <i>Journal of Alzheimer's Disease</i> . 2019;67(1):257-63.	7
417	Iulita MF, Allard S, Richter L, Munter LM, Ducatenzeiler A, Weise C, et al. Intracellular Abeta pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study. <i>Acta Neuropathologica Communications</i> . 2014;2:61.	1
418	Iwatsubo T. Amyloid beta protein in plasma as a diagnostic marker for Alzheimer's disease. <i>Neurobiology of Aging</i> . 1998;19(2):161-3.	6
419	Jack CR, Jr., Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Lowe V, et al. Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. <i>Archives of Neurology</i> . 2012;69(7):856-67.	7
420	Jack CR. The transformative potential of plasma phosphorylated tau. <i>The Lancet Neurology</i> . 2020;19(5):373-4.	2
421	Jacobs KR, Lim CK, Blennow K, Zetterberg H, Chatterjee P, Martins RN, et al. Correlation between plasma and CSF concentrations of kynurenine pathway metabolites in Alzheimer's disease and relationship to amyloid-beta and tau. <i>Neurobiology of Aging</i> . 2019;80:11-20.	7
422	Janelidze S, Pannee J, Mikulskis A, Chiao P, Zetterberg H, Blennow K, et al. Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment. <i>JAMA Neurology</i> . 2017;74(12):1492-501.	7
423	Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, van Westen D, Jeromin A, et al. Plasma beta-amyloid in Alzheimer's disease and vascular disease. <i>Scientific Reports</i> . 2016;6:26801.	7
424	Janelidze S, Stomrud E, Smith R, Palmqvist S, Mattsson N, Airey DC, et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. <i>Nature Communications</i> . 2020;11 (1) (no pagination)(1683).	7
425	Janssens J, Vermeiren Y, Franssen E, Aerts T, Van Dam D, Engelborghs S, et al. Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis. <i>Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring</i> . 2018;10:172-81.	7
426	Jantarotnotai N, Ling A, Cheng J, Schwab C, McGeer PL, McLarnon JG. Upregulation and expression patterns of the angiogenic transcription factor ets-1 in Alzheimer's disease brain. <i>Journal of Alzheimer's Disease</i> . 2013;37(2):367-77.	7
427	Jellinger KA, Janetzky B, Attems J, Kienzl E. Biomarkers for early diagnosis of Alzheimer disease: 'ALzheimer ASSociated gene'--a new blood biomarker? <i>Journal of Cellular & Molecular Medicine</i> . 2008;12(4):1094-117.	2
428	Jellinger KA. Neurochemical biomarkers in the differential diagnosis of movement disorders. <i>Movement Disorders</i> . 2010;25(4):500.	2

연번	서지정보	배제 사유
429	Jellinger KA. New possibilities for early diagnosis of Alzheimer disease: "Alzheimer associated gene" and blood biomarkers. Psychogeriatrics Polska. 2007;4(4):159-77.	2
430	Jensen M, Basun H, Lannfelt L. Increased cerebrospinal fluid tau in patients with Alzheimer's disease. Neuroscience Letters. 1995;186(2-3):189-91.	7
431	Jensen M, Hartmann T, Engvall B, Wang R, Uljon SN, Sennvik K, et al. Quantification of Alzheimer amyloid beta peptides ending at residues 40 and 42 by novel ELISA systems. Molecular Medicine. 2000;6(4):291-302.	7
432	Jesse S, Brettschneider J, Sussmuth SD, Landwehrmeyer BG, von Arnim CA, Ludolph AC, et al. Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases. Journal of Neurology. 2011;258(6):1034-41.	7
433	Jesse S, Steinacker P, Cepek L, Arnim CV, Tuman H, Lehnert S, et al. Glial fibrillary acidic protein and protein S-100B: Different concentration pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer's disease and Creutzfeldt-Jakob disease. Journal of Alzheimer's Disease. 2009;17(3):541-51.	7
434	Jia JP, Meng R, Sun YX, Sun WJ, Ji XM, Jia LF. Cerebrospinal fluid tau, Aβ ₁₋₄₂ and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia. Neuroscience Letters. 2005;383(1-2):12-6.	7
435	Jiao F, Yi F, Wang Y, Zhang S, Guo Y, Du W, et al. The Validation of Multifactor Model of Plasma Aβ ₄₂ and Total-Tau in Combination With MoCA for Diagnosing Probable Alzheimer Disease. Frontiers in Aging Neuroscience. 2020;12 (no pagination)(212).	6
436	Jingami N, Asada-Utsugi M, Uemura K, Noto R, Takahashi M, Ozaki A, et al. Idiopathic normal pressure hydrocephalus has a different cerebrospinal fluid biomarker profile from Alzheimer's disease. Journal of Alzheimer's Disease. 2015;45(1):109-15.	7
437	Johansson A, Katzov H, Zetterberg H, Feuk L, Johansson B, Bogdanovic N, et al. Variants of CYP46A1 may interact with age and APOE to influence CSF Aβ ₄₂ levels in Alzheimer's disease. Human Genetics. 2004;114(6):581-7.	7
438	Johansson V, Jakobsson J, Fortgang RG, Zetterberg H, Blennow K, Cannon TD, et al. Cerebrospinal fluid microglia and neurodegenerative markers in twins concordant and discordant for psychotic disorders. European Archives of Psychiatry & Clinical Neuroscience. 2017;267(5):391-402.	7
439	Jongbloed W, Bruggink KA, Kester MI, Visser PJ, Scheltens P, Blankenstein MA, et al. Amyloid-beta oligomers relate to cognitive decline in Alzheimer's disease. Journal of Alzheimer's Disease. 2015;45(1):35-43.	7
440	Jongbloed W, van Dijk KD, Mulder SD, van de Berg WD, Blankenstein MA, van der Flier W, et al. Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease. Journal of Alzheimer's Disease. 2015;46(4):1103-10.	7
441	Jonsson M, Zetterberg H, Rolstad S, Edman A, Gouw AA, Bjerke M, et al. Low cerebrospinal fluid sulfatide predicts progression of white matter lesions - The LADIS study. Dementia and Geriatric Cognitive Disorders. 2012;34(1):61-7.	7
442	Kaerst L, Kuhlmann A, Wedekind D, Stoek K, Lange P, Zerr I. Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease. Journal of Alzheimer's Disease. 2014;38(1):63-73.	7
443	Kakuda N, Shoji M, Furukawa K, Ikeuchi T, Akazawa K, Takami M, et al. Altered gamma-secretase activity in mild cognitive impairment and Alzheimer's disease. EMBO Molecular Medicine. 2012;4(4):344-52.	7
444	Kalinina J, Cheon K, Stone J, Kennedy M, Forman M, Egan MF, et al. Acute administration of a BACE inhibitor in healthy humans results in a significant reduction of Aβ oligomers in cerebrospinal fluid. Alzheimer's and dementia Conference: Alzheimer's Association International Conference, AAIC 2017 United Kingdom. 2017;13(7):P574.	7
445	Kalm M, E. Abel, P. Wasling, J. Nyman, M.A. Hietala, D. Bremell, et al. Neurochemical evidence of potential neurotoxicity after prophylactic cranial irradiation. International Journal of Radiation Oncology Biology Physics. 2014. 89(3): p. 607-614.	7

연번	서지정보	배제 사유
446	Kamalainen A, Herukka SK, Hartikainen P, Helisalmi S, Moilanen V, Knuuttila A, et al. Cerebrospinal fluid biomarkers for Alzheimer's disease in patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis with the C9orf72 repeat expansion. <i>Dementia and Geriatric Cognitive Disorders</i> . 2015;39(5-6):287-93.	7
447	Kamali-Moghaddam M, Pettersson FE, Wu D, Englund H, Darmanis S, Lord A, et al. Sensitive detection of Aβ ₄₂ protofibrils by proximity ligation—relevance for Alzheimer's disease. <i>BMC Neuroscience</i> . 2010;11:124.	1
448	Kameshima N, Nanjou T, Fukuhara T, Yanagisawa D, Tooyama I. Correlation of Aβ ₄₂ deposition in the nasal cavity with the formation of senile plaques in the brain of a transgenic mouse model of Alzheimer's disease. <i>Neuroscience Letters</i> .	1
449	Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, et al. Longitudinal study of cerebrospinal fluid levels of tau, Aβ ₄₀ , and Aβ ₄₂ (43) in Alzheimer's disease: A study in Japan. <i>Annals of Neurology</i> . 1998;44(1):17-26.	8
450	Kandimalla RJ, S P, Bk B, Wani WY, Sharma DR, Grover VK, et al. Cerebrospinal fluid profile of amyloid β ₄₂ (Aβ ₄₂), hTau and ubiquitin in North Indian Alzheimer's disease patients. <i>Neuroscience Letters</i> . 2011;487(2):134-8.	7
451	Kang JH, Korecka M, Figurski MJ, Toledo JB, Blennow K, Zetterberg H, et al. The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. <i>Alzheimer's and Dementia</i> . 2015;11(7):772-91.	2
452	Kang JH, Korecka M, Toledo JB, Trojanowski JQ, Shaw LM. Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β ₁₋₄₂ and tau proteins as Alzheimer disease biomarkers. <i>Clinical Chemistry</i> . 2013;59(6):903-16.	2
453	Kang JH, Korecka M, Toledo JB, Trojanowski JQ, Shaw LM. Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β ₁₋₄₂ and tau proteins as Alzheimer disease biomarkers. [Italian]. <i>Biochimica Clinica</i> . 2014;38(3):255-67.	2
454	Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease. <i>Methods</i> . 2012;56(4):484-93.	2
455	Kantarci A, Aytan N, Palaska I, Stephens D, Crabtree L, Benincasa C, et al. Combined administration of resolvin E1 and lipoxin A4 resolves inflammation in a murine model of Alzheimer's disease. <i>Experimental Neurology</i> . 2018;300:111-20.	1
456	Kapaki E, Kilidireas K, Paraskevas GP, Michalopoulou M, Patsouris E. Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: A discrimination from Alzheimer's disease? <i>Journal of Neurology Neurosurgery and Psychiatry</i> . 2001;71(3):401-3.	8
457	Kaplow J, Vandijck M, Gray J, Kanekiyo M, Huyck E, Traynham CJ, et al. Concordance of Lumipulse cerebrospinal fluid t-tau/Aβ ₄₂ ratio with amyloid PET status. <i>Alzheimer's and Dementia</i> . 2020;16(1):144-52.	7
458	Karadas O, Koc G, Ozon AO, Ozturk B, Konukoglu D. Biomarkers of Alzheimer's disease and vascular dementia simultaneously sampled from serum and cerebrospinal fluid. <i>Turk Geriatri Dergisi</i> . 2017;20(1):1-7.	7
459	Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. <i>Lancet Neurology</i> . 2020;19(5):422-33.	7
460	Kasai T, Kondo M, Ishii R, Tanaka A, Ataka S, Shimada H, et al. Aβ ₄₂ levels in the jugular vein and high molecular weight Aβ ₄₂ oligomer levels in CSF can be used as biomarkers to indicate the anti-amyloid effect of IVIg for Alzheimer's disease. <i>PLoS ONE [Electronic Resource]</i> . 2017;12(4):e0174630.	7
461	Kasai T, Tokuda T, Taylor M, Kondo M, Mann DM, Foulds PG, et al. Correlation of Aβ ₄₂ oligomer levels in matched cerebrospinal fluid and serum samples. <i>Neuroscience Letters</i> . 2013;551:17-22.	7
462	Kasai T, Tokuda T, Taylor M, Nakagawa M, Allsop D. Utilization of a multiple antigenic peptide as a calibration standard in the BAN50 single antibody sandwich ELISA for Aβ ₄₂ oligomers. <i>Biochemical and Biophysical Research Communications</i> . 2012;422(3):375-80.	7

연번	서지정보	배제 사유
463	Kasuga K, Tokutake T, Ishikawa A, Uchiyama T, Tokuda T, Onodera O, et al. Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry. 2010;81(6):608-10.	7
464	Katayama T, Sawada J, Kikuchi-Takeguchi S, Kano K, Takahashi K, Saito T, et al. Cerebrospinal fluid levels of alpha-synuclein, amyloid beta, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings. Neuroscience Letters. 2020;715 (no pagination):134564.	7
465	Kato M, Kawaguchi K, Nakai S, Murakami K, Hori H, Ohashi A, et al. Potential therapeutic system for Alzheimer's disease: removal of blood Abetas by hemodialyzers and its effect on the cognitive functions of renal-failure patients. Journal of Neural Transmission. 2012;119(12):1533-44.	7
466	Kaushik, A., R.D. Jayant, S. Tiwari, A. Vashist, and M. Nair. Nano-biosensors to detect beta-amyloid for Alzheimer's disease management. Biosensors and Bioelectronics, 2016. 80: p. 273-287.	2
467	Kauwe JS, Jacquart S, Chakraverty S, Wang J, Mayo K, Fagan AM, et al. Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. Annals of Neurology. 2007;61(5):446-53.	7
468	Kawarabayashi T, Shoji M. Biomarker and imaging of Alzheimer's disease. [Japanese]. No to shinkei. 2005;Brain and nerve. 57(10):839-52.	2
469	Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. Journal of Neuroscience. 2001;21(2):372-81.	1
470	Keating CD. Nanoscience enables ultrasensitive detection of Alzheimer's biomarker. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(7):2263-4.	2
471	Kehoe PG, Al Mulhim N, Zetterberg H, Blennow K, Miners JS. Cerebrospinal Fluid Changes in the Renin-Angiotensin System in Alzheimer's Disease. Journal of Alzheimer's disease : JAD. 2019;72(2):525-35.	7
472	Kelliny S, Lam HY, Parikh A, Wang YJ, Bobrovskaya L, Upton R, et al. Preclinical Study of the Pharmacokinetics of p75ECD-Fc, a Novel Human Recombinant Protein for Treatment of Alzheimer's Disease, in Sprague Dawley Rats. Current Drug Metabolism. 2020;21(3):235-44.	1
473	Kern S, Syrjanen JA, Blennow K, Zetterberg H, Skoog I, Waern M, et al. Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment. JAMA Neurology. 2019;76(2):187-93.	7
474	Keshavan A, Heslegrave A, Zetterberg H, Schott JM. Stability of blood-based biomarkers of Alzheimer's disease over multiple freeze-thaw cycles. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 2018;10:448-51.	7
475	Kevadiya BD, Ottemann BM, Thomas MB, Mukadam I, Nigam S, McMillan J, et al. Neurotheranostics as personalized medicines. Advanced Drug Delivery Reviews. 2019;148:252-89.	2
476	Khatoun S, Chalbot S, Bolognin S, Puolivali J, Iqbal K. Elevated Tau Level in Aged Rat Cerebrospinal Fluid Reduced by Treatment with a Neurotrophic Compound. Journal of Alzheimer's Disease. 2015;47(3):557-64.	1
477	Khoonsari PE, Shevchenko G, Herman S, Remnestal J, Giedraitis V, Brundin R, et al. Improved differential diagnosis of Alzheimer's disease by integrating elisa and mass spectrometry-based cerebrospinal fluid biomarkers. Journal of Alzheimer's Disease. 2019;67(2):639-51.	6
478	Khorkova OE, Pate K, Heroux J, Sahasrabudhe S. Modulation of amyloid precursor protein processing by compounds with various mechanisms of action: Detection by liquid phase electrochemiluminescent system. Journal of Neuroscience Methods. 1998;82(2):159-66.	7
479	Kim H, Lee JU, Kim S, Song S, Sim SJ. A Nanoplasmonic Biosensor for Ultrasensitive Detection of Alzheimer's Disease Biomarker Using a Chaotropic Agent. ACS Sensors. 2019;4(3):595-602.	6
480	Kim HD, Kong FK, Cao Y, Lewis TL, Kim H, Tang DC, et al. Immunization of Alzheimer model mice with adenovirus vectors encoding amyloid beta-protein and GM-CSF reduces amyloid load in the brain. Neuroscience Letters. 2004;370(2-3):218-23.	1

연번	서지정보	배제 사유
481	Kim HJ, Lim TS, Lee SM, Kim TS, Kim Y, An YS, et al. Cerebrospinal fluid levels of beta-amyloid 40 and beta-amyloid 42 are proportionately decreased in amyloid positron-emission tomography negative idiopathic normal-pressure hydrocephalus patients. <i>Journal of Clinical Neurology (Korea)</i> . 2019;15(3):353-9.	7
482	Kim HJ, Park KW, Kim TE, Im JY, Shin HS, Kim S, et al. Elevation of the Plasma Abeta40/Abeta42 Ratio as a Diagnostic Marker of Sporadic Early-Onset Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> . 2015;48(4):1043-50.	6
483	Kim W, Raya M, Visnick Y, Miro S, Saman S, Jackson B, et al. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. <i>Journal of Biological Chemistry</i> . 2012;287(6):3842-9.	7
484	Kim, H.D., J.A. Maxwell, F.K. Kong, D.C.C. Tang, and K.I. Fukuchi. Induction of anti-inflammatory immune response by an adenovirus vector encoding 11 tandem repeats of Abeta1-6: Toward safer and effective vaccines against Alzheimer's disease. <i>Biochemical and Biophysical Research Communications</i> , 2005. 336(1): p. 84-92.	7
485	Kirkwood CM, MacDonald ML, Schempf TA, Vatsavayi AV, Ikonovic MD, Koppel JL, et al. Altered levels of visinin-like protein 1 correspond to regional neuronal loss in Alzheimer disease and frontotemporal lobar degeneration. <i>Journal of Neuropathology and Experimental Neurology</i> . 2016;75(2):175-82.	7
486	Kitaguchi N, Tokushima Y, Oishi K, Takahashi Y, Shiojiri S, Nakamura S, et al. Determination of amyloid beta protein precursors harboring active form of proteinase inhibitor domains in cerebrospinal fluid of Alzheimer's disease patients by trypsin-antibody sandwich ELISA. <i>Biochemical and Biophysical Research Communications</i> . 1990;166(3):1453-9.	7
487	Kitazume S, Yoshihisa A, Yamaki T, Oikawa M, Tachida Y, Ogawa K, et al. Soluble amyloid precursor protein 770 is released from inflamed endothelial cells and activated platelets: A novel biomarker for acute coronary syndrome. <i>Journal of Biological Chemistry</i> . 2012;287(48):40817-25.	6
488	Klafki HW, Hafermann H, Bauer C, Haussmann U, Kraus I, Schuchhardt J, et al. Validation of a Commercial Chemiluminescence Immunoassay for the Simultaneous Measurement of Three Different Amyloid-beta Peptides in Human Cerebrospinal Fluid and Application to a Clinical Cohort. <i>Journal of Alzheimer's Disease</i> . 2016;54(2):691-705.	7
489	Klafki HW, Lewczuk P, Kamrowski-Kruck H, Maler JM, Muller K, Peters O, et al. Measurement of ERK 1/2 in CSF from patients with neuropsychiatric disorders and evidence for the presence of the activated form. <i>Journal of Alzheimer's Disease</i> . 2009;18(3):613-22.	7
490	Klener J, Hofbauerova K, Bartos A, Ricny J, Ripova D, Kopecky V. Instability of cerebrospinal fluid after delayed storage and repeated freezing: a holistic study by drop coating deposition Raman spectroscopy. <i>Clinical Chemistry & Laboratory Medicine</i> . 2014;52(5):657-64.	7
491	Knapkog AB, Henjum K, Idland AV, Eldholm RS, Persson K, Saltvedt I, et al. Cerebrospinal fluid sTREM2 in Alzheimer's disease: comparisons between clinical presentation and AT classification. <i>Scientific Reports</i> . 2020;10(1):15886.	7
492	Kofanova OA, Mommaerts K, Betsou F. Tube Polypropylene: A Neglected Critical Parameter for Protein Adsorption During Biospecimen Storage. <i>Biopreservation and Biobanking</i> . 2015;13(4):296-8.	7
493	Koivunen J, Pirttilä T, Kemppainen N, Aalto S, Herukka SK, Jauhianen AM, Hänninen T, Hallikainen M, Nägren K, Rinne JO, Soininen H. PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. <i>Dement Geriatr Cogn Disord</i> . 2008;26(4):378-83.	7
494	Kokkinou M, Smailagic N, Noel-Storr AH, Hyde C, Ukoumunne O, Worrall RE, et al. Plasma and Cerebrospinal fluid (CSF) Abeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting. <i>Cochrane Database of Systematic Reviews</i> . 2014;2014 (1) (no pagination)(CD010945).	2
495	Kolarova M, Sengupta U, Bartos A, Ricny J, Kaye R. Tau Oligomers in Sera of Patients with Alzheimer's Disease and Aged Controls. <i>Journal of Alzheimer's Disease</i> . 2017;58(2):471-8.	7
496	Kollhoff AL, Howell JC, Hu WT. Automation vs. experience: Measuring Alzheimer's beta-amyloid 1-42 peptide in the CSF. <i>Frontiers in Aging Neuroscience</i> . 2018;10 (AUG) (no pagination)(253).	7

연번	서지정보	배제 사유
497	Kong XL, Zuo XY. Correlation analysis on beta amyloid protein and expression of amyloid precursor protein gene in 32 patients with Alzheimer disease for 3 years in Yimeng mountainous area. Chinese Journal of Clinical Rehabilitation. 2006;10(6):173-5.	7
498	Konno T, Hata S, Hamada Y, Horikoshi-Sakuraba Y, Nakaya T, Saito Y, et al. Coordinated increase of gamma-secretase reaction products in the plasma of some female Japanese sporadic Alzheimer's disease patients: Quantitative analysis of p3-Alcalpha with a new ELISA system. Molecular Neurodegeneration. 2011;6 (1) (no pagination)(76).	7
499	Koper OM, Kaminska J, Kemona H, Dymicka-Piekarska V. Application of the Bead-Based Technique in Neurodegeneration: A Literature Review. Neurodegenerative Diseases. 2015;15(5):281-93.	2
500	Korecka M, Waligorska T, Figurski M, Toledo JB, Arnold SE, Grossman M, et al. Qualification of a surrogate matrix-based absolute quantification method for amyloid-beta42 in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry. Journal of Alzheimer's disease : JAD. 2014;41(2):441-51.	6
501	Koric L, Felician O, Ceccaldi M. [Use of CSF biomarkers in the diagnosis of Alzheimer's disease in clinical practice]. Revue Neurologique. 2011;167(6-7):474-84.	2
502	Koric L, Felician O, Guedj E, Hubert AM, Mancini J, Boucraut J, et al. Could clinical profile influence CSF biomarkers in early-onset Alzheimer disease? Alzheimer Disease & Associated Disorders. 2010;24(3):278-83.	7
503	Korolainen MA, Pirttilä T. Cerebrospinal fluid, serum and plasma protein oxidation in Alzheimer's disease. Acta Neurologica Scandinavica. 2009;119(1):32-8.	7
504	Kou J, Kim H, Pattanayak A, Song M, Lim JE, Taguchi H, et al. Anti-Amyloid-beta Single-Chain Antibody Brain Delivery Via AAV Reduces Amyloid Load But May Increase Cerebral Hemorrhages in an Alzheimer's Disease Mouse Model. Journal of Alzheimer's Disease. 2011;27(1):23-38.	1
505	Koudinov AR, Berezov TT, Koudinova NV. The levels of soluble amyloid beta in different high density lipoprotein subfractions distinguish Alzheimer's and normal aging cerebrospinal fluid: implication for brain cholesterol pathology? Neuroscience Letters. 2001;314(3):115-8.	7
506	Kounnas MZ, Durakoglulugil MS, Herz J, Comer WT. NGP 555, a gamma-secretase modulator, shows a beneficial shift in the ratio of amyloid biomarkers in human cerebrospinal fluid at safe doses. Alzheimer's and Dementia: Translational Research and Clinical Interventions. 2019;5:458-67.	7
507	Kouzuki M, Asaina F, Taniguchi M, Musha T, Urakami K. The relationship between the diagnosis method of neuronal dysfunction (DIMENSION) and brain pathology in the early stages of Alzheimer's disease. Psychogeriatrics:The Official Journal of the Japanese Psychogeriatric Society. 2013;13(2):63-70.	7
508	Kristofikova Z, Bockova M, Hegnerova K, Bartos A, Klaschka J, Ricny J, et al. Enhanced levels of mitochondrial enzyme 17beta-hydroxysteroid dehydrogenase type 10 in patients with Alzheimer disease and multiple sclerosis. Molecular BioSystems. 2009;5(10):1174-9.	7
509	Kristofikova Z, Ricny J, Kolarova M, Vyhnaek M, Hort J, Laczó J, et al. Interactions between amyloid-beta and tau in cerebrospinal fluid of people with mild cognitive impairment and Alzheimer's disease. Journal of Alzheimer's Disease. 2014;42 Suppl 3:S91-8.	7
510	Kristofikova Z, Ricny J, Vyhnaek M, Hort J, Laczó J, Sirova J, et al. Levels of 17beta-Hydroxysteroid Dehydrogenase Type 10 in Cerebrospinal Fluid of People with Mild Cognitive Impairment and Various Types of Dementias. Journal of Alzheimer's Disease. 2015;48(1):105-14.	6
511	Kristofikova Z, Ripova D, Bartos A, Bockova M, Hegnerova K, Ricny J, et al. Neuroinflammation and complexes of 17beta-hydroxysteroid dehydrogenase type 10 - amyloid beta in alzheimers disease. Current Alzheimer Research. 2013;10(2):165-73.	7
512	Kristofikova Z, Springer T, Gedeonova E, Hofmannova A, Ricny J, Hromadkova L, et al. Interactions of 17beta-Hydroxysteroid Dehydrogenase Type 10 and Cyclophilin D in Alzheimer's Disease. Neurochemical Research. 2020;45(4):915-27.	6
513	Kruse N, Schlossmacher MG, Schulz-Schaeffer WJ, Vanmechelen E, Vanderstichele H, El-Agnaf OM, et al. A First Tetraplex Assay for the Simultaneous Quantification of Total alpha-Synuclein, Tau, beta-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid. PLoS ONE [Electronic Resource]. 2016;11(4):e0153564.	7

연번	서지정보	배제 사유
514	Krut JJ, Zetterberg H, Blennow K, Cinque P, Hagberg L, Price RW, et al. Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections. <i>Journal of Neurology</i> . 2013;260(2):620-6.	7
515	Kuhlmann J, Andreasson U, Pannee J, Bjerke M, Portelius E, Leinenbach A, et al. CSF Abeta ₁₋₄₂ - an excellent but complicated Alzheimer's biomarker - a route to standardisation. <i>Clinica Chimica Acta</i> . 2016;16.	7
516	Kuhlmann J, Andreasson U, Pannee J, Bjerke M, Portelius E, Leinenbach A, et al. CSF Aβ ₁₋₄₂ - an excellent but complicated Alzheimer's biomarker - a route to standardisation. <i>Clinica Chimica Acta</i> . 2017;467:27-33.	2
517	Kulkarni AP, Govender DA, Kotwal GJ, Kellaway LA. Modulation of anxiety behavior by intranasally administered vaccinia virus complement control protein and curcumin in a mouse model of Alzheimer's disease. <i>Current Alzheimer Research</i> . 2011;8(1):95-113.	1
518	Kulstad JJ, Green PS, Cook DG, Watson GS, Reger MA, Baker LD, et al. Differential modulation of plasma beta-amyloid by insulin in patients with Alzheimer disease. <i>Neurology</i> . 2006;66(10):1506-10.	6
519	Kummer MP, Vogl T, Axt D, Griep A, Vieira-Saecker A, Jessen F, et al. Mrp14 deficiency ameliorates amyloid beta burden by increasing microglial phagocytosis and modulation of amyloid precursor protein processing. <i>Journal of Neuroscience</i> . 2012;32(49):17824-9.	1
520	Kunding AH, Busk LL, Webb H, Klafki HW, Otto M, Kutter JP, et al. Micro-droplet arrays for micro-compartmentalization using an air/water interface. <i>Lab on a Chip</i> . 2018;18(18):2797-805.	7
521	Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, et al. Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. <i>Journal of Biological Chemistry</i> . 1996;271(8):4077-81.	7
522	Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, Ohrfelt A, Andersson K, et al. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. <i>Alzheimer's and Dementia</i> . 2015;11(10):1180-90.	7
523	La Joie R, Bejanin A, Fagan AM, Ayakta N, Baker SL, Bourakova V, et al. Associations between [¹⁸ F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. <i>Neurology</i> . 2018;90(4):e282-e90.	7
524	Lachno DR, Evert BA, Maloney K, Willis BA, Talbot JA, Vandijck M, et al. Validation and Clinical Utility of ELISA Methods for Quantification of Amyloid-beta Peptides in Cerebrospinal Fluid Specimens from Alzheimer's Disease Studies. <i>Journal of Alzheimer's Disease</i> . 2015;45(2):527-42.	7
525	Lachno DR, Evert BA, Vanderstichele H, Robertson M, Demattos RB, Konrad RJ, et al. Validation of assays for measurement of amyloid-beta peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab. <i>Journal of Alzheimer's Disease</i> . 2013;34(4):897-910.	7
526	Laforce R, Bensaidane MR. Amyloid imaging for dementia in Canada. <i>Cmaj</i> . 2016;188(8):598-602.	7
527	Lahiri DK, Farlow MR, Hintz N, Utsuki T, Greig NH. Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease. <i>Acta Neurologica Scandinavica, Supplement</i> . 2000;102(176):60-7.	7
528	Laitera T, Kurki MI, Pursiheimo JP, Zetterberg H, Helisalmi S, Rauramaa T, et al. The expression of transthyretin and amyloid-beta protein precursor is altered in the brain of idiopathic normal pressure hydrocephalus patients. <i>Journal of Alzheimer's Disease</i> . 2015;48(4):959-68.	7
529	Lana E, Gellerbring A, Jung S, Nordberg A, Unger Lithner C, Darreh-Shori T. Homomeric and Heteromeric Abeta Species Exist in Human Brain and CSF Regardless of Alzheimer's Disease Status and Risk Genotype. <i>Frontiers in Molecular Neuroscience</i> . 2019;12 (no pagination)(176).	7
530	Lannfelt L, Basun H, Vigo-Pelfrey C, Wahlund LO, Winblad B, Lieberburg I, et al. Amyloid beta-peptide in cerebrospinal fluid in individuals with the Swedish Alzheimer amyloid precursor protein mutation. <i>Neuroscience Letters</i> . 1995;199(3):203-6.	7
531	Lannfelt L, Basun H, Wahlund LO, Rowe BA, Wagner SL. Decreased alpha-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer's disease. <i>Nature Medicine</i> . 1995;1(8):829-32.	7
532	Lanoiselee HM, Nicolas G, Wallon D, Rovelet-Lecrux A, Lacour M, Rousseau S, et al. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. <i>PLoS Medicine</i> . 2017;14 (3) (no pagination)(e1002270).	7

연번	서지정보	배제 사유
533	Lantero Rodriguez J, Karikari TK, Suarez-Calvet M, Troakes C, King A, Emersic A, et al. Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. <i>Acta Neuropathologica</i> . 2020;140(3):267-78.	6
534	Lanz TA, Salatto CT, Semproni AR, Marconi M, Brown TM, Richter KEG, et al. Peripheral elevation of IGF-1 fails to alter Abeta clearance in multiple in vivo models. <i>Biochemical Pharmacology</i> . 2008;75(5):1093-103.	1
535	Lanz TA, Schachter JB. Solid-phase extraction enhances detection of beta-amyloid peptides in plasma and enables Abeta quantification following passive immunization with Abeta antibodies. <i>Journal of Neuroscience Methods</i> . 2008;169(1):16-22.	7
536	Lashley T, Schott JM, Weston P, Murray CE, Wellington H, Keshavan A, et al. Molecular biomarkers of Alzheimer's disease: progress and prospects. <i>DMM Disease Models and Mechanisms</i> . 2018;11 (5) (no pagination)(dmm031781).	2
537	Laske C, Stellos K, Stransky E, Leyhe T, Gawaz M. Decreased plasma levels of granulocyte-colony stimulating factor (G-CSF) in patients with early alzheimer's disease. <i>Journal of Alzheimer's Disease</i> . 2009;17(1):115-23.	7
538	Laske C, Stransky E, Fritsche A, Eschweiler GW, Leyhe T. Inverse association of cortisol serum levels with T-tau, P-tau 181 and P-tau 231 peptide levels and T-tau/Abeta 1-42 ratios in CSF in patients with mild Alzheimer's disease dementia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> . 2009;259(2):80-5.	7
539	Laske C, Stransky E, Leyhe T, Eschweiler GW, Wittorf A, Richartz E, et al. Stage-dependent BDNF serum concentrations in Alzheimer's disease. <i>Journal of Neural Transmission</i> . 2006;113(9):1217-24.	7
540	Laske C. Alzheimer disease: Blood-based biomarkers in AD-a silver lining on the horizon. <i>Nature Reviews Neurology</i> . 2012;8(10):541-2.	2
541	Lasser R, Ostrowitzki S, Scheltens P, Boada M, Dubois B, Dorflinger E, et al. Efficacy and safety of gantenerumab in prodromal Alzheimer's disease: results from scarlet road-a global, multicenter trial. <i>Alzheimer's & dementia</i> . 2015;11(7 SUPPL. 1):P331-P2.	7
542	Lasser R, Scheltens P, Dubois B, Nikolcheva T, Retout S, Volz D, et al. Efficacy, safety and biomarker data from scarlet road-a global phase 3 study of gantenerumab in patients with prodromal ad. <i>American journal of geriatric psychiatry</i> . 2016;24(3):S161-S2.	7
543	Lauridsen C, Sando SB, Shabnam A, Moller I, Berge G, Grontvedt GR, et al. Cerebrospinal Fluid Levels of Amyloid Beta 1-43 in Patients with Amnesic Mild Cognitive Impairment or Early Alzheimer's Disease: A 2-Year Follow-Up Study. <i>Frontiers in aging neuroscience</i> . 2016;8:30.	7
544	Law LL, Rol RN, Schultz SA, Dougherty RJ, Edwards DF, Kosciak RL, et al. Moderate intensity physical activity associates with CSF biomarkers in a cohort at risk for Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> . 2018;10:188-95.	7
545	Law LL, Sprecher KE, Dougherty RJ, Edwards DF, Kosciak RL, Gallagher CL, et al. Cardiorespiratory Fitness Modifies Influence of Sleep Problems on Cerebrospinal Fluid Biomarkers in an At-Risk Cohort. <i>Journal of Alzheimer's Disease</i> . 2019;69(1):111-21.	7
546	Le Bastard N, Aerts L, Leurs J, Blomme W, De Deyn PP, Engelborghs S. No correlation between time-linked plasma and CSF Abeta levels. <i>Neurochemistry International</i> . 2009;55(8):820-5.	7
547	Le Bastard N, De Deyn PP, Engelborghs S. Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid. <i>Clinical Chemistry</i> . 2015;61(5):734-43.	7
548	Le Bastard N, Leurs J, Blomme W, De Deyn PP, Engelborghs S. Plasma amyloid-beta forms in Alzheimer's disease and non-Alzheimer's disease patients. <i>Journal of Alzheimer's Disease</i> . 2010;21(1):291-301.	6
549	Le Bastard N, Van Buggenhout M, De Leenheir E, Martin JJ, De Deyn PP, Engelborghs S. LOW specificity limits the use of the cerebrospinal fluid AB1-42/P-TAU181P ratio to discriminate alzheimer's disease from vascular dementia. <i>Journals of Gerontology Series A-Biological Sciences & Medical Sciences</i> . 2007;62(8):923-4; author reply 4-5.	2
550	Lee JM, Blennow K, Andreasen N, Laterza O, Modur V, Olander J, et al. The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. <i>Clinical Chemistry</i> . 2008;54(10):1617-23.	7

연번	서지정보	배제 사유
551	Lee SM, Hyeon JW, Kim SJ, Kim H, Noh R, Kim S, et al. Sensitivity and specificity evaluation of multiple neurodegenerative proteins for Creutzfeldt-Jakob disease diagnosis using a deep-learning approach. <i>Prion</i> . 2019;13(1):141-50.	5
552	Lehmann S, Delaby C, Paquet C, Gabelle A. Analytical challenges related to the use of biomarker ratios for the biological diagnosis of Alzheimer's disease. <i>Clinical Chemistry & Laboratory Medicine</i> . 2015;53(8):e175-7.	2
553	Lehmann S, Paquet C, Malaplate-Armand C, Magnin E, Schraen S, Quillard-Muraine M, et al. Diagnosis associated with Tau higher than 1200pg/mL: Insights from the clinical and laboratory practice. <i>Clinica Chimica Acta</i> . 2019;495:451-6.	7
554	Lehmann S, Schraen S, Quadrio I, Paquet C, Bombois S, Delaby C, et al. Impact of harmonization of collection tubes on Alzheimer's disease diagnosis. <i>Alzheimer's and Dementia</i> . 2014;Part S. 10(5):S390-S4.	7
555	Lehmann S, Teunissen CE. Editorial: Biomarkers of Alzheimer's disease: The present and the future. <i>Frontiers in Neurology</i> . 2016;7 (SEP) (no pagination)(158).	2
556	Leinenbach A, Pannetier J, Dulffer T, Huber A, Bittner T, Andreasson U, et al. Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-beta in Cerebrospinal fluid. <i>Clinical Chemistry</i> . 2014;60(7):987-94.	7
557	Leinonen V, Menon LG, Carroll RS, Dello Iacono D, Grevet J, Jaaskelainen JE, et al. Cerebrospinal fluid biomarkers in idiopathic normal pressure hydrocephalus. <i>International journal of Alzheimer's disease</i> . 2011;2011:312526.	7
558	Lelental N, Brandner S, Kofanova O, Blennow K, Zetterberg H, Andreasson U, et al. Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. <i>Journal of Alzheimer's Disease</i> . 2016;52(1):51-64.	2
559	Lemere CA, Beierschmitt A, Iglesias M, Spooner ET, Bloom JK, Leverone JF, et al. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. <i>American Journal of Pathology</i> . 2004;165(1):283-97.	1
560	Leoni V, Shafaati M, Salomon A, Kivipelto M, Bjorkhem I, Wahlund LO. Are the CSF levels of 24S-hydroxycholesterol a sensitive biomarker for mild cognitive impairment? <i>Neuroscience Letters</i> . 2006;397(1-2):83-7.	7
561	Letra L, Matafome P, Rodrigues T, Duro D, Lemos R, Baldeiras I, et al. Association between adipokines and biomarkers of Alzheimer's disease: A cross-sectional study. <i>Journal of Alzheimer's Disease</i> . 2019;67(2):725-35.	7
562	Leuzy A, Chiotis K, Hasselbalch SG, Rinne JO, de Mendonca A, Otto M, et al. Pittsburgh compound B imaging and cerebrospinal fluid amyloid-beta in a multicentre European memory clinic study. <i>Brain</i> . 2016;139(Pt 9):2540-53.	7
563	Lewczuk P, Beck G, Esselmann H, Bruckmoser R, Zimmermann R, Fiszer M, et al. Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides [4]. <i>Clinical Chemistry</i> . 2006;52(2):332-4.	2
564	Lewczuk P, Esselmann H, Bibl M, Beck G, Maler JM, Otto M, et al. Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: Original data and review of the literature. <i>Journal of Molecular Neuroscience</i> . 2004;23(1-2):115-22.	7
565	Lewczuk P, Esselmann H, Groemer TW, Bibl M, Maler JM, Steinacker P, et al. Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: Evidence of novel biomarkers in Alzheimer's disease. <i>Biological Psychiatry</i> . 2004;55(5):524-30.	7
566	Lewczuk P, Gaignaux A, Kofanova O, Ermann N, Betsou F, Brandner S, et al. Interlaboratory proficiency processing scheme in CSF aliquoting: Implementation and assessment based on biomarkers of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> . 2018;10 (1) (no pagination)(87).	7
567	Lewczuk P, Kornhuber J, Vanderstichele H, Vanmechelen E, Esselmann H, Bibl M, et al. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study. <i>Neurobiology of Aging</i> . 2008;29(6):812-8.	7
568	Lewczuk P, Kornhuber J, Vanmechelen E, Peters O, Heuser I, Maier W, et al. Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing. <i>Experimental Neurology</i> . 2010;223(2):366-70.	6

연번	서지정보	배제 사유
569	Lewczuk P, Kornhuber J. Do we still need positron emission tomography for early Alzheimer's disease diagnosis? Brain. 2016;139(11):e60.	7
570	Lewczuk P, Matzen A, Blennow K, Parnetti L, Molinuevo JL, Eusebi P, et al. Cerebrospinal Fluid Abeta42/40 Corresponds Better than Abeta42 to Amyloid PET in Alzheimer's Disease. Journal of Alzheimer's Disease. 2017;55(2):813-22.	7
571	Li D, Mielke MM. An Update on Blood-Based Markers of Alzheimer's Disease Using the SiMoA Platform. Neurology and Therapy. 2019;8(Supplement 2):73-82.	2
572	Li QX, Villemagne VL, Doecke JD, Rembach A, Sarros S, Varghese S, et al. Alzheimer's disease normative cerebrospinal fluid biomarkers validated in pet amyloid-beta characterized subjects from the australian imaging, biomarkers and lifestyle (AIBL) study. Journal of Alzheimer's Disease. 2015;48(1):175-87.	7
573	Li W, Zhang JW, Lu F, Ma MM, Wang JQ, Suo AQ, et al. Effects of telmisartan on the level of Abeta1-42, interleukin-1beta, tumor necrosis factor alpha and cognition in hypertensive patients with Alzheimer's disease. [Chinese]. National Medical Journal of China. 2012;92(39):2743-6.	3
574	Lidon L, Urrea L, Llorens F, Gil V, Alvarez I, Diez-fairen M, et al. Disease-specific changes in reelin protein and mRNA in neurodegenerative diseases. Cells. 2020;9 (5) (no pagination)(1252).	6
575	Liebsch F, Kulic L, Teunissen C, Shobo A, Ulku I, Engelschalt V, et al. Abeta34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression. Nature Communications. 2019;10 (1) (no pagination)(2240).	7
576	Liguori C, Olivola E, Pierantozzi M, Cerroni R, Galati S, Saviozzi V, et al. Cerebrospinal-fluid Alzheimer's disease biomarkers and blood-brain barrier integrity in a natural population of cognitive intact Parkinson's disease patients. CNS and Neurological Disorders - Drug Targets. 2017;16(3):339-45.	7
577	Lim ASP, Gaiteri C, Yu L, Sohail S, Swardfager W, Tasaki S, et al. Seasonal plasticity of cognition and related biological measures in adults with and without Alzheimer disease: Analysis of multiple cohorts. PLoS Medicine. 2018;15 (9) (no pagination)(e1002647).	7
578	Lim B, Sando SB, Grontvedt GR, Brathen G, Diamandis EP. Cerebrospinal fluid neuronal pentraxin receptor as a biomarker of long-term progression of Alzheimer's disease: a 24-month follow-up study. Neurobiology of Aging. 2020;93:97.e1-.e7.	7
579	Lim B, Tsolaki M, Soosaipillai A, Brown M, Zilakaki M, Tagaraki F, et al. Liquid biopsy of cerebrospinal fluid identifies neuronal pentraxin receptor (NPTXR) as a biomarker of progression of Alzheimer's disease. Clinical Chemistry and Laboratory Medicine. 2019.	7
580	Lim TS, Choi JY, Park SA, Youn YC, Lee HY, Kim BG, et al. Evaluation of coexistence of Alzheimer's disease in idiopathic normal pressure hydrocephalus using ELISA analyses for CSF biomarkers. BMC Neurology. 2014;14 (1) (no pagination)(66).	7
581	Lin YT, Cheng JT, Yao YC, Juo, Lo YK, Lin CH, et al. Increased total TAU but not amyloid-beta(42) in cerebrospinal fluid correlates with short-term memory impairment in Alzheimer's disease. Journal of Alzheimer's Disease. 2009;18(4):907-18.	7
582	Lin YT, Wu YC, Sun GC, Ho CY, Wong TY, Lin CH, et al. Effect of resveratrol on reactive oxygen species-induced cognitive impairment in rats with angiotensin II-induced early alzheimer's disease. Journal of Clinical Medicine. 2018;7 (10) (no pagination)(329).	1
583	Lindberg O, Martensson G, Stomrud E, Palmqvist S, Wahlund LO, Westman E, et al. Atrophy of the posterior subiculum is associated with memory impairment, Tau- and Abeta pathology in non-demented individuals. Frontiers in Aging Neuroscience. 2017;9 (SEP) (no pagination)(306).	7
584	Lins H, Wichart I, Bancher C, Wallesch CW, Jellinger KA, Rosler N. Immunoreactivities of amyloid beta peptide((1-42)) and total tau protein in lumbar cerebrospinal fluid of patients with normal pressure hydrocephalus. Journal of Neural Transmission. 2004;111(3):273-80.	7
585	Lista S, Toschi N, Baldacci F, Zetterberg H, Blennow K, Kilimann I, et al. Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study. Journal of Alzheimer's Disease. 2017;59(4):1327-34.	7
586	Liu L, Duff K. A technique for serial collection of cerebrospinal fluid from the cisterna magna in mouse. Journal of Visualized Experiments. 2008;21:10.	1

연번	서지정보	배제 사유
587	Liu L, He Q, Zhao F, Xia N, Liu H, Li S, et al. Competitive electrochemical immunoassay for detection of beta-amyloid (1-42) and total beta-amyloid peptides using p-aminophenol redox cycling. <i>Biosensors and Bioelectronics</i> . 2014;51:208-12.	7
588	Liu L, Orozco IJ, Planel E, Wen Y, Bretteville A, Krishnamurthy P, et al. A transgenic rat that develops Alzheimer's disease-like amyloid pathology, deficits in synaptic plasticity and cognitive impairment. <i>Neurobiology of Disease</i> . 2008;31(1):46-57.	1
589	Liu Q, Waltz S, Woodruff G, Ouyang J, Israel MA, Herrera C, et al. Effect of potent gamma-secretase modulator in human neurons derived from multiple presenilin 1-induced pluripotent stem cell mutant carriers. <i>JAMA Neurology</i> . 2014;71(12):1481-9.	7
590	Liu W, Bai X, Zhang A, Huang J, Xu S, Zhang J. Role of Exosomes in Central Nervous System Diseases. <i>Frontiers in Molecular Neuroscience</i> . 2019;12 (no pagination)(240).	2
591	Liu Z, Chen HH, Li TL, Xu L, Du HQ. A cross-sectional study on cerebrospinal fluid biomarker levels in cognitively normal elderly subjects with or without a family history of Alzheimer's disease. <i>CNS Neuroscience & Therapeutics</i> . 2013;19(1):38-42.	7
592	Ljubenkov PA, Staffaroni AM, Rojas JC, Allen IE, Wang P, Heuer H, et al. Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory. <i>Annals of Clinical and Translational Neurology</i> . 2018;5(10):1250-63.	7
593	Lleo A, Irwin DJ, Illan-Gala I, McMillan CT, Wolk DA, Lee EB, et al. A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes. <i>JAMA Neurology</i> . 2018;75(6):738-45.	7
594	Llorens F, Schmitz M, Karch A, Cramm M, Lange P, Gherib K, et al. Comparative analysis of cerebrospinal fluid biomarkers in the differential diagnosis of neurodegenerative dementia. <i>Alzheimer's and Dementia</i> . 2016;12(5):577-89.	2
595	Llorens F, Schmitz M, Varges D, Kruse N, Gotzmann N, Gmitterova K, et al. Cerebrospinal alpha-synuclein in alpha-synuclein aggregation disorders: tau/alpha-synuclein ratio as potential biomarker for dementia with Lewy bodies. <i>Journal of Neurology</i> . 2016;263(11):2271-7.	5
596	Llorens F, Schmitz M, Zerr I. Progress in CSF biomarker discovery in sCJD. <i>Oncotarget</i> . 2017;8(4):5666-7.	2
597	Lolli F, Mazzanti B, Rovero P, Papini AM. Synthetic peptides in the diagnosis of neurological diseases. <i>Current Protein and Peptide Science</i> . 2003;4(4):277-84.	2
598	Lopez-Font I, Boix CP, Zetterberg H, Blennow K, Saez-Valero J. Alterations in the Balance of Amyloid-beta Protein Precursor Species in the Cerebrospinal Fluid of Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> . 2017;57(4):1281-91.	7
599	Lopez-Perez O, Bernal-Martin M, Hernaiz A, Llorens F, Betancor M, Otero A, et al. BAMBI and CHGA in prion diseases: Neuropathological assessment and potential role as disease biomarkers. <i>Biomolecules</i> . 2020;10 (5) (no pagination)(706).	2
600	Lord A, Englund H, Soderberg L, Tucker S, Clausen F, Hillered L, et al. Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. <i>FEBS Journal</i> . 2009;276(4):995-1006.	7
601	Loureiro RM, Dumin JA, McKee TD, Austin WF, Fuller NO, Hubbs JL, et al. Efficacy of SPI-1865, a novel gamma-secretase modulator, in multiple rodent models. <i>Alzheimer's Research and Therapy</i> . 2013;5 (2) (no pagination)(19).	1
602	Lovestone S, Boada M, Dubois B, Hull M, Rinne JO, Huppertz HJ, et al. A phase II trial of tideglusib in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> . 2015;45(1):75-88.	7
603	Lu R, Tao R, Wang J, Zhu T, Guo W, Sun Y, et al. Reduced TRPC6 mRNA levels in the blood cells of patients with Alzheimer's disease and mild cognitive impairment. <i>Molecular Psychiatry</i> . 2018;23(3):767-76.	7
604	Lu Y, Hoyte K, Montgomery WH, Luk W, He D, Meilandt WJ, et al. Characterization of a sensitive mouse Abeta40 PD biomarker assay for Alzheimer's disease drug development in wild-type mice. <i>Bioanalysis</i> . 2016;8(10):1067-75.	1
605	Lucey BP, Gonzales C, Das U, Li J, Siemers ER, Slemmon JR, et al. An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-beta concentrations collected by lumbar puncture and indwelling lumbar catheter. <i>Alzheimer's Research & Therapy</i> . 2015;7(1):53.	7

연번	서지정보	배제 사유
606	Lucey BP, Mawuenyega KG, Patterson BW, Elbert DL, Ovod V, Kasten T, et al. Associations Between beta-Amyloid Kinetics and the beta-Amyloid Diurnal Pattern in the Central Nervous System. <i>JAMA Neurology</i> . 2017;74(2):207-15.	7
607	Lue LF, Guerra A, Walker DG. Amyloid Beta and Tau as Alzheimer's Disease Blood Biomarkers: Promise From New Technologies. <i>Neurology and Therapy</i> . 2017;6(Supplement 1):25-36.	2
608	Lue LF, Kuo YM, Sabbagh M. Advance in Plasma AD Core Biomarker Development: Current Findings from Immunomagnetic Reduction-Based SQUID Technology. <i>Neurology and Therapy</i> . 2019;8(Supplement 2):95-111.	2
609	Luo X, Hou L, Shi H, Zhong X, Zhang Y, Zheng D, et al. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies. <i>Journal of Neurochemistry</i> . 2013;127(5):681-90.	7
610	Luo X, Shi H, Hou L, Zhong X, Chen X, Zhang Y, et al. Different cerebrospinal fluid levels of Alzheimer-type biomarker Abeta42 between general paresis and asymptomatic neurosyphilis. <i>European Journal of Neurology</i> . 2015;22(5):853-8.	7
611	Maarouf CL, Beach TG, Adler CH, Malek-Ahmadi M, Kokjohn TA, Dugger BN, et al. Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinson's disease cases lacking Alzheimer's disease pathology. <i>Biomarker Insights</i> . 2013;8:19-28.	7
612	Maccioni RB, Lavados M, Guillon M, Mujica C, Bosch R, Farias G, et al. Anomalous phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects. <i>Neurobiology of Aging</i> . 2006;27(2):237-44.	7
613	Maccioni RB, Lavados M, Maccioni CB, Mendoza-Naranjo A. Biological markers of Alzheimer's disease and mild cognitive impairment. <i>Current Alzheimer Research</i> . 2004;1(4):307-14.	2
614	Machaczka M, Arce MP, Rucinska M, Yoshitake T, Kehr J, Jurczak W, et al. A twelve-year follow-up study on a case of early-onset parkinsonism preceding clinical manifestation of Gaucher disease. <i>Jimd Reports</i> . 2012;3:53-7.	7
615	Maddalena A, Papassotiropoulos A, Muller-Tillmanns B, Jung HH, Hegi T, Nitsch RM, et al. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. <i>Archives of Neurology</i> . 2003;60(9):1202-6.	8
616	Maddalena, A.S., A. Papassotiropoulos, C. Gonzalez-Agosti, A. Signorell, T. Hegi, T. Pasch, et al. Cerebrospinal fluid profile of amyloid beta peptides in patients with Alzheimer's disease determined by protein biochip technology. <i>Neurodegenerative Diseases</i> , 2004. 1(4-5): p. 231-235.	7
617	Maetzler W, Berg D, Synofzik M, Brockmann K, Godau J, Melms A, et al. Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of lewy body-associated dementias. <i>Journal of Alzheimer's Disease</i> . 2011;26(1):171-9.	7
618	Maftei M, Thurm F, Leirer VM, von Arnim CA, Elbert T, Przybylski M, et al. Antigen-bound and free beta-amyloid autoantibodies in serum of healthy adults. <i>PLoS ONE [Electronic Resource]</i> . 2012;7(9):e44516.	7
619	Maftei M, Thurm F, Schnack C, Tuman H, Otto M, Elbert T, et al. Increased levels of antigen-bound beta-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer's disease patients. <i>PLoS ONE [Electronic Resource]</i> . 2013;8(7):e68996.	7
620	Magdalinou N, Lees AJ, Zetterberg H. Cerebrospinal fluid biomarkers in parkinsonian conditions: An update and future directions. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> . 2014;85(10):1065-75.	2
621	Majbour NK, Vaikath NN, van Dijk KD, Ardah MT, Varghese S, Vesterager LB, et al. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease. <i>Molecular Neurodegeneration</i> . 2016;11:7.	7
622	Maler JM, Klafki HW, Paul S, Spitzer P, Groemer TW, Henkel AW, et al. Urea-based two-dimensional electrophoresis of beta-amyloid peptides in human plasma: Evidence for novel Abeta species. <i>Proteomics</i> . 2007;7(20):3815-20.	6
623	Malnar M, Kosicek M, Bene R, Tarnik IP, Pavelin S, Babic I, et al. Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting. <i>Acta Neurobiologiae Experimentalis</i> . 2012;72(3):264-71.	7

연번	서지정보	배제 사유
624	Manczak M, Mao P, Nakamura K, Bebbington C, Park B, Reddy PH. Neutralization of granulocyte macrophage colony-stimulating factor decreases amyloid beta 1-42 and suppresses microglial activity in a transgenic mouse model of Alzheimer's disease. Human Molecular Genetics. 2009;18(20):3876-93.	1
625	Mandic G, Markovic I, Ostojic M, Stojkovic T, Misirlic-Dencic S, Zivanovic-Radnic T, et al. Cerebrospinal fluid amyloid beta and tau protein: Biomarkers for Alzheimer's disease. [Croatian]. Vojnosanitetski Pregled. 2008;65(12):901-5.	3
626	Manniche C, Simonsen AH, Hasselbalch SG, Andreasson U, Zetterberg H, Blennow K, et al. Cerebrospinal Fluid Biomarkers to Differentiate Idiopathic Normal Pressure Hydrocephalus from Subcortical Ischemic Vascular Disease. Journal of Alzheimer's Disease. 2020;75(3):937-47.	7
627	Marelli C, Hourregue C, Gutierrez LA, Paquet C, Menjot De Champfleure N, De Verbizier D, et al. Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia. Journal of Alzheimer's Disease. 2020;74(3):903-11.	7
628	Mares J, Kanovsky P, Herzig R, Stejskal D, Vavrouskova J, Hlustik P, et al. New laboratory markers in diagnosis of alzheimer dementia. Neurological research. 2009;31(10):1056-9.	7
629	Marksteiner J, Hinterhuber H, Humpel C. Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein. Drugs of Today. 2007;43(6):423-31.	2
630	Marksteiner J, Pirchl M, Ullrich C, Oberbauer H, Blasko I, Lederer W, et al. Analysis of cerebrospinal fluid of Alzheimer patients. Biomarkers and toxic properties. Pharmacology. 2008;82(3):214-20.	7
631	Martins RN, Muir J, Brooks WS, Creasey H, Montgomery P, Sellers P, et al. Plasma amyloid precursor protein is decreased in Alzheimer's disease. Neuroreport. 1993;4(6):757-9.	7
632	Martone RL, Snyder R, Xu ASL, Reams RY. The Analytical Aspects and Regulatory Challenges of Biomarker Discovery: Examples from the Field of Neurodegeneration. Current Translational Geriatrics and Gerontology Reports. 2012;1(2):94-103.	2
633	Maruyama M, Arai H, Sugita M, Tanji H, Higuchi M, Okamura N, et al. Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease. Experimental Neurology. 2001;172(2):433-6.	2
634	Matsubara E, Soto C, Governale S, Frangione B, Ghiso J. Apolipoprotein J and Alzheimer's amyloid beta solubility. Biochemical Journal. 1996;316(Pt 2):671-9.	7
635	Matsubara E. Biological marker for Alzheimer disease. [Japanese]. Brain and Nerve. 2010;62(7):769-75.	3
636	Matsui T, Nemoto M, Maruyama M, Yuzuriha T, Yao H, Tanji H, et al. Plasma homocysteine and risk of coexisting silent brain infarction in Alzheimer's disease. Neurodegenerative Diseases. 2005;2(6):299-304.	7
637	Mattsson N, Andreasson U, Carrillo MC, Persson S, Shaw LM, Zegers I, et al. Proficiency testing programs for Alzheimers disease cerebrospinal fluid biomarkers. Biomarkers in Medicine. 2012;6(4):401-7.	2
638	Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's & Dementia. 2011;7(4):386-95.e6.	7
639	Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, et al. CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's & Dementia. 2013;9(3):251-61.	7
640	Mattsson N, Tabatabaei S, Johansson P, Hansson O, Andreasson U, Mansson JE, et al. Cerebrospinal fluid microglial markers in Alzheimer's disease: Elevated chitotriosidase activity but lack of diagnostic utility. NeuroMolecular Medicine. 2011;13(2):151-9.	7
641	Mattsson N, Zegers I, Andreasson U, Bjerke M, Blankenstein MA, Bowser R, et al. Reference measurement procedures for Alzheimers disease cerebrospinal fluid biomarkers: Definitions and approaches with focus on amyloid 42. Biomarkers in Medicine. 2012;6(4):409-17.	2
642	Mattsson N, Zetterberg H. Alzheimer's disease and CSF biomarkers: Key challenges for broad clinical applications. Biomarkers in Medicine. 2009;3(6):735-7.	2

연번	서지정보	배제 사유
643	Matveeva EG, Moll JR, Khan MM, Thompson RB, Cliff RO. Surface Assay for Specific Detection of Soluble Amyloid Oligomers Utilizing Pronucleon Peptides Instead of Antibodies. ACS Chemical Neuroscience. 2017;8(6):1213-21.	7
644	May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, et al. Robust central reduction of amyloid-beta in humans with an orally available, non-peptidic beta-secretase inhibitor. Journal of Neuroscience. 2011;31(46):16507-16.	7
645	McLean CA, Beyreuther K, Masters CL. Amyloid Abeta levels in Alzheimer's disease - A diagnostic tool and the key to understanding the natural history of Abeta? Journal of Alzheimer's Disease. 2001;3(3):305-12.	2
646	Mehta PD, Blain JF, Freeman EA, Patrick BA, Barshatzky M, Hrdlicka LA, et al. Generation and Partial Characterization of Rabbit Monoclonal Antibody to Amyloid-beta Peptide 1-37 (Abeta37). Journal of Alzheimer's Disease. 2017;57(1):135-45.	1
647	Mehta PD, Patrick BA, Barshatzky M, Mehta SP, Frackowiak J, Mazur-Kolecka B, et al. Generation and Partial Characterization of Rabbit Monoclonal Antibody to Pyroglutamate Amyloid-beta3-42 (pE3-Abeta). Journal of Alzheimer's Disease. 2018;62(4):1635-49.	1
648	Mehta PD, Pirttila T, Patrick BA, Barshatzky M, Mehta SP. Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neuroscience Letters. 2001;304(1-2):102-6.	7
649	Mehta PD, Pirttila T. Increased cerebrospinal fluid A beta38/A beta42 ratio in Alzheimer disease. Neurodegenerative Diseases. 2005;2(5):242-5.	7
650	Mehta SH, Adler CH. Advances in Biomarker Research in Parkinson's Disease. Current Neurology and Neuroscience Reports. 2016;16(1):1-8.	2
651	Meleleo D, Galliani A, Notaracchille G. AbetaP1-42 incorporation and channel formation in planar lipid membranes: the role of cholesterol and its oxidation products. Journal of Bioenergetics & Biomembranes. 2013;45(4):369-81.	7
652	Meng Y, Li H, Hua R, Wang H, Lu J, Yu X, et al. A correlativity study of plasma APL1beta28 and clusterin levels with MMSE/MoCA/CASI in aMCI patients. Scientific Reports. 2015;5:15546.	2
653	Merrill CA, Jonsson MA, Minthon L, Egnell H, H CsS, Blennow K, et al. Vagus nerve stimulation in patients with Alzheimer's disease: Additional follow-up results of a pilot study through 1 year. Journal of Clinical Psychiatry. 2006;67(8):1171-8.	7
654	Mertens J, Stuber K, Wunderlich P, Ladewig J, Kesavan JC, Vandenberghe R, et al. APP processing in human pluripotent stem cell-derived neurons is resistant to NSAID-based gamma-secretase modulation. Stem Cell Reports. 2013;1(6):491-8.	7
655	Meyne F, Gloeckner SF, Ciesielczyk B, Heinemann U, Krasnianski A, Meissner B, et al. Total prion protein levels in the cerebrospinal fluid are reduced in patients with various neurological disorders. Journal of Alzheimer's Disease. 2009;17(4):863-73.	7
656	Mielke MM, Syrjanen JA, Blennow K, Zetterberg H, Skoog I, Vemuri P, et al. Comparison of variables associated with cerebrospinal fluid neurofilament, total-tau, and neurogranin. Alzheimer's and Dementia. 2019;15(11):1437-47.	7
657	Miklosy J, Khalili K, Gern L, Ericson RL, Darekar P, Bolle L, et al. Borrelia burgdorferi persists in the brain in chronic lyme neuroborreliosis and may be associated with Alzheimer disease. Journal of Alzheimer's Disease. 2004;6(6):639-49; discussion 73-81.	7
658	Mila-Aloma M, Salvado G, Gisbert JD, Vilor-Tejedor N, Grau-Rivera O, Sala-Vila A, et al. Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum. Alzheimer's and Dementia. 2020.	7
659	Miller BB, Mandell JW. Multiplex method for measuring biomarkers of Alzheimer disease in cerebrospinal fluid. Clinical Chemistry. 2005;51(2):289-90.	2
660	Miners JS, Kehoe PG, Love S, Zetterberg H, Blennow K. CSF evidence of pericyte damage in Alzheimer's disease is associated with markers of blood-brain barrier dysfunction and disease pathology. Alzheimer's Research and Therapy. 2019;11 (1) (no pagination)(81).	7
661	Minta K, Portelius E, Janelidze S, Hansson O, Zetterberg H, Blennow K, et al. Cerebrospinal fluid concentrations of extracellular matrix proteins in Alzheimer's disease. Journal of Alzheimer's Disease. 2019;69(4):1213-20.	7

연번	서지정보	배제 사유
662	Mitrasinovic OM, Perez GV, Zhao F, Lee YL, Poon C, Murphy Jr GM. Overexpression of Macrophage Colony-stimulating Factor Receptor on Microglial Cells Induces an Inflammatory Response. <i>Journal of Biological Chemistry</i> . 2001;276(32):30142-9.	7
663	Miyajima M, Nakajima M, Ogino I, Miyata H, Motoi Y, Arai H. Soluble amyloid precursor protein alpha in the cerebrospinal fluid as a diagnostic and prognostic biomarker for idiopathic normal pressure hydrocephalus. <i>European Journal of Neurology</i> . 2013;20(2):236-42.	6
664	Mizoi M, Yoshida M, Saiki R, Waragai M, Uemura K, Akatsu H, et al. Distinction between mild cognitive impairment and Alzheimer's disease by CSF amyloid beta40 and beta42, and protein-conjugated acrolein. <i>Clinica Chimica Acta</i> . 2014;430:150-5.	7
665	Mo JA, Lim JH, Sul AR, Lee M, Youn YC, Kim HJ. Cerebrospinal fluid β -amyloid1-42 levels in the differential diagnosis of Alzheimer's disease - Systematic review and meta-analysis. <i>PLoS ONE</i> . 2015;10 (2) (no pagination)(e0116802).	2
666	Modreanu R, Cerquera SC, Marti MJ, Rios J, Sanchez-Gomez A, Camara A, et al. Cross-sectional and longitudinal associations of motor fluctuations and non-motor predominance with cerebrospinal tau and Abeta as well as dementia-risk in Parkinson's disease. <i>Journal of the Neurological Sciences</i> . 2017;373:223-9.	7
667	Mohapatra D, Jena S, Prusty SK, Sahu PK. Biomarkers of alzheimer's disease: A review. <i>Systematic Reviews in Pharmacy</i> . 2020;11(6):151-7.	2
668	Moir RD, Atwood CS, Romano DM, Laurans MH, Huang X, Bush AI, et al. Differential effects of apolipoprotein E isoforms on metal-induced aggregation of A beta using physiological concentrations. <i>Biochemistry</i> . 1999;38(14):4595-603.	7
669	Mollenhauer B, Esselmann H, Roeber S, Schulz-Schaeffer WJ, Trenkwalder C, Bibl M, et al. Different CSF beta-amyloid processing in Alzheimer's and Creutzfeldt-Jakob disease. <i>Journal of Neural Transmission</i> . 2011;118(5):691-7.	7
670	Mollenhauer B, Parnetti L, Rektorova I, Kramberger MG, Pikkarainen M, Schulz-Schaeffer WJ, et al. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. <i>Journal of Neurochemistry</i> . 2016:290-317.	2
671	Mollenhauer B, Trenkwalder C, Von Ahsen N, Bibl M, Steinacker P, Brechlin P, et al. Beta-amyloid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. <i>Dementia and Geriatric Cognitive Disorders</i> . 2006;22(3):200-8.	7
672	Monacelli F, Borghi R, Pacini D, Serrati C, Traverso N, Odetti P. Pentosidine determination in CSF: a potential biomarker of Alzheimer's disease? <i>Clinical Chemistry & Laboratory Medicine</i> . 2014;52(1):117-20.	7
673	Monge-Argiles JA, Gasparini-Berenguer R, Gutierrez-Agullo M, Munoz-Ruiz C, Sanchez-Paya J, Leiva-Santana C. Influence of APOE Genotype on Alzheimer's Disease CSF Biomarkers in a Spanish Population. <i>BioMed Research International</i> . 2016;2016:1390620.	7
674	Monge-Argiles JA, Munoz-Ruiz C, Sanchez-Paya J, Gasparini Berenguer R, Blanco Canto ME, Leiva-Santana C. Comparison of two analytical platforms for CSF biomarkers of Alzheimer's disease. <i>BioMed Research International</i> . 2014;2014 (no pagination)(765130).	7
675	Monge-Argiles JA, Sanchez-Paya J, Munoz-Ruiz C, Pampliega-Perez A, Gomez-Lopez MJ, Rodriguez Borja E, et al. [Patients with mild cognitive impairment and a reduced CSF Abeta1-42 protein progress rapidly to Alzheimer's disease]. <i>Neurologia</i> . 2012;27(1):28-33.	3
676	Montine TJ. PD biomarkersg-use of alpha-synuclein reaches new levels. <i>Nature Reviews Neurology</i> . 2011;7(6):308-9.	2
677	Moreth J, Mavoungou C, Schindowski K. Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review. <i>Frontiers in Aging Neuroscience</i> . 2013;5 (JUL) (no pagination)(Article 25).	2
678	Motsinger-Reif AA, Zhu H, Kling MA, Matson W, Sharma S, Fiehn O, et al. Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer's disease from normal cognitive aging. <i>Acta neuropathologica communications</i> . 2013;1(1):28.	7
679	Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. <i>Annals of Neurology</i> . 1995;38(4):643-8.	7

연번	서지정보	배제 사유
680	Mouton-Liger F, Dumurgier J, Cognat E, Hourregue C, Zetterberg H, Vanderstichele H, et al. CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> . 2020;12 (1) (no pagination)(88).	7
681	Mouton-Liger F, Paquet C, Dumurgier J, Lapalus P, Gray F, Laplanche JL, et al. Increased Cerebrospinal Fluid Levels of Double-Stranded RNA-Dependant Protein Kinase in Alzheimer's Disease. <i>Biological Psychiatry</i> .	7
682	Mroczo B, Groblewska M, Zboch M, Kulczynska A, Koper OM, Szmitkowski M, et al. Concentrations of matrix metalloproteinases and their tissue inhibitors in the cerebrospinal fluid of patients with Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> . 2014;40(2):351-7.	6
683	Mroczo B, Groblewska M, Zboch M, Muszynski P, Zajkowska A, Borawska R, et al. Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> . 2015;43(3):1031-7.	7
684	Mukaetova-Ladinska EB, Abdel-All Z, Dodds S, Andrade J, Alves da Silva J, Kalaria RN, et al. Platelet immunoglobulin and amyloid precursor protein as potential peripheral biomarkers for Alzheimer's disease: findings from a pilot study. <i>Age & Ageing</i> . 2012;41(3):408-12.	7
685	Mukaetova-Ladinska EB, Li M, Kalaria RN. Tau protein, ischemic injury and vascular dementia. <i>Future Neurology</i> . 2015;10(6):559-75.	2
686	Mukaetova-Ladinska EB, Monteith R, Perry EK. Cerebrospinal fluid biomarkers for Dementia with Lewy Bodies. <i>International Journal of Alzheimer's Disease</i> . 2010;(no pagination)(536538).	2
687	Mulder SD, van der Flier WM, Verheijen JH, Mulder C, Scheltens P, Blankenstein MA, et al. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology. <i>Journal of Alzheimer's Disease</i> . 2010;20(1):253-60.	7
688	Mullan GM, McEneny J, Fuchs M, McMaster C, Todd S, McGuinness B, et al. Plasma clusterin levels and the rs11136000 genotype in individuals with mild cognitive impairment and Alzheimer's disease. <i>Current Alzheimer Research</i> . 2013;10(9):973-8.	7
689	Muller, M., J.A. Classen, H.B. Kuiperij, and M.M. Verbeek. Cerebrospinal fluid NrCAM is not a suitable biomarker to discriminate between dementia disorders—a pilot study. <i>Journal of Alzheimer's Disease</i> , 2015. 46(3): p. 605-609.	7
690	Mulugeta E, Londos E, Ballard C, Alves G, Zetterberg H, Blennow K, et al. CSF amyloid beta38 as a novel diagnostic marker for dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> . 2011;82(2):160-4.	7
691	Murakami K, Tokuda M, Suzuki T, Irie Y, Hanaki M, Izuo N, et al. Monoclonal antibody with conformational specificity for a toxic conformer of amyloid beta42 and its application toward the Alzheimer's disease diagnosis. <i>Scientific Reports</i> . 2016;6:29038.	7
692	Murphy GM, Jr., Zhao F, Yang L, Cordell B. Expression of macrophage colony-stimulating factor receptor is increased in the AβPP(V717F) transgenic mouse model of Alzheimer's disease. <i>American Journal of Pathology</i> . 2000;157(3):895-904.	1
693	Musaeus CS, Nielsen MS, Musaeus JS, Hogh P. Electroencephalographic Cross-Frequency Coupling as a Sign of Disease Progression in Patients With Mild Cognitive Impairment: A Pilot Study. <i>Frontiers in Neuroscience</i> . 2020;14 (no pagination)(790).	7
694	Muszynski P, Groblewska M, Kulczynska-Przybik A, Kulakowska A, Mroczo B. YKL-40 as a potential biomarker and a possible target in therapeutic strategies of Alzheimer's disease. <i>Current Neuropharmacology</i> . 2017;15(6):906-17.	2
695	Muszynski P, Kulczynska-Przybik A, Borawska R, Litman-Zawadzka A, Slowik A, Klimkowicz-Mrowiec A, et al. The Relationship between Markers of Inflammation and Degeneration in the Central Nervous System and the Blood-Brain Barrier Impairment in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> . 2017;59(3):903-12.	7
696	Nagata Y, Hirayama A, Ikeda S, Shirahata A, Shoji F, Maruyama M, et al. Comparative analysis of cerebrospinal fluid metabolites in Alzheimer's disease and idiopathic normal pressure hydrocephalus in a Japanese cohort. <i>Biomarker Research</i> . 2018;6 (1) (no pagination)(5).	7
697	Nagga K, Gottfries J, Blennow K, Marcusson J. Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia. <i>Dementia & Geriatric Cognitive Disorders</i> . 2002;14(4):183-90.	7

연번	서지정보	배제 사유
698	Nakamura T, Shoji M, Harigaya Y, Watanabe M, Hosoda K, Cheung TT, et al. Amyloid beta protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease. <i>Annals of Neurology</i> . 1994;36(6):903-11.	7
699	Nakayama Y, Morimoto S, Yoneda M, Kuzuhara S, Kokubo Y. Cerebrospinal fluid biomarkers for kii amyotrophic lateral sclerosis/parkinsonism-dementia complex. <i>Journal of Neurodegenerative Diseases</i> . 2013;(no pagination)(679089).	7
700	Nam E, Lee YB, Moon C, Chang KA. Serum tau proteins as potential biomarkers for the assessment of alzheimer's disease progression. <i>International Journal of Molecular Sciences</i> . 2020;21(14):1-20.	7
701	Namiki C, Hake A, Siemers E, Carlson C, Sundell K, Henley D, et al. Effects of solanezumab on biomarkers in patients with Alzheimer's disease. <i>Clinical neurology</i> . 2014;Conference: 55th Annual Meeting of the Japanese Society of Neurology. Japan. 54(pp S223).	4
702	Naveed M, Mubeen S, Khan A, Ibrahim S, Meer B. Plasma Biomarkers: Potent Screeners of Alzheimer's Disease. <i>American Journal of Alzheimer's Disease and other Dementias</i> . 2019;34(5):290-301.	2
703	Neergaard JS, Dragsbaek K, Christiansen C, Karsdal MA, Brix S, Henriksen K. Two novel blood-based biomarker candidates measuring degradation of tau are associated with dementia: A prospective study. <i>PLoS ONE [Electronic Resource]</i> . 2018;13(4):e0194802.	6
704	Newell AJ, Sue LI, Scott S, Rauschkolb PK, Walker DG, Potter PE, et al. Thiorphan-induced neprilysin inhibition raises amyloid beta levels in rabbit cortex and cerebrospinal fluid. <i>Neuroscience Letters</i> . 2003;350(3):178-80.	7
705	Nielsen MS, Simonsen AH, Siersma V, Hasselbalch SG, Hoegh P. The Diagnostic and Prognostic Value of a Dual-Tasking Paradigm in a Memory Clinic. <i>Journal of Alzheimer's Disease</i> . 2018;61(3):1189-99.	7
706	Niemantsverdriet E, Goossens J, Struyfs H, Martin JJ, Goeman J, De Deyn PP, et al. Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> . 2016;51(1):97-106.	7
707	Nikolcheva T, Lasser R, Ostrowitzki S, Scheltens P, Boada M, Dubois B, et al. CSF and amyloid pet biomarker data from scarlet road-a global phase 3 study of gantenerumab in patients with prodromal AD. <i>Neurobiology of aging</i> . 2016;39:S28-S9.	4
708	Nishida N, Nagata N, Toda H, Jingami N, Uemura K, Ozaki A, et al. Association of lipocalin-type prostaglandin D synthase with disproportionately enlarged subarachnoid-space in idiopathic normal pressure hydrocephalus. <i>Fluids and Barriers of the CNS</i> . 2014;11 (1) (no pagination)(9).	5
709	Noelker C, Hampel H, Dodel R. Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: Current progress and clinical potential. <i>Molecular Diagnosis and Therapy</i> . 2011;15(2):83-102.	2
710	Nordengen K, Kirsebom BE, Henjum K, Selnes P, Gisladdottir B, Wettergreen M, et al. Glial activation and inflammation along the Alzheimer's disease continuum. <i>Journal of Neuroinflammation</i> . 2019;16(1):46.	7
711	Nutu M, Bourgeois P, Zetterberg H, Portelius E, Andreasson U, Parent S, et al. Abeta1-15/16 as a potential diagnostic marker in neurodegenerative diseases. <i>NeuroMolecular Medicine</i> . 2013;15(1):169-79.	6
712	Nutu M, Zetterberg H, Londos E, Minthon L, Nagga K, Blennow K, et al. Evaluation of the cerebrospinal fluid amyloid-beta1-42/amyloid-beta1-40 ratio measured by alpha-LISA to distinguish Alzheimer's disease from other dementia disorders. <i>Dementia & Geriatric Cognitive Disorders</i> . 2013;36(1-2):99-110.	7
713	Oberstein TJ, Taha L, Spitzer P, Hellstern J, Herrmann M, Kornhuber J, et al. Imbalance of circulating T _H 17 and regulatory T cells in Alzheimer's disease: A case control study. <i>Frontiers in Immunology</i> . 2018;9 (JUN) (no pagination)(1213).	7
714	Oboudiyat C, Gefen T, Varelas E, Weintraub S, Rogalski E, Bigio EH, et al. Cerebrospinal fluid markers detect Alzheimer's disease in nonamnesic dementia. <i>Alzheimer's and Dementia</i> . 2017;13(5):598-601.	7
715	Obrocki P, Khatun A, Ness D, Senkevich K, Hanrieder J, Capraro F, et al. Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course - A joint PhD student course at University College London and University of Gothenburg. <i>Alzheimer's Research and Therapy</i> . 2020;12 (1) (no pagination)(20).	2

연번	서지정보	배제 사유
716	O'Bryant SE. Blood Biomarkers for Use in Alzheimer Disease – Moving from "if" to "how?". JAMA Neurology. 2019;76(9):1009–10.	2
717	Oe T, Ackermann BL, Inoue K, Berna MJ, Garner CO, Gelfanova V, et al. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry. Rapid Communications in Mass Spectrometry. 2006;20(24):3723–35.	7
718	Oeckl P, Otto M. A Review on MS-Based Blood Biomarkers for Alzheimer's Disease. Neurology and Therapy. 2019;8(Supplement 2):113–27.	2
719	Ohrfelt A, Grognet P, Andreasen N, Wallin A, Vanmechelen E, Blennow K, et al. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders—A marker of synapse loss? Neuroscience Letters. 2009;450(3):332–5.	7
720	Okamura N, Yanai K, Furukawa K, Arai H, Kudo Y. Biomarkers of neurological disease. [Japanese]. Japanese Journal of Clinical Pharmacology and Therapeutics. 2010;41(3):101–6.	3
721	Okonkwo OC, Alosco ML, Griffith HR, Mielke MM, Shaw LM, Trojanowski JQ, et al. Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: Normal aging, mild cognitive impairment, and Alzheimer disease. Archives of Neurology. 2010;67(6):688–96.	7
722	Okonkwo OC, Mielke MM, Griffith HR, Moghekar AR, O'Brien RJ, Shaw LM, et al. Cerebrospinal fluid profiles and prospective course and outcome in patients with amnesic mild cognitive impairment. Archives of Neurology. 2011;68(1):113–9.	7
723	Olah Z, Kalman J, Toth ME, Zvara A, Santha M, Ivitz E, et al. Proteomic analysis of cerebrospinal fluid in Alzheimer's disease: wanted dead or alive. Journal of Alzheimer's disease : JAD. 2015;44(4):1303–12.	7
724	Olsson A, Csajbok L, Ost M, Hoglund K, Nylen K, Rosengren L, et al. Marked increase of beta-amyloid(1–42) and amyloid precursor protein in ventricular cerebrospinal fluid after severe traumatic brain injury. Journal of Neurology. 2004;251(7):870–6.	7
725	Olsson A, Hoglund K, Sjogren M, Andreasen N, Minthon L, Lannfelt L, et al. Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Experimental Neurology. 2003;183(1):74–80.	7
726	Omori C, Kaneko M, Nakajima E, Akatsu H, Waragai M, Maeda M, et al. Increased levels of plasma p3-Alcalpha35, a major fragment of alcadeinalpha by gamma-secretase cleavage, in Alzheimer's disease. Journal of Alzheimer's Disease. 2014;39(4):861–70.	7
727	Ono K, Noguchi-Shinohara M, Samuraki M, Matsumoto Y, Yanase D, Iwasa K, et al. Blood-borne factors inhibit Alzheimer's beta-amyloid fibril formation in vitro. Experimental Neurology. 2006;202(1):125–32.	7
728	Ono K, Tsuji M. Protofibrils of amyloid-beta are important targets of a disease-modifying approach for alzheimer's disease. International Journal of Molecular Sciences. 2020;21 (3) (no pagination)(952).	2
729	Ota M, Imai K, Saito N, Ito F, Tsujisaki M, Sugiyama T, et al. Immunological study of Alzheimer's disease using anti-beta-protein monoclonal antibodies. [Japanese]. Japanese Journal of Geriatrics. 1993;30(1):23–9.	3
730	Otto M, Esselmann H, Schulz-Shaeffer W, Neumann M, Schroter A, Ratzka P, et al. Decreased beta-amyloid1–42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology. 2000;54(5):1099–102.	7
731	Ouwens DM, van Duinkerken E, Schoonenboom SN, Herzfeld de Wiza D, Klein M, van Golen L, et al. Cerebrospinal fluid levels of Alzheimer's disease biomarkers in middle-aged patients with type 1 diabetes. Diabetologia. 2014;57(10):2208–14.	7
732	Ou-Yang MH, Van Nostrand WE. The absence of myelin basic protein promotes neuroinflammation and reduces amyloid beta-protein accumulation in Tg-5xFAD mice. Journal of Neuroinflammation. 2013;10:134.	1
733	Ozerlat I. Alzheimer disease: CSF biomarkers could be used in Abeta immunotherapy trials for AD. Nature Reviews Neurology. 2012;8(6):297.	2

연번	서지정보	배제 사유
734	Padayachee ER, Zetterberg H, Portelius E, Boren J, Molinuevo JL, Andreasen N, et al. Cerebrospinal fluid-induced retardation of amyloid beta aggregation correlates with Alzheimer's disease and the APOE epsilon4 allele. Brain Research. 2016;1651:11-6.	7
735	Padmanabhan J, Levy M, Dickson DW, Potter H. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons. Brain. 2006;129(Pt 11):3020-34.	7
736	Palmert MR, Podlisny MB, Witker DS, Oltersdorf T, Younkin LH, Selkoe DJ, et al. The beta-amyloid protein precursor of Alzheimer disease has soluble derivatives found in human brain and cerebrospinal fluid. Proceedings of the National Academy of Sciences of the United States of America. 1989;86(16):6338-42.	7
737	Palmert MR, Usiak M, Mayeux R, Raskind M, Tourtellotte WW, Younkin SG. Soluble derivatives of the beta amyloid protein precursor in cerebrospinal fluid: alterations in normal aging and in Alzheimer's disease. Neurology. 1990;40(7):1028-34.	7
738	Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K, et al. Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related beta-Amyloid Status. JAMA Neurology. 2019;76(9):1060-9.	6
739	Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-Amyloid 42: A cross-validation study against amyloid positron emission tomography. JAMA Neurology. 2014;71(10):1282-9.	7
740	Palumbo B, Siepi D, Sabalich I, Tranfaglia C, Parnetti L. Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease? Functional Neurology. 2008;23(2):93-6.	7
741	Pannee J, Blennow K, Zetterberg H, Portelius E. Absolute Quantification of Abeta1-42 in CSF Using a Mass Spectrometric Reference Measurement Procedure. Journal of visualized experiments : JoVE. 2017(pagination).	6
742	Pannee J, Goborn J, Shaw LM, Korecka M, Chambers EE, Lane M, et al. Round robin test on quantification of amyloid-beta 1-42 in cerebrospinal fluid by mass spectrometry. Alzheimer's & Dementia. 2016;12(1):55-9.	7
743	Pannee J, Portelius E, Oppermann M, Atkins A, Hornshaw M, Zegers I, et al. A selected reaction monitoring (SRM)-based method for absolute quantification of Abeta38, Abeta40, and Abeta42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls. Journal of Alzheimer's Disease. 2013;33(4):1021-32.	7
744	Paquet C, Bouaziz-Amar E, Cognat E, Volpe-Gillot L, Haddad V, Mahieux F, et al. Distribution of cerebrospinal fluid biomarker profiles in patients explored for cognitive disorders. Journal of Alzheimer's Disease. 2018;64(3):889-97.	7
745	Paquet C, Dumurgier J, Hugon J. Pro-apoptotic kinase levels in cerebrospinal fluid as potential future biomarkers in Alzheimer's disease. Frontiers in Neurology. 2015;6 (Aug) (no pagination)(168).	7
746	Paranjape GS, Terrill SE, Gouwens LK, Ruck BM, Nichols MR. Amyloid-beta(1-42) protofibrils formed in modified artificial cerebrospinal fluid bind and activate microglia. Journal Of Neuroimmune Pharmacology: The Official Journal Of The Society On Neuroimmune Pharmacology. 2013;8(1):312-22.	7
747	Paraskevaidi M, Allsop D, Karim S, Martin FL, Crean S. Diagnostic biomarkers for alzheimer's disease using non-invasive specimens. Journal of Clinical Medicine. 2020;9 (6) (no pagination)(1673).	2
748	Paraskevas GP, Bougea A, Constantinides VC, Bourboulis M, Petropoulou O, Kapaki E. In vivo Prevalence of Alzheimer Biomarkers in Dementia with Lewy Bodies. Dementia & Geriatric Cognitive Disorders. 2019;47(4-6):289-96.	7
749	Paraskevas GP, Constantinides VC, Pyrgelis ES, Kapaki E. Mixed small vessel disease in a patient with dementia with lewy bodies. Brain Sciences. 2019;9 (7) (no pagination)(159).	7
750	Paraskevas GP, Kasselimis D, Kourtidou E, Constantinides V, Bougea A, Potagas C, et al. Cerebrospinal Fluid Biomarkers as a Diagnostic Tool of the Underlying Pathology of Primary Progressive Aphasia. Journal of Alzheimer's Disease. 2017;55(4):1453-61.	7

연번	서지정보	배제 사유
751	Park JC, Han SH, Lee H, Jeong H, Byun MS, Bae J, et al. Prognostic plasma protein panel for Abeta deposition in the brain in Alzheimer's disease. Progress in Neurobiology. 2019;183 (no pagination)(101690).	6
752	Parnetti L, Amici S, Lanari A, Romani C, Antognelli C, Andreasen N, et al. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. Neurological Sciences. 2002;23 Suppl 2:S95-6.	7
753	Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, De Carlo C, Qureshi MM, et al. Cerebrospinal fluid Tau/alpha-synuclein ratio in Parkinson's disease and degenerative dementias. Movement Disorders. 2011;26(8):1428-35.	7
754	Parnetti L, Lanari A, Amici S, Gallai V, Vanmechelen E, Hulstaert F. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2001;22(1):77-8.	6
755	Pascoal TA, Mathotaarachchi S, Kang MS, Mohaddes S, Shin M, Park AY, et al. Abeta-induced vulnerability propagates via the brain's default mode network. Nature Communications. 2019;10 (1) (no pagination)(2353).	7
756	Paternico D, Galluzzi S, Drago V, Bocchio-Chiavetto L, Zanardini R, Pedrini L, et al. Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults. Alzheimer's & Dementia. 2012;8(6):520-7.	7
757	Paterson RW, Heywood WE, Heslegrave AJ, Magdalinou NK, Andreasson U, Sirka E, et al. A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology. Translational Psychiatry. 2016;6 (11) (no pagination)(e952).	7
758	Paterson RW, Slattery CF, Magdalinou NK, Toombs J, Chapman MD, Lunn M, et al. Csf in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. Alzheimer's and dementia Conference: alzheimer's association international conference 2016 Canada Conference start: 20160722 Conference end: 20160728. 2016;12(7 Supplement):P203-P4.	4
759	Pedrinolla A, Venturelli M, Tamburin S, Fonte C, Stabile AM, Galazzo IB, et al. Non-abeta-dependent factors associated with global cognitive and physical function in alzheimer's disease: A pilot multivariate analysis. Journal of Clinical Medicine. 2019;8 (2) (no pagination)(224).	7
760	Peng HB, Noh K, Pan SR, Saldivia V, Serson S, Toscan A, et al. Human Amyloid- β_{40} Kinetics after Intravenous and Intracerebroventricular Injections and Calcitriol Treatment in Rats In Vivo. Drug Metabolism & Disposition. 2020;48(10):944-55.	1
761	Pera M, Alcolea D, Sanchez-Valle R, Guardia-Laguarta C, Colom-Cadena M, Badiola N, et al. Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease. Acta Neuropathologica. 2013;125(2):201-13.	7
762	Perez-Grijalba V, Fandos N, Canudas J, Insua D, Casabona D, Lacosta AM, et al. Validation of Immunoassay-Based Tools for the Comprehensive Quantification of Abeta40 and Abeta42 Peptides in Plasma. Journal of Alzheimer's Disease. 2016;54(2):751-62.	6
763	Perez-Grijalba V, Pesini P, Allue JA, Sarasa L, Montanes M, Lacosta AM, et al. A β 1-17 is a major amyloid- β fragment isoform in cerebrospinal fluid and blood with possible diagnostic value in Alzheimer's disease. Journal of Alzheimer's Disease. 2014;43(1):47-56.	7
764	Perez-Grijalba V, Pesini P, Allue JA, Sarasa L, Montanes M, Lacosta AM, et al. Abeta1-17 is a major amyloid-beta fragment isoform in cerebrospinal fluid and blood with possible diagnostic value in Alzheimer's disease. Journal of Alzheimer's Disease. 2015;43(1):47-56.	7
765	Pernecky R, Alexopoulos P. Soluble amyloid precursor proteins in blood: Methods and challenges. Neuromethods. 2018;137:179-87.	2
766	Pernecky R, Tsolakidou A, Arnold A, Diehl-Schmid J, Grimmer T, Forstl H, et al. CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease. Neurology. 2011;77(1):35-8.	7
767	Perret-Liaudet A, Pelpel M, Tholance Y, Dumont B, Vanderstichele H, Zorzi W, et al. Cerebrospinal fluid collection tubes: A critical issue for alzheimer disease diagnosis. Clinical Chemistry. 2012;58(4):787-9.	2

연번	서지정보	배제 사유
768	Perret-Liaudet A, Pelpel M, Tholance Y, Dumont B, Vanderstichele H, Zorzi W, et al. Risk of alzheimer's disease biological misdiagnosis linked to cerebrospinal collection tubes. Journal of Alzheimer's Disease. 2012;31(1):13-20.	7
769	Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE, et al. Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease. PLoS ONE. 2011;6 (1) (no pagination)(e16032).	7
770	Peskind ER, Leverenz J, Farlow MR, Ito RK, Provow SA, Siegel RS, et al. Clinicopathologic correlations of soluble amyloid beta-protein precursor in cerebrospinal fluid in patients with Alzheimer disease and controls. Alzheimer Disease and Associated Disorders. 1997;11(4):201-6.	7
771	Peskind ER, Li G, Shofer J, Quinn JF, Kaye JA, Clark CM, et al. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Archives of Neurology. 2006;63(7):936-9.	7
772	Petzold A, Verwey NA, van Uffelen K, Blankenstein MA, Teunissen C. Batch prepared protein standards for cerebrospinal fluid (CSF) biomarkers for neurodegeneration. Journal of Neuroscience Methods. 2010;193(2):296-9.	7
773	Petzold A. CSF biomarkers for improved prognostic accuracy in acute CNS disease. Neurological Research. 2007;29(7):691-708.	2
774	Pi J, Long Y, Huang N, Cheng Y, Zheng H. A sandwich immunoassay for detection of Abeta(1-42) based on quantum dots. Talanta. 2016;146:10-5.	7
775	Pillai A, Bruno D, Nierenberg J, Pandya C, Feng T, Reichert C, et al. Complement component 3 levels in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder. Biomarkers in Neuropsychiatry. 2019;1.	7
776	Pirttila T, Kim KS, Mehta PD, Frey H, Wisniewski HM. Soluble amyloid beta-protein in the cerebrospinal fluid from patients with Alzheimer's disease, vascular dementia and controls. Journal of the Neurological Sciences. 1994;127(1):90-5.	7
777	Pirttila T, Mehta PD, Soininen H, Kim KS, Heinonen O, Paljarvi L, et al. Cerebrospinal fluid concentrations of soluble amyloid beta-protein and apolipoprotein E in patients with Alzheimer's disease: correlations with amyloid load in the brain. Archives of Neurology. 1996;53(2):189-93.	6
778	Podlisny MB, Mammen AL, Schlossmacher MG, Palmert MR, Younkin SG, Selkoe DJ. Detection of soluble forms of the beta-amyloid precursor protein in human plasma. Biochemical & Biophysical Research Communications. 1990;167(3):1094-101.	7
779	Polanco JC, Li C, Bodea LG, Martinez-Marmol R, Meunier FA, Gotz J. Amyloid-beta and tau complexity - Towards improved biomarkers and targeted therapies. Nature Reviews Neurology. 2018;14(1):22-40.	2
780	Porro C, Trotta T, Panaro MA. Microvesicles in the brain: Biomarker, messenger or mediator? Journal of Neuroimmunology. 2015;288:70-8.	2
781	Portelius E, Brinkmalm G, Pannee J, Zetterberg H, Blennow K, Dahlen R, et al. Proteomic studies of cerebrospinal fluid biomarkers of Alzheimer's disease: an update. Expert Review of Proteomics. 2017;14(11):1007-20.	2
782	Portelius E, Brinkmalm G, Tran A, Andreasson U, Zetterberg H, Westman-Brinkmalm A, et al. Identification of novel N-terminal fragments of amyloid precursor protein in cerebrospinal fluid. Experimental Neurology. 2010;223(2):351-8.	7
783	Portelius E, Olsson B, Hoglund K, Cullen NC, Kvartsberg H, Andreasson U, et al. Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathologica. 2018;136(3):363-76.	7
784	Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, Persson R, et al. A novel pathway for amyloid precursor protein processing. Neurobiology of Aging. 2011;32(6):1090-8.	7
785	Portelius E, Soininen H, Andreasson U, Zetterberg H, Persson R, Karlsson G, et al. Exploring alzheimer molecular pathology in down's syndrome cerebrospinal fluid. Neurodegenerative Diseases. 2014;14(2):98-106.	7
786	Portelius E, Zetterberg H, Dean RA, Marciel A, Bourgeois P, Nutu M, et al. Amyloid-beta1-15/16 as a marker for -secretase inhibition in Alzheimer's disease. Journal of alzheimer's disease. 2012;31(2):335-41.	6

연번	서지정보	배제 사유
787	Portelius E, Zetterberg H, Gobom J, Andreasson U, Blennow K. Targeted proteomics in Alzheimer's disease: Focus on amyloid-beta. <i>Expert Review of Proteomics</i> . 2008;5(2):225-37.	2
788	Post A, Ackl N, Rucker M, Schreiber Y, Binder EB, Ising M, et al. Toward a reliable distinction between patients with mild cognitive impairment and Alzheimer-type dementia versus major depression. <i>Biological Psychiatry</i> . 2006;59(9):858-62.	7
789	Post A, Muller MB, Engelmann M, Keck ME. Repetitive transcranial magnetic stimulation in rats: evidence for a neuroprotective effect in vitro and in vivo. <i>European Journal of Neuroscience</i> . 1999;11(9):3247-54.	1
790	Pottiez G, Yang L, Stewart T, Song N, Aro P, Galasko DR, et al. Mass-Spectrometry-Based Method To Quantify in Parallel Tau and Amyloid beta 1-42 in CSF for the Diagnosis of Alzheimer's Disease. <i>Journal of Proteome Research</i> . 2017;16(3):1228-38.	6
791	Prabhakar S, Piatyszek R, Cirrito JR, Wu ZZ, Li CZ. Microbiosensor for Alzheimer's disease diagnostics: Detection of amyloid beta biomarkers. <i>Journal of Neurochemistry</i> . 2012;122(2):374-81.	7
792	Preishe O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. <i>Nature Medicine</i> . 2019;25(2):277-83.	6
793	Prince JA, Feuk L, Gu HF, Johansson B, Gatz M, Blennow K, et al. Genetic Variation in a Haplotype Block Spanning IDE Influences Alzheimer Disease. <i>Human Mutation</i> . 2003;22(5):363-71.	7
794	Prince JA, Zetterberg H, Andreasen N, Marcusson J, Blennow K. A-POE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. <i>Neurology</i> . 2004;62(11):2116-8.	7
795	Prior R, Monning U, Schreiter-Gasser U, Weidemann A, Blennow K, Gottfries CG, et al. Quantitative changes in the amyloid beta A4 precursor protein in Alzheimer cerebrospinal fluid. <i>Neuroscience Letters</i> . 1991;124(1):69-73.	7
796	Pyun JM, Kang MJ, Ryoo N, Suh J, Youn YC, Park YH, et al. Amyloid Metabolism and Amyloid-Targeting Blood-Based Biomarkers of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> . 2020;75(3):685-96.	2
797	Qiao F, Shang S, Li P, Chen C, Dang L, Jiang Y, et al. Elevation of Plasma Amyloid-beta Level is More Significant in Early Stage of Cognitive Impairment: A Population-Based Cross-Sectional Study. <i>Journal of Alzheimer's Disease</i> . 2018;64(1):61-9.	6
798	Qin W, Ho L, Wang J, Peskind E, Pasinetti GM. S100A7, a Novel Alzheimer's disease biomarker with non-amyloidogenic alpha-secretase activity acts via selective promotion of ADAM-10. <i>PLoS ONE</i> . 2009;4 (1) (no pagination)(e4183).	1
799	Qiu XY. Levels of tau protein and beta-amyloid 42 protein in cerebrospinal fluid and the levels of beta-amyloid 42 protein and transforming growth factor-alpha in serum of patients with vascular dementia. [Chinese]. <i>Chinese Journal of Clinical Rehabilitation</i> . 2005;9(16):122-4.	3
800	Qiu Z, Naten DL, Liston JC, Yess J, Rebeck GW. A novel approach for studying endogenous Abeta processing using cultured primary neurons isolated from APP transgenic mice. <i>Experimental Neurology</i> . 2001;170(1):186-94.	1
801	Quinn JF. Biomarkers for Alzheimer's disease: Showing the way or leading us astray? <i>Alzheimer's Disease: Advances For A New Century</i> . 2012;Advances in Alzheimer's Disease. 3:371-6.	2
802	Quintela T, Alves CH, Goncalves I, Baltazar G, Saraiva MJ, Santos CRA. 5alpha-dihydrotestosterone up-regulates transthyretin levels in mice and rat choroid plexus via an androgen receptor independent pathway. <i>Brain Research</i> . 2008;1229:18-26.	1
803	Rabelo AGB, Teixeira CVL, Magalhaes TNC, Carletti-Cassani AFMK, Amato Filho ACS, Joaquim HPG, et al. Is cerebral microbleed prevalence relevant as a biomarker in amnesic mild cognitive impairment and mild Alzheimer's disease? <i>Neuroradiology Journal</i> . 2017;30(5):477-85.	7
804	Raby CA, Morganti-Kossmann MC, Kossmann T, Stahel PF, Watson MD, Evans LM, et al. Traumatic brain injury increases beta-amyloid peptide 1-42 in cerebrospinal fluid. <i>Journal of Neurochemistry</i> . 1998;71(6):2505-9.	5
805	Radanovic M, Oshiro CA, Freitas TQ, Talib LL, Forlenza OV. Correlation between CSF biomarkers of Alzheimer's disease and global cognition in a psychogeriatric clinic cohort. <i>Brazilian Journal of Psychiatry</i> . 2019;41(6):479-84.	7

연번	서지정보	배제 사유
806	Raha-Chowdhury R, Henderson JW, Raha AA, Vuono R, Bickerton A, Jones E, et al. Choroid plexus acts as gatekeeper for TREM2, abnormal accumulation of ApoE, and fibrillary tau in Alzheimer's disease and in down syndrome dementia. <i>Journal of Alzheimer's Disease</i> . 2019;69(1):91-109.	6
807	Ramakers IH, Verhey FR, Scheltens P, Hampel H, Soininen H, Aalten P, et al. Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. <i>Psychological medicine</i> . 2013;43(5):911-20.	7
808	Rami L, Fortea J, Bosch B, Sole-Padullés C, Llado A, Iranzo A, et al. Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients. <i>Journal of Alzheimer's Disease</i> . 2011;23(2):319-26.	7
809	Ranaldi S, Caillava C, Prome S, Rubrecht L, Cobo S, Salvatat N, et al. N-truncated Abeta peptides in complex fluids unraveled by new specific immunoassays. <i>Neurobiology of Aging</i> . 2013;34(2):523-39.	7
810	Ray B, Reyes PF, Lahiri DK. Biochemical studies in Normal Pressure Hydrocephalus (NPH) patients: Change in CSF levels of amyloid precursor protein (APP), amyloid-beta (Abeta) peptide and phospho-tau. <i>Journal of Psychiatric Research</i> . 2011;45(4):539-47.	5
811	Rayford A, Rao JS, Festoff BW. Characterization of the serpin, alpha 1-antichymotrypsin, in normal human cerebrospinal fluid. <i>Journal of Neurochemistry</i> . 1992;58(1):88-94.	7
812	Reijls BLR, Vos SJB, Soininen H, Lotjonen J, Koikkalainen J, Pikkariainen M, et al. Association Between Later Life Lifestyle Factors and Alzheimer's Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study. <i>Journal of Alzheimer's Disease</i> . 2017;60(4):1387-95.	7
813	Reis T, Brandao CO, Freire Coutinho ES, Engelhardt E, Laks J. Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Geriatric Depression: Preliminary Findings from Brazil. <i>CNS Neuroscience and Therapeutics</i> . 2012;18(7):524-9.	7
814	Madeira C, Vargas-Lopes C, Brandão CO, Reis T, Laks J, Panizzutti R, Ferreira ST. Elevated Glutamate and Glutamine Levels in the Cerebrospinal Fluid of Patients With Probable Alzheimer's Disease and Depression. <i>Front Psychiatry</i> . 2018;9:561.	7
815	Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. <i>Neurobiology of Aging</i> . 2009;30(11):1728-36.	7
816	Rentzos M, Paraskevas GP, Kapaki E, Nikolaou C, Zoga M, Rombos A, et al. Interleukin-12 is reduced in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. <i>Journal of the Neurological Sciences</i> . 2006;249(2):110-4.	7
817	Richens JL, Spencer HL, Butler M, Cantlay F, Vere KA, Bajaj N, et al. Rationalising the role of Keratin 9 as a biomarker for Alzheimer's disease. <i>Scientific Reports</i> . 2016;6:22962.	6
818	Richens JL, Vere KA, Light RA, Soria D, Garibaldi J, Smith AD, et al. Practical detection of a definitive biomarker panel for Alzheimer's disease: comparisons between matched plasma and cerebrospinal fluid. <i>International Journal of Molecular Epidemiology and Genetics</i> . 2014;5(2):53-70.	7
819	Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. <i>Archives of Neurology</i> . 2002;59(11):1729-34.	7
820	Riemenschneider M, Wagenpfeil S, Diehl J, Lautenschlager N, Theml T, Heldmann B, et al. Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration. <i>Neurology</i> . 2002;58(11):1622-8.	8
821	Rinne JO, Suotunen T, Rummukainen J, Herukka SK, Nerg O, Koivisto AM, et al. [11C]PIB PET Is Associated with the Brain Biopsy Amyloid-beta Load in Subjects Examined for Normal Pressure Hydrocephalus. <i>Journal of Alzheimer's Disease</i> . 2019;67(4):1343-51.	7
822	Rissman RA, Trojanowski JQ, Shaw LM, Aisen PS. Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease. <i>Journal of Neural Transmission</i> . 2012;119(7):843-50.	2
823	Ritter A, Cummings J. Fluid biomarkers in clinical trials of Alzheimer's disease therapeutics. <i>Frontiers in Neurology</i> . 2015;6 (Aug) (no pagination)(186).	2
824	Robert M, Mathuranath P. Tau and tauopathies. <i>Neurology India</i> . 2007;55(1):11-6.	2

연번	서지정보	배제 사유
825	Roberts RF, Wade-Martins R. Can pathological oligomeric proteins make good biomarkers? (Commentary on Williams et al.). <i>European Journal of Neuroscience</i> . 2016;43(1):1-2.	2
826	Robinson RAS, Amin B, Guest PC. Multiplexing biomarker methods, proteomics and considerations for alzheimer's disease. <i>Advances in Experimental Medicine and Biology</i> . 2017;974:21-48.	2
827	Rogeberg M, Almdahl IS, Wettergreen M, Nilsson LN, Fladby T. Isobaric Quantification of Cerebrospinal Fluid Amyloid-beta Peptides in Alzheimer's Disease: C-Terminal Truncation Relates to Early Measures of Neurodegeneration. <i>Journal of Proteome Research</i> . 2015;14(11):4834-43.	7
828	Rohan Z, Smetakova M, Kukal J, Rusina R, Matej R. Proteinase-activated receptor 2 and disease biomarkers in cerebrospinal fluid in cases with autopsy-confirmed prion diseases and other neurodegenerative diseases. <i>BMC Neurology</i> . 2015;15 (1) (no pagination)(50).	7
829	Rojas JC, Bang J, Lobach IV, Tsai RM, Rabinovici GD, Miller BL, et al. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. <i>Neurology</i> . 2018;90(4):E273-E81.	7
830	Rolstad S, Nordlund A, Eckerstrom C, Gustavsson MH, Blennow K, Olesen PJ, et al. High education may offer protection against tauopathy in patients with mild cognitive impairment. <i>Journal of Alzheimer's Disease</i> . 2010;21(1):221-8.	7
831	Romeo, M.J., V. Espina, M. Lowenthal, B.H. Espina, I.E.F. Petricoin, and L.A. Liotta. CSF proteome: A protein repository for potential biomarker identification. <i>Expert Review of Proteomics</i> , 2005. 2(1): p. 57-70.	7
832	Rosales-Corral S, Tan DX, Reiter RJ, Valdivia-Velazquez M, Martinez-Barboza G, Acosta-Martinez JP, et al. Orally administered melatonin reduces oxidative stress and proinflammatory cytokines induced by amyloid-beta peptide in rat brain: A comparative, in vivo study versus vitamin C and E. <i>Journal of Pineal Research</i> . 2003;35(2):80-4.	1
833	Rosa-Neto P, Hsiung GYR, Masellis M. Fluid biomarkers for diagnosing dementia: Rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians. <i>Alzheimer's Research and Therapy</i> . 2013;5 (SUPPL. 1) (no pagination)(S8).	2
834	Rosen C, Hansson O, Blennow K, Zetterberg H. Fluid biomarkers in Alzheimer's disease - Current concepts. <i>Molecular Neurodegeneration</i> . 2013;8 (1) (no pagination)(20).	2
835	Rosenberg RN. Evolutionary time and human memory. <i>Journal of the American Medical Association</i> . 2002;288(23):3045-7.	2
836	Rosenberg RN. Time will be of the essence in treating alzheimer disease. <i>Journal of the American Medical Association</i> . 2006;296(3):327-9.	2
837	Rosler N, Wichart I, Jellinger KA. Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients. <i>Journal of Neural Transmission</i> . 2001;108(2):231-46.	8
838	Rosso SM, van Herpen E, Pijnenburg YA, Schoonenboom NS, Scheltens P, Heutink P, et al. Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations. <i>Archives of Neurology</i> . 2003;60(9):1209-13.	7
839	Rostgaard N, Roos P, Portelius E, Blennow K, Zetterberg H, Simonsen AH, et al. CSF neurofilament light concentration is increased in presymptomatic CHMP2B mutation carriers. <i>Neurology</i> . 2018;90(2):e157-e63.	7
840	Roubaud-Baudron C, Krolak-Salmon P, Quadrio I, Megraud F, Salles N. Impact of chronic <i>Helicobacter pylori</i> infection on Alzheimer's disease: preliminary results. <i>Neurobiology of Aging</i> . 2012;33(5):1009.e11-9.	7
841	Rozga M, Bittner T, Hoglund K, Blennow K. Accuracy of cerebrospinal fluid Abeta1-42 measurements: evaluation of pre-analytical factors using a novel Elecsys immunoassay. <i>Clinical Chemistry & Laboratory Medicine</i> . 2017;55(10):1545-54.	7
842	Rudinskiy N, Fuerer C, Demurtas D, Zamorano S, De Piano C, Herrmann AG, et al. Amyloid-beta oligomerization is associated with the generation of a typical peptide fragment fingerprint. <i>Alzheimer's & Dementia</i> . 2016;12(9):996-1013.	7

연번	서지정보	배제 사유
843	Ruetschi U, Zetterberg H, Podust VN, Gottfries J, Li S, Hviid Simonsen A, et al. Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. <i>Experimental Neurology</i> . 2005;196(2):273-81.	5
844	Russell CL, Mitra V, Hansson K, Blennow K, Gobom J, Zetterberg H, et al. Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass Spectrometry Provides New Biomarker Candidates. <i>Journal of Alzheimer's Disease</i> . 2017;55(1):303-13.	7
845	Sabbagh JJ, Kinney JW, Cummings JL. Alzheimer's disease biomarkers in animal models: Closing the translational gap. <i>American Journal of Neurodegenerative Diseases</i> . 2013;2(2):108-20.	2
846	Sabbagh MN. Editorial Introduction to the Special Issue from the International Symposium on Biomarkers for Alzheimer's Disease and Related Disorders. <i>Neurology and Therapy</i> . 2017;6(Supplement 1).	2
847	Salehi Z, Mashayekhi F, Naji M. Insulin like growth factor-1 and insulin like growth factor binding proteins in the cerebrospinal fluid and serum from patients with Alzheimer's disease. <i>Biofactors</i> . 2008;33(2):99-106.	7
848	Salvado G, Molinuevo JL, Brugulat-Serrat A, Falcon C, Grau-Rivera O, Suarez-Calvet M, et al. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. <i>Alzheimer's Research and Therapy</i> . 2019;11 (1) (no pagination)(27).	7
849	Sancesario GM, Esposito Z, Nuccetelli M, Bernardini S, Sorge R, Martorana A, et al. Abeta1-42 Detection in CSF of Alzheimer's disease is influenced by temperature: Indication of reversible Abeta1-42 aggregation? <i>Experimental Neurology</i> . 2010;223(2):371-6.	7
850	Sandelius A, Portelius E, Kallen A, Zetterberg H, Rot U, Olsson B, et al. Elevated CSF GAP-43 is Alzheimer's disease specific and associated with tau and amyloid pathology. <i>Alzheimer's & Dementia</i> . 2019;15(1):55-64.	7
851	Sanfilippo C, Forlenza O, Zetterberg H, Blennow K. Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD. <i>Journal of Neural Transmission</i> . 2016;123(12):1443-7.	7
852	Sankaranarayanan S, Holahan MA, Colussi D, Crouthamel MC, Devanarayan V, Ellis J, et al. First demonstration of cerebrospinal fluid and plasma Abeta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates. <i>Journal of Pharmacology and Experimental Therapeutics</i> . 2009;328(1):131-40.	1
853	Santos AN, Ewers M, Minthon L, Simm A, Silber RE, Blennow K, et al. Amyloid-beta oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> . 2012;29(1):171-6.	7
854	Santos, L.M., D. Rodrigues, M. Alemi, S.C. Silva, C.A. Ribeiro, and I. Cardoso. Resveratrol administration increases transthyretin protein levels, ameliorating AD features: The importance of transthyretin tetrameric stability. <i>Molecular Medicine</i> , 2016. 22: p. 597-607.	7
855	Saresella M, Marventano I, Piancone F, La Rosa F, Galimberti D, Fenoglio C, et al. IL-33 and its decoy sST2 in patients with Alzheimer's disease and mild cognitive impairment. <i>Journal of Neuroinflammation</i> . 2020;17 (1) (no pagination)(174).	6
856	Sarlus H, Eyjolfssdottir H, Eriksdotter M, Oprica M, Schultzberg M. Influence of Allergy on Immunoglobulins and Amyloid-beta in the Cerebrospinal Fluid of Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> . 2015;48(2):495-505.	7
857	Sarrafpour S, Ormseth C, Chiang A, Arakaki X, Harrington M, Fonteh A. Lipid metabolism in late-onset alzheimer's disease differs from patients presenting with other dementia phenotypes. <i>International Journal of Environmental Research and Public Health</i> . 2019;16 (11) (no pagination)(1995).	7
858	Savage MJ, Holder DJ, Wu G, Kaplow J, Siuciak JA, Potter WZ, et al. Soluble BACE-1 Activity and sAbetaPPbeta Concentrations in Alzheimer's Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer's Disease Neuroimaging Initiative-1 Baseline Cohort. <i>Journal of Alzheimer's Disease</i> . 2015;46(2):431-40.	7
859	Savage MJ, Kalinina J, Wolfe A, Tugusheva K, Korn R, Cash-Mason T, et al. A sensitive Abeta oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid. <i>Journal of Neuroscience</i> . 2014;34(8):2884-97.	6

연번	서지정보	배제 사유
860	Schaffer C, Sarad N, DeCrumpe A, Goswami D, Herrmann S, Morales J, et al. Biomarkers in the Diagnosis and Prognosis of Alzheimer's Disease. <i>Journal of Laboratory Automation</i> . 2015;20(5):589-600.	2
861	Schartner J, Nabers A, Budde B, Lange J, Hoeck N, Wiltfang J, et al. An ATR-FTIR Sensor Unraveling the Drug Intervention of Methylene Blue, Congo Red, and Berberine on Human Tau and Abeta. <i>ACS Medicinal Chemistry Letters</i> . 2017;8(7):710-4.	2
862	Schauer SP, Mylott WR, Yuan M, Jenkins RG, Rodney Mathews W, Honigberg LA, et al. Preanalytical approaches to improve recovery of amyloid-beta peptides from CSF as measured by immunological or mass spectrometry-based assays. <i>Alzheimer's Research and Therapy</i> . 2018;10(1) (no pagination)(118).	7
863	Schelle J, Hasler LM, Gopfert JC, Joos TO, Vanderstichele H, Stoops E, et al. Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition. <i>Alzheimer's & Dementia</i> . 2017;13(6):701-9.	7
864	Schelle J, Wegenast-Braun BM, Fritsch SK, Kaeser SA, Jahrling N, Eicke D, et al. Early Abeta reduction prevents progression of cerebral amyloid angiopathy. <i>Annals of Neurology</i> . 2019;86(4):561-71.	1
865	Scheltens P, Nikolcheva T, Lasser R, Ostrowitzki S, Boada M, Dubois B, et al. Biomarker data from scarlet road: a global phase 3 study of gantenerumab in patients with prodromal Alzheimer's disease. <i>Alzheimer's & dementia</i> . 2015;11(7 SUPPL. 1):P331.	4
866	Schindler SE, Gray JD, Gordon BA, Xiong C, Batrla-Utermann R, Quan M, et al. Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. <i>Alzheimer's & Dementia</i> . 2018;14(11):1460-9.	7
867	Schindler SE, Sutphen CL, Teunissen C, McCue LM, Morris JC, Holtzman DM, et al. Upward drift in cerebrospinal fluid amyloid beta 42 assay values for more than 10 years. <i>Alzheimer's & Dementia</i> . 2018;14(1):62-70.	7
868	Schipke CG, De Vos A, Fuentes M, Jacobs D, Vanmechelen E, Peters O. Neurogranin and BACE1 in CSF as Potential Biomarkers Differentiating Depression with Cognitive Deficits from Early Alzheimer's Disease: A Pilot Study. <i>Dementia and Geriatric Cognitive Disorders Extra</i> . 2018;8(2):277-89.	7
869	Schipke CG, Jessen F, Teipel S, Luckhaus C, Wiltfang J, Esselmann H, et al. Long-term stability of Alzheimer's disease biomarker proteins in cerebrospinal fluid. <i>Journal of Alzheimer's Disease</i> . 2011;26(2):255-62.	7
870	Schipke CG, Prokop S, Heppner FL, Heuser I, Peters O. Comparison of immunosorbent assays for the quantification of biomarkers for Alzheimer's disease in human cerebrospinal fluid. <i>Dementia and Geriatric Cognitive Disorders</i> . 2011;31(2):139-45.	7
871	Schipper HM. The role of biologic markers in the diagnosis of Alzheimer's disease. <i>Alzheimer's and Dementia</i> . 2007;3(4):325-32.	2
872	Schmitz M, Hermann P, Oikonomou P, Stoeck K, Ebert E, Poliakova T, et al. Cytokine profiles and the role of cellular prion protein in patients with vascular dementia and vascular encephalopathy. <i>Neurobiology of Aging</i> . 2015;36(9):2597-606.	7
873	Scholl M, Maass A, Mattsson N, Ashton NJ, Blennow K, Zetterberg H, et al. Biomarkers for tau pathology. <i>Molecular and Cellular Neuroscience</i> . 2019;97:18-33.	2
874	Schonknecht P, Henze M, Hunt A, Klinga K, Haberkorn U, Schroder J. Hippocampal glucose metabolism is associated with cerebrospinal fluid estrogen levels in postmenopausal women with Alzheimer's disease. <i>Psychiatry Research - Neuroimaging</i> . 2003;124(2):125-7.	7
875	Schonrock N, Matamalas M, Ittner LM, Gotz J. MicroRNA networks surrounding APP and amyloid-beta metabolism - Implications for Alzheimer's disease. <i>Experimental Neurology</i> . 2012;235(2):447-54.	2
876	Schoonenboom NS, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM, et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. <i>Neurology</i> . 2012;78(1):47-54.	7
877	Schoonenboom NSM, Mulder C, Vanderstichele H, Pijnenburg YAL, Van Kamp GJ, Scheltens P, et al. Differences and similarities between two frequently used assays for amyloid beta42 in cerebrospinal fluid. <i>Clinical Chemistry</i> . 2005;51(6):1057-60.	7

연번	서지정보	배제 사유
878	Schuitmaker A, Dik MG, Veerhuis R, Scheltens P, Schoonenboom NS, Hack CE, et al. Inflammatory markers in AD and MCI patients with different biomarker profiles. <i>Neurobiology of Aging</i> . 2009;30(11):1885-9.	7
879	Schultz K, Wiehager S, Nilsson K, Nielsen JE, Lindquist SG, Hjermind LE, et al. Reduced CSF CART in dementia with Lewy bodies. <i>Neuroscience Letters</i> . 2009;453(2):104-6.	7
880	Schultz N, Janelidze S, Byman E, Minthon L, Nagga K, Hansson O, et al. Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer's disease. <i>PLoS ONE</i> . 2019;14 (6) (no pagination)(e0218561).	7
881	Schultz SA, Boots EA, Almeida RP, Oh JM, Einerson J, Korcarz CE, et al. Cardiorespiratory Fitness Attenuates the Influence of Amyloid on Cognition. <i>Journal of the International Neuropsychological Society : JINS</i> . 2015;21(10):841-50.	7
882	Schultz SA, Boots EA, Darst BF, Zetterberg H, Blennow K, Edwards DF, et al. Cardiorespiratory fitness alters the influence of a polygenic risk score on biomarkers of AD. <i>Neurology</i> . 2017;88(17):1650-8.	7
883	Schuster J, Funke SA. Methods for the Specific Detection and Quantitation of Amyloid-beta Oligomers in Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> . 2016;53(1):53-67.	2
884	Schwagerl AL, Mohan PS, Cataldo AM, Vonsattel JP, Kowall NW, Nixon RA. Elevated levels of the endosomal-lysosomal proteinase cathepsin D in cerebrospinal fluid in Alzheimer disease. <i>Journal of Neurochemistry</i> . 1995;64(1):443-6.	7
885	Sehlin D, Sollvander S, Paulie S, Brundin R, Ingelsson M, Lannfelt L, et al. Interference from heterophilic antibodies in amyloid-beta oligomer ELISAs. <i>Journal of Alzheimer's Disease</i> . 2010;21(4):1295-301.	7
886	Seibyl J, Shaw LM, Blennow K, Widmann M, Corradini V, Wahl S, et al. Amyloid-PET concordance of elecsys& CSF biomarker immunoassays for Alzheimer's disease. <i>Alzheimer's & dementia</i> . 2017;13(7):P199-P200.	4
887	Selnes P, Stav AL, Johansen KK, Bjørnerud A, Coello C, Auning E, et al. Impaired synaptic function is linked to cognition in Parkinson's disease. <i>Annals of Clinical and Translational Neurology</i> . 2017;4(10):700-13.	5
888	Senanarong V, Siwasariyanon N, Washirutmangkur L, Pongvarin N, Ratanabunakit C, Aonkaew N, et al. Alzheimers disease dementia as the diagnosis best supported by the cerebrospinal fluid biomarkers: Difference in cut-off levels from Thai experience. <i>International Journal of Alzheimer's Disease</i> . 2012;(no pagination)(212063).	7
889	Sennvik K, Fastbom J, Blomberg M, Wahlund LO, Winblad B, Benedikz E. Levels of alpha- and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients. <i>Neuroscience Letters</i> . 2000;278(3):169-72.	7
890	Seo H, Ferree AW, Isacson O. Cortico-hippocampal APP and NGF levels are dynamically altered by cholinergic muscarinic antagonist or M1 agonist treatment in normal mice. <i>European Journal of Neuroscience</i> . 2002;15(3):498-506.	1
891	Seppala TT, Koivisto AM, Hartikainen P, Helisalmi S, Soininen H, Herukka SK. Longitudinal changes of CSF biomarkers in alzheimer's disease. <i>Journal of Alzheimer's Disease</i> . 2011;25(4):583-94.	7
892	Seppala TT, Louhija UM, Appelberg B, Herukka SK, Juva K. Comparison between clinical diagnosis and csf biomarkers of alzheimer disease in elderly patients with late onset psychosis: Helsinki Old Age Psychosis Study (HOPS). <i>American Journal of Geriatric Psychiatry</i> . 2014;22(9):908-16.	7
893	Seppala TT, Nerg O, Koivisto AM, Rummukainen J, Puli L, Zetterberg H, et al. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. <i>Neurology</i> . 2012;78(20):1568-75.	7
894	Serrano-Pozo A, Vega GL, Lutjohann D, Locascio JJ, Tennis MK, Deng A, et al. Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers. <i>Alzheimer Disease and Associated Disorders</i> . 2010;24(3):220-6.	7
895	Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. <i>Nature</i> . 1992;359(6393):325-7.	7

연번	서지정보	배제 사유
896	Shahpasand-Kroner H, Klafki HW, Bauer C, Schuchhardt J, Huttenrauch M, Stazi M, et al. A two-step immunoassay for the simultaneous assessment of Abeta38, Abeta40 and Abeta42 in human blood plasma supports the Abeta42/Abeta40 ratio as a promising biomarker candidate of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> . 2018;10 (1) (no pagination)(121).	6
897	Sharma N, Singh AN. Exploring biomarkers for Alzheimer's disease. <i>Journal of Clinical and Diagnostic Research</i> . 2016;10(7):KE01-KE6.	2
898	Sharma RA, Varga AW, Bubu OM, Pirraglia E, Kam K, Parekh A, et al. Obstructive Sleep Apnea Severity Affects Amyloid Burden in Cognitively Normal Elderly. A Longitudinal Study. <i>American Journal of Respiratory & Critical Care Medicine</i> . 2018;197(7):933-43.	7
899	Shaw LM, Hansson O, Manuilova E, Masters CL, Doecke JD, Li QX, et al. Method comparison study of the Elecsys R beta-Amyloid (1-42) CSF assay versus comparator assays and LC-MS/MS. <i>Clinical Biochemistry</i> . 2019;72:7-14.	7
900	Shaw LM, Korecka M, Clark CM, Lee VMY, Trojanowski JQ. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. <i>Nature Reviews Drug Discovery</i> . 2007;6(4):295-303.	2
901	Shaw LM, Korecka M, Figurski M, Toledo J, Irwin D, Hee Kang J, et al. Detection of Alzheimer Disease Pathology in Patients Using Biochemical Biomarkers: Prospects and Challenges for Use in Clinical Practice. <i>The Journal of Applied Laboratory Medicine</i> . 2020;5(1):183-93.	2
902	Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. <i>Acta Neuropathologica</i> . 2011;121(5):597-609.	7
903	Shaw LM, Waligorska T, Fields L, Korecka M, Figurski M, Trojanowski JQ, et al. Derivation of cutoffs for the Elecsys® amyloid beta (1-42) assay in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> . 2018;10:698-705.	7
904	Shea YF, Chu LW, Mok MYM, Lam MF. Amyloid beta 1-42 and tau in the cerebrospinal fluid of renal failure patients for the diagnosis of Alzheimer's disease. <i>Journal of Nephrology</i> . 2014;27(2):217-20.	7
905	Sheline YI, West T, Yarasheski K, Swarm R, Jasielec MS, Fisher JR, et al. An antidepressant decreases CSF Abeta production in healthy individuals and in transgenic AD mice. <i>Science Translational Medicine</i> . 2014;6(236):236re4.	1
906	Shen X, Xia L, Liu L, Jiang H, Shannahan J, Du Y, et al. Altered clearance of beta-amyloid from the cerebrospinal fluid following subchronic lead exposure in rats: Roles of RAGE and LRP1 in the choroid plexus. <i>Journal of Trace Elements in Medicine and Biology</i> . 2020;61 (no pagination)(126520).	1
907	Sherbaf FG, Mohajer B, Ashraf-Ganjouei A, Zadeh MM, Javinani A, Moghaddam HS, et al. Serum insulin-like growth factor-1 in Parkinson's disease; study of cerebrospinal fluid biomarkers and white matter microstructure. <i>Frontiers in Endocrinology</i> . 2018;9 (no pagination)(608).	7
908	Shinohara M, Bu G. What can we learn from regional vulnerability to amyloid-beta accumulation in nondemented individuals? <i>Neurodegenerative Disease Management</i> . 2013;3(3):187-9.	2
909	Shipp G. Ultra-sensitive measurement of protein and nucleic acid biomarkers may enable earlier disease detection and more effective therapies. <i>Drug Discovery World</i> . 2007;8(1):79-82.	7
910	Shoji M, Golde TE, Ghiso J, Cheung TT, Estus S, Shaffer LM, et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. <i>Science</i> . 1992;258(5079):126-9.	7
911	Shoji M, Kanai M, Matsubara E, Tomidokoro Y, Shizuka M, Ikeda Y, et al. The levels of cerebrospinal fluid Abeta40 and Abeta42(43) are regulated age-dependently. <i>Neurobiology of Aging</i> . 2001;22(2):209-15.	7
912	Shoji M, Matsubara E, Kanai M, Watanabe M, Nakamura T, Tomidokoro Y, et al. Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease. <i>Journal of the Neurological Sciences</i> . 1998;158(2):134-40.	7
913	Siderowf A, Logroscino G. beta-amyloid in CSF: A window into Parkinson disease dementia. <i>Neurology</i> . 2014;82(20):1758-9.	2
914	Siemers E, Skinner M, Dean RA, Gonzales C, Satterwhite J, Farlow M, et al. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. <i>Clinical Neuropharmacology</i> . 2005;28(3):126-32.	7

연번	서지정보	배제 사유
915	Siemers ER, Dean RA, Demattos R, May PC. New pathways in drug discovery for Alzheimer's disease. <i>Current Neurology and Neuroscience Reports</i> . 2006;6(5):372-8.	2
916	Siemers ER, Dean RA, Friedrich S, Ferguson-Sells L, Gonzales C, Farlow MR, et al. Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. <i>Clinical Neuropharmacology</i> . 2007;30(6):317-25.	7
917	Silva JC, Dikler S, Mamaev S, Worsfold C, Moghekar A, Wiederhold T, et al. A Targeted Multiplexed MALDI MS Assay Platform using Affinity-Bead Assisted Mass Spectrometry (Affi-BAMS) for Monitoring Brain and CSF Biomarkers. <i>Journal of biomolecular techniques : JBT</i> . 2020;31(Supplement):S28.	6
918	Simic G, Boban M, Hof PR. Cerebrospinal fluid phosphorylated tau proteins as predictors of Alzheimer's disease in subjects with mild cognitive impairment. <i>Periodicum Biologorum</i> . 2008;110(1):27-30.	7
919	Simonsen AH, Hansson SF, Ruetschi U, McGuire J, Podust VN, Davies HA, et al. Amyloid beta1-40 quantification in CSF: Comparison between chromatographic and immunochemical methods. <i>Dementia and Geriatric Cognitive Disorders</i> . 2007;23(4):246-50.	6
920	Simonsen AH, Hansson SF, Ruetschi U, McGuire J, Podust VN, Davies HA, et al. Amyloid beta1-40 quantification in CSF: comparison between chromatographic and immunochemical methods. <i>Dementia & Geriatric Cognitive Disorders</i> . 2007;23(4):246-50.	6
921	Simonsen AH, Kuiperij B, El-Agnaf OMA, Engelborghs S, Herukka SK, Parnetti L, et al. The utility of alpha-synuclein as biofluid marker in neurodegenerative diseases: A systematic review of the literature. <i>Biomarkers in Medicine</i> . 2016;10(1):19-34.	2
922	Sjogren M, Andreasen N, Blennow K. Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers. <i>Clinica Chimica Acta</i> . 2003;332(1-2):1-10.	2
923	Sjogren M, Davidsson P, Gottfries J, Vanderstichele H, Edman A, Vanmechelen E, et al. The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process. <i>Dementia and Geriatric Cognitive Disorders</i> . 2001;12(4):257-64.	7
924	Sjogren M, Davidsson P, Wallin A, Granerus AK, Grundstrom E, Askmark H, et al. Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. <i>Dementia and Geriatric Cognitive Disorders</i> . 2002;13(2):112-8.	7
925	Sjogren M, Vanderstichele H, Agren H, Zachrisson O, Edsbacke M, Wikkelso C, et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. <i>Clinical Chemistry</i> . 2001;47(10):1776-81.	7
926	Skillback T, Farahmand BY, Rosen C, Mattsson N, Nagga K, Kilander L, et al. Cerebrospinal fluid tau and amyloid-beta1-42 in patients with dementia. <i>Brain</i> . 2015;138(Pt 9):2716-31.	7
927	Skoda D, Hort J, Vyhnaek M, Glosova L, Minarikova M, Jinoch P, et al. Specific anti-beta tubulin antibodies in differential diagnosis of dementias. [Czech]. <i>Ceska a Slovenska Neurologie a Neurochirurgie</i> . 2007;70(2):152-7.	3
928	Skogseth R, Mulugeta E, Ballard C, Rongve A, Nore S, Alves G, et al. Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> . 2008;25(6):559-63.	7
929	Slats D, Claassen JA, Spies PE, Borm G, Besse KT, van Aalst W, et al. Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers. <i>Neurobiology of Aging</i> . 2012;33(4):831.e1-9.	7
930	Slemmon JR, Meredith J, Guss V, Andreasson U, Andreasen N, Zetterberg H, et al. Measurement of Abeta1-42 in cerebrospinal fluid is influenced by matrix effects. <i>Journal of Neurochemistry</i> . 2012;120(2):325-33.	7
931	Slot RER, Kester MI, Van Harten AC, Jongbloed W, Bouwman FH, Teunissen CE, et al. ApoE and clusterin CSF levels influence associations between APOE genotype and changes in CSF tau, but not CSF Abeta42, levels in non-demented elderly. <i>Neurobiology of Aging</i> . 2019;79:101-9.	7
932	Smach MA, Charfeddine B, Ben Othman L, Lammouchi T, Dridi H, Nafati S, et al. Evaluation of cerebrospinal Fluid Tau/Beta-Amyloid(42) ratio as diagnostic markers for alzheimer disease. <i>European Neurology</i> . 2009;62(6):349-55.	7

연번	서지정보	배제 사유
933	Sodeyama N, Saito F, Saito K, Miyatake T, Yanagisawa K. Developmental changes of sialylation of soluble beta/A4 amyloid protein precursor derivatives in human cerebrospinal fluid. Brain Research Molecular Brain Research. 1994;27(2):320-2.	7
934	Sogorb-Esteve A, Garcia-Ayllon MS, Gobom J, Alom J, Zetterberg H, Blennow K, et al. Levels of ADAM10 are reduced in Alzheimer's disease CSF. Journal of Neuroinflammation. 2018;15 (1) (no pagination)(213).	7
935	Somers C, Lewczuk P, Sieben A, Van Broeckhoven C, De Deyn PP, Kornhuber J, et al. Validation of the Erlangen Score Algorithm for Differential Dementia Diagnosis in Autopsy-Confirmed Subjects. Journal of Alzheimer's Disease. 2019;68(3):1151-9.	6
936	Somers C, Struyfs H, Goossens J, Niemantsverdriet E, Luyckx J, De Roeck N, et al. A decade of cerebrospinal fluid biomarkers for Alzheimer's disease in Belgium. Journal of Alzheimer's Disease. 2016;54(1):383-95.	2
937	Sorensen KC, Simonsen AH, Holmetoft UB, Hasselbalch SG, Heegaard NH. Neprilysin-like activity correlates with CSF-Tau and phospho-tau in patients with Alzheimer's disease. Journal of Alzheimer's Disease. 2013;37(2):379-87.	7
938	Souslova T, Marple TC, Spiekerman AM, Mohammad AA. Personalized medicine in Alzheimer's disease and depression. Contemporary Clinical Trials. 2013;36(2):616-23.	2
939	Southwick PC, Yamagata SK, Echols Jr CL, Higson GJ, Neynaber SA, Parson RE, et al. Assessment of amyloid beta protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. Journal of Neurochemistry. 1996;66(1):259-65.	6
940	Spagnuolo MS, Maresca B, La Marca V, Carrizzo A, Veronesi C, Cupidi C, et al. Haptoglobin interacts with apolipoprotein E and beta-amyloid and influences their crosstalk. Acs Chemical Neuroscience. 2014;5(9):837-47.	7
941	Spies PE, Slats D, Rikkert MG, Tseng J, Claassen JA, Verbeek MM. CSF alpha-synuclein concentrations do not fluctuate over hours and are not correlated to amyloid beta in humans. Neuroscience Letters. 2011;504(3):336-8.	7
942	Spitzer P, Lang R, Oberstein TJ, Lewczuk P, Ermann N, Huttner HB, et al. A specific reduction in Aβ1-42 vs. a universal loss of Aβeta peptides in CSF differentiates Alzheimer's disease from meningitis and multiple sclerosis. Frontiers in Aging Neuroscience. 2018;10 (MAY) (no pagination)(152).	7
943	Spitzer P, Schieb H, Kamrowski-Kruck H, Otto M, Chiasserini D, Parnetti L, et al. Evidence for elevated cerebrospinal fluid ERK1/2 levels in Alzheimer dementia. International Journal of Alzheimer's Disease. 2011;(no pagination)(739847).	7
944	Spuch C, Antequera D, Pascual C, Abilleira S, Blanco M, Moreno-Carretero MJ, et al. Soluble megalin is reduced in cerebrospinal fluid samples of alzheimer's disease patients. Frontiers in Cellular Neuroscience. 2015;9(APR).	7
945	Stanley M, Macauley SL, Caesar EE, Koscal LJ, Moritz W, Robinson GO, et al. The effects of peripheral and central high insulin on brain insulin signaling and amyloid-beta in young and old APP/PS1 mice. Journal of Neuroscience. 2016;36(46):11704-15.	1
946	Stefani A, Martorana A, Bernardini S, Panella M, Mercati F, Orlicchio A, et al. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment. Journal of the Neurological Sciences. 2006;251(1-2):124-8.	7
947	Stefani A, Olivola E, Bassi MS, Pisani V, Imbriani P, Pisani A, et al. Strength and weaknesses of cerebrospinal fluid biomarkers in alzheimer's disease and possible detection of overlaps with frailty process. CNS and Neurological Disorders - Drug Targets. 2013;12(4):538-46.	7
948	Steinerman JR, Honig LS. Laboratory biomarkers in Alzheimer's disease. Current Neurology and Neuroscience Reports. 2007;7(5):381-7.	2
949	Stoeck K, Schmitz M, Ebert E, Schmidt C, Zerr I. Immune responses in rapidly progressive dementia: A comparative study of neuroinflammatory markers in Creutzfeldt-Jakob disease, Alzheimer's disease and multiple sclerosis. Journal of Neuroinflammation. 2014;11 (1) (no pagination)(170).	7
950	Stopa EG, Berzin TM, Kim S, Song P, Kuo-LeBlanc V, Rodriguez-Wolf M, et al. Human choroid plexus growth factors: What are the implications for CSF dynamics in Alzheimer's disease? Experimental Neurology. 2001;167(1):40-7.	7

연번	서지정보	배제 사유
951	Straten G, Eschweiler GW, Maetzler W, Laske C, Leyhe T. Glial cell-line derived neurotrophic factor (GDNF) concentrations in cerebrospinal fluid and serum of patients with early Alzheimer's disease and normal controls. <i>Journal of Alzheimer's Disease</i> . 2009;18(2):331-7.	7
952	Struyfs H, Molinuevo JL, Martin JJ, De Deyn PP, Engelborghs S. Validation of the AD-CSF-index in autopsy-confirmed Alzheimer's disease patients and healthy controls. <i>Journal of Alzheimer's disease : JAD</i> . 2014;41(3):903-9.	6
953	Struyfs H, Van Broeck B, Timmers M, Fransen E, Sleegers K, Van Broeckhoven C, et al. Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-beta Isoforms for Early and Differential Dementia Diagnosis. <i>Journal of Alzheimer's Disease</i> . 2015;45(3):813-22.	7
954	Stylianaki I, Polizopoulou ZS, Theodoridis A, Koutouzidou G, Baka R, Papaioannou NG. Amyloid-beta plasma and cerebrospinal fluid biomarkers in aged dogs with cognitive dysfunction syndrome. <i>Journal of Veterinary Internal Medicine</i> . 2020;34(4):1532-40.	1
955	Su H, Zhang C, Zou X, Lu F, Zeng Y, Guan H, et al. Jiao-tai-wan inhibits inflammation of the gut-brain-axis and attenuates cognitive impairment in insomnic rats. <i>Journal of Ethnopharmacology</i> . 2020;250 (no pagination)(112478).	1
956	Suarez-Calvet M, Morenas-Rodriguez E, Kleinberger G, Schlepckow K, Araque Caballero MA, Franzmeier N, et al. Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-beta pathology. <i>Molecular Neurodegeneration</i> . 2019;14(1):1.	7
957	Subramanian ML, Vig V, Chung J, Fiorello MG, Xia W, Zetterberg H, et al. Neurofilament light chain in the vitreous humor of the eye. <i>Alzheimer's research & therapy</i> . 2020;12(1):111.	6
958	Succol F, Pratico D. A role for 12/15 lipoxygenase in the amyloid beta precursor protein metabolism. <i>Journal of Neurochemistry</i> . 2007;103(1):380-7.	7
959	Sun HL, Li WW, Zhu C, Jin WS, Liu YH, Zeng F, et al. The Correlations of Plasma and Cerebrospinal Fluid Amyloid-Beta Levels with Platelet Count in Patients with Alzheimer's Disease. <i>BioMed Research International</i> . 2018;2018:7302045.	7
960	Sun Q, Hampel H, Blennow K, Lista S, Levey A, Tang B, et al. Increased plasma TACE activity in subjects with mild cognitive impairment and patients with Alzheimer's disease. <i>Journal of Alzheimer's disease : JAD</i> . 2014;41(3):877-86.	7
961	Sun R, Wang H, Shi Y, Gao D, Sun Z, Chen Z, et al. A Pilot Study of Urinary Exosomes in Alzheimer's Disease. <i>Neurodegenerative Diseases</i> . 2020;19(5-6):184-91.	6
962	Sundelof J, Sundstrom J, Hansson O, Eriksdotter-Jonhagen M, Giedraitis V, Larsson A, et al. Higher cathepsin B levels in plasma in Alzheimer's disease compared to healthy controls. <i>Journal of Alzheimer's Disease</i> . 2010;22(4):1223-30.	7
963	Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. <i>JAMA</i> . 2003;289(16):2094-103.	7
964	Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, et al. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. <i>Biological Psychiatry</i> . 2004;56(9):670-6.	7
965	Sung WH, Hung JT, Lu YJ, Cheng CM. Paper-based detection device for Alzheimer's disease-detecting beta-amyloid peptides (1-42) in human plasma. <i>Diagnostics</i> . 2020;10 (5) (no pagination)(272).	6
966	Surace E, Cohen G, Martinetto H, Chremmendez P, Martin E, Smyth E, et al. Latin American experience with Alzheimer's disease cerebrospinal fluid biomarkers. <i>Journal of the American Geriatrics Society</i> . 2013;61(7):1229-31.	2
967	Sutphen CL, Jasielec MS, Shah AR, Macy EM, Xiong C, Vlassenko AG, et al. Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age. <i>JAMA Neurology</i> . 2015;72(9):1029-42.	7
968	Sutphen CL, McCue L, Herries EM, Xiong C, Ladenson JH, Holtzman DM, et al. Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease. <i>Alzheimer's and Dementia</i> . 2018;14(7):869-79.	7
969	Tabaraud F, Leman JP, Milor AM, Roussie JM, Barriere G, Tartary M, et al. Alzheimer CSF biomarkers in routine clinical setting. <i>Acta Neurologica Scandinavica</i> . 2012;125(6):416-23.	7

연번	서지정보	배제 사유
970	Tagami S, Okochi M, Yanagida K, Kodama T, Arai T, Kuwano R, et al. Relative ratio and level of amyloid-beta 42 surrogate in cerebrospinal fluid of familial Alzheimer disease patients with presenilin 1 mutations. <i>Neurodegenerative Diseases</i> . 2014;13(2-3):166-70.	7
971	Tai LM, Bilousova T, Jungbauer L, Roeske SK, Youmans KL, Yu C, et al. Levels of soluble apolipoprotein E/amyloid-beta (Abeta) complex are reduced and oligomeric Abeta increased with APOE4 and alzheimer disease in a transgenic mouse model and human samples. <i>Journal of Biological Chemistry</i> . 2013;288(8):5914-26.	7
972	Takamura A, Kawarabayashi T, Yokoseki T, Shibata M, Morishima-Kawashima M, Saito Y, et al. Dissociation of beta-amyloid from lipoprotein in cerebrospinal fluid from Alzheimer's disease accelerates beta-amyloid-42 assembly. <i>Journal of Neuroscience Research</i> . 2011;89(6):815-21.	7
973	Takeda M, Tanaka T, Kudo T, Okochi M, Kamino A, Tagami S. [Biological markers for diagnosis of Alzheimer's disease]. <i>Seishin Shinkeigaku Zasshi - Psychiatria et Neurologia Japonica</i> . 2004;106(12):1610-4.	2
974	Talab R, Masopust J, Andrys C, Stourae P, Hort J, Valis M. Tau protein, phosphorylated tau protein, and beta-amyloid 42 levels in patients with neurodegenerative diseases complicated by cognitive deficits: A non-randomized, concurrent, case-control investigation. <i>Neural Regeneration Research</i> . 2009;4(11):951-7.	9
975	Tamaoka A, Fukushima T, Sawamura N, Ishikawa K, Oguni E, Komatsuzaki Y, et al. Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. <i>Journal of the Neurological Sciences</i> . 1996;141(1-2):65-8.	6
976	Tamaoka A, Sawamura N, Fukushima T, Shoji S, Matsubara E, Shoji M, et al. Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease. <i>Journal of the Neurological Sciences</i> . 1997;148(1):41-5.	7
977	Tamaoka A. Characterization of amyloid beta protein species in the plasma, cerebrospinal fluid and brains of patients with Alzheimer's disease. [Japanese]. <i>Japanese Journal of Geriatrics</i> . 1998;35(4):273-7.	3
978	Tanaka M, Saito S, Inoue T, Satoh-Asahara N, Ihara M. Potential therapeutic approaches for cerebral amyloid angiopathy and alzheimer's disease. <i>International Journal of Molecular Sciences</i> . 2020;21 (6) (no pagination)(1992).	2
979	Tang JX, Baranov D, Hammond M, Shaw LM, Eckenhoff MF, Eckenhoff RG. Human alzheimer and inflammation biomarkers after anesthesia and surgery. <i>Anesthesiology</i> . 2011;115(4):727-32.	7
980	Tang W, Huang Q, Wang Y, Wang ZY, Yao YY. Assessment of CSF Abeta42 as an aid to discriminating Alzheimer's disease from other dementias and mild cognitive impairment: a meta-analysis of 50 studies. <i>Journal of the Neurological Sciences</i> . 2014;345(1-2):26-36.	2
981	Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, et al. Cerebrospinal fluid beta-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. <i>Archives of Neurology</i> . 2009;66(3):382-9.	7
982	Tapiola T, Pirttila T, Mehta PD, Alafuzoff I, Lehtovirta M, Soininen H. Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease. <i>Neurobiology of Aging</i> . 2000;21(5):735-40.	8
983	Tapiola T, Pirttila T, Mikkonen M, Mehta PD, Alafuzoff I, Koivisto K, et al. Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease. <i>Neuroscience Letters</i> . 2000;280(2):119-22.	7
984	Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes development of Alzheimer's disease. <i>Journal of Neurology, Neurosurgery & Psychiatry</i> . 2003;74(9):1200-5.	7
985	Tarkowski E, Issa R, Sjogren M, Wallin A, Blennow K, Tarkowski A, et al. Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. <i>Neurobiology of Aging</i> . 2002;23(2):237-43.	7
986	Tarkowski E, Liljeroth AM, Nilsson A, Minthon L, Blennow K. Decreased levels of intrathecal interleukin 1 receptor antagonist in Alzheimer's disease. <i>Dementia & Geriatric Cognitive Disorders</i> . 2001;12(5):314-7.	7
987	Tarkowski E, Liljeroth AM, Nilsson A, Ricksten A, Davidsson P, Minthon L, et al. TNF gene polymorphism and its relation to intracerebral production of TNFalpha and TNFbeta in AD. <i>Neurology</i> . 2000;54(11):2077-81.	7

연번	서지정보	배제 사유
988	Tarnaris A, Toma AK, Kitchen ND, Watkins LD. Ongoing search for diagnostic biomarkers in idiopathic normal pressure hydrocephalus. <i>Biomarkers in Medicine</i> . 2009;3(6):787-805.	2
989	Tatebe H, Kasai T, Ohmichi T, Kishi Y, Kakeya T, Waragai M, et al. Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer's disease and down syndrome. <i>Molecular Neurodegeneration</i> . 2017;12(1):63.	6
990	Taverna M, Straub T, Hampel H, Rujescu D, Lichtenthaler SF. A new sandwich immunoassay for detection of the alpha-secretase cleaved, soluble amyloid-beta protein precursor in cerebrospinal fluid and serum. <i>Journal of Alzheimer's Disease</i> . 2013;37(4):667-78.	7
991	Taylor HM, Palmer JC, Thomas TL, Kehoe PG, Paton JFR, Love S. Cerebral A β ₄₀ and systemic hypertension. <i>Journal of Cerebral Blood Flow and Metabolism</i> . 2018;38(11):1993-2005.	1
992	Teipel SJ, Sabri O, Grothe M, Barthel H, Prvulovic D, Buerger K, et al. Perspectives for multimodal neurochemical and imaging biomarkers in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> . 2013;33(SUPPL. 1):S329-S47.	2
993	Teng E, Taylor K, Bilousova T, Weiland D, Pham T, Zuo X, et al. Dietary DHA supplementation in an APP/PS1 transgenic rat model of AD reduces behavioral and Abeta pathology and modulates Abeta oligomerization. <i>Neurobiology of Disease</i> . 2015;82:552-60.	1
994	Terryberry JW, Thor G, Peter JB. Autoantibodies in neurodegenerative diseases: Antigen-specific frequencies and intrathecal analysis. <i>Neurobiology of Aging</i> . 1998;19(3):205-16.	7
995	Teunissen CE, Chiu MJ, Yang CC, Yang SY, Scheltens P, Zetterberg H, et al. Plasma Amyloid-beta (Abeta42) Correlates with Cerebrospinal Fluid Abeta42 in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> . 2018;62(4):1857-63.	7
996	Thompson AGB, Mead SH. Review: Fluid biomarkers in the human prion diseases. <i>Molecular and Cellular Neuroscience</i> . 2019;97:81-92.	2
997	Thompson PW, Lockhart A. Monitoring the amyloid beta-peptide in vivo - caveat emptor. <i>Drug Discovery Today</i> . 2009;14(5-6):241-51.	2
998	Tiepol S, Patt M, Hoffmann KT, Schroeter ML, Sabri O, Barthel H. Alzheimer's Disease FDG PET Imaging Pattern in an Amyloid-Negative Mild Cognitive Impairment Subject. <i>Journal of Alzheimer's Disease</i> . 2015;47(3):539-43.	7
999	Tolboom N, Koedam ELGE, Schott JM, Yaqub M, Blankenstein MA, Barkhof F, et al. Dementia mimicking Alzheimer s disease owing to a Tau mutation: CSF and PET findings. <i>Alzheimer Disease and Associated Disorders</i> . 2010;24(3):303-7.	7
1000	Toledo JB, Bretschneider J, Grossman M, Arnold SE, Hu WT, Xie SX, et al. CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. <i>Acta Neuropathologica</i> . 2012;124(1):23-35.	7
1001	Toledo JB, Korff A, Shaw LM, Trojanowski JQ, Zhang J. Low levels of cerebrospinal fluid complement 3 and factor H predict faster cognitive decline in mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> . 2014;6 (3) (no pagination)(36).	7
1002	Toledo JB, Xie SX, Trojanowski JQ, Shaw LM. Longitudinal change in CSF Tau and Abeta biomarkers for up to 48 months in ADNI. <i>Acta Neuropathologica</i> . 2013;126(5):659-70.	7
1003	Toledo JB, Zetterberg H, Van Harten AC, Glodzik L, Martinez-Lage P, Bocchio-Chiavetto L, et al. Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. <i>Brain</i> . 2015;138(9):2701-15.	7
1004	Tomic JL, Pensalfini A, Head E, Glabe CG. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. <i>Neurobiology of Disease</i> . 2009;35(3):352-8.	7
1005	Toombs J, Foiani MS, Wellington H, Paterson RW, Arber C, Heslegrave A, et al. Amyloid beta peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> . 2018;10:311-21.	7
1006	Travassos M, Santana I, Baldeiras I, Tsolaki M, Gkatzima O, Genc S, et al. Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid-beta Levels in Patients with Alzheimer's Disease? <i>Journal of Alzheimer's Disease</i> . 2015;47(4):1069-78.	7

연번	서지정보	배제 사유
1007	Trombetta BA, Carlyle BC, Koenig AM, Shaw LM, Trojanowski JQ, Wolk DA, et al. The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologies in Alzheimer's disease. PLoS ONE. 2018;13 (3) (no pagination)(e0193707).	7
1008	Trotta T, Panaro MA, Cianciulli A, Mori G, Di Benedetto A, Porro C. Microglia-derived extracellular vesicles in Alzheimer's Disease: A double-edged sword. Biochemical Pharmacology. 2018;148:184-92.	2
1009	Tucker S, Moller C, Tegerstedt K, Lord A, Laudon H, Sjodahl J, et al. The murine Version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-ArcSwe Mice. Journal of Alzheimer's Disease. 2015;43(2):575-88.	1
1010	Ulrich JD, Burchett JM, Restivo JL, Schuler DR, Verghese PB, Mahan TE, et al. In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Molecular Neurodegeneration. 2013;8:13.	1
1011	Umlauf, A., B. Soontornniyomkij, E.E. Sundermann, B. Gouaux, R.J. Ellis, A.J. Levine, et al. Risk of developing cerebral beta-amyloid plaques with posttranslational modification among HIV-infected adults. AIDS (London, England), 2019. 33(14): p. 2157-2166.	7
1012	Urakami K, Nakashima K. [Corticobasal degeneration and progressive supranuclear palsy--biochemical marker]. Rinsho Shinkeigaku - Clinical Neurology. 2002;42(11):1162-4.	3
1013	Urakami K, Okada A, Ohno K, Kitaguchi N, Tanaka S, Nakamura S, et al. Amyloid beta protein precursor with Kunitz-type protease inhibitor domains (APPI) in cerebrospinal fluid and APPI mRNAs in cultured skin fibroblasts of patients with Alzheimer's disease. Tohoku Journal of Experimental Medicine. 1994;174(3):199-207.	7
1014	Urakami K, Takahashi K, Okada A, Oshima T, Adachi Y, Nakamura S, et al. Clinical course and CSF amyloid beta protein precursor having the site of application of the protease inhibitor (APPI) levels in patients with dementia of the Alzheimer type [1]. Dementia. 1993;4(1):59-60.	2
1015	Urakami K, Takahashi K, Saito H, Okada A, Nakamura S, Tanaka S, et al. Amyloid beta protein precursors with kunitz-type inhibitor domains and acetylcholinesterase in cerebrospinal fluid from patients with dementia of the Alzheimer type. Acta Neurologica Scandinavica. 1992;85(5):343-6.	7
1016	Urakami K, Taniguchi M, Inoue M, Wada-Isoe K, Wakutani Y, Nakashima K. Studies on diagnostic markers for Alzheimer's disease. Psychogeriatrics. 2005;5(3):99-102.	2
1017	Vafadar-Isfahani B, Ball G, Coveney C, Lemetre C, Boocock D, Minthon L, et al. Identification of SPARC-like 1 protein as part of a biomarker panel for Alzheimer's disease in cerebrospinal fluid. Journal of Alzheimer's Disease. 2012;28(3):625-36.	7
1018	Vakilian A, Masoumi J, Mirzaee S, Khorramdelazad H. Expression analysis of beta-secretase 1 (BACE1) enzyme in peripheral blood of patients with Alzheimer's disease. Caspian Journal of Internal Medicine. 2019;10(3):276-80.	6
1019	Van Everbroeck B, Green AJE, Pals P, Martin JJ, Cras P. Decreased levels of amyloid-beta 1-42 in cerebrospinal fluid of Creutzfeldt-Jakob disease patients. Journal of Alzheimer's Disease. 1999;1(6):419-24.	7
1020	Van Everbroeck B, Michotte A, Sciot R, Godfraind C, Deprez M, Quoilin S, et al. Increased incidence of sporadic Creutzfeldt-Jakob disease in the age groups between 70 and 90 years in Belgium. European Journal of Epidemiology. 2006;21(6):443-7.	7
1021	Van Gool WA, Schenk DB, Bolhuis PA. Concentrations of amyloid-beta protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease. Neuroscience Letters. 1994;172(1-2):122-4.	7
1022	Van Harten AC, Wiste HJ, Weigand SD, Mielke MM, Kremers WK, Eichenlaub U, et al. CSF biomarkers in Olmsted County: Evidence of 2 subclasses and associations with demographics. Neurology. 2020;95(3):e256-e67.	7
1023	van Maurik IS, Zwan MD, Tijms BM, Bouwman FH, Teunissen CE, Scheltens P, et al. Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project. JAMA neurology. 2017;74(12):1481-91.	7
1024	Van Nostrand WE, Wagner SL, Haan J, Bakker E, Roos RAC. Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis- Dutch type share a decrease in cerebrospinal fluid levels of amyloid beta- protein precursor. Annals of Neurology. 1992;32(2):215-8.	7

연번	서지정보	배제 사유
1025	Van Nostrand WE, Wagner SL, Shankle WR, Farrow JS, Dick M, Rozemuller JM, et al. Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proceedings of the National Academy of Sciences of the United States of America. 1992;89(7):2551-5.	7
1026	van Steenoven I, Majbour NK, Vaikath NN, Berendse HW, van der Flier WM, van de Berg WDJ, et al. alpha-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies. Movement Disorders. 2018;33(11):1724-33.	7
1027	van Steenoven I, Noli B, Cocco C, Ferri G, Oeckl P, Otto M, et al. VGF peptides in cerebrospinal fluid of patients with dementia with lewy bodies. International Journal of Molecular Sciences. 2019;20 (19) (no pagination)(4674).	7
1028	van Waalwijk van Doorn LJ, Koel-Simmelink MJ, Hausmann U, Klafki H, Struyfs H, Linning P, et al. Validation of soluble amyloid-beta precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases. Journal of Neurochemistry. 2016;137(1):112-21.	7
1029	Vanderstichele H, De Meyer G, Andreasen N, Kostanjevecki V, Wallin A, Olsson A, et al. Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. Clinical Chemistry. 2005;51(9):1650-60.	7
1030	Vanderstichele H, Demeyer L, Janelidze S, Coart E, Stoops E, Mauroo K, et al. Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, alpha-synuclein, and total tau in combination with Abeta(1-42)/Abeta(1-40). Alzheimer's Research and Therapy. 2017;9 (1) (no pagination)(40).	7
1031	Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, et al. Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid. 2000;7(4):245-58.	7
1032	Vanderstichele HM, Janelidze S, Demeyer L, Coart E, Stoops E, Herbst V, et al. Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Abeta42 and the Ratios of Abeta Isoforms Using Low Protein Binding Tubes. Journal of Alzheimer's Disease. 2016;53(3):1121-32.	7
1033	Vanderstichele HM, Shaw L, Vandijck M, Jeromin A, Zetterberg H, Blennow K, et al. Alzheimer disease biomarker testing in cerebrospinal fluid: A method to harmonize assay platforms in the absence of an absolute reference standard. Clinical Chemistry. 2013;59(4):710-2.	2
1034	Vanderstichele HM, Teunissen CE, Vanmechelen E. Critical Steps to be Taken into Consideration Before Quantification of beta-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment. Neurology and Therapy. 2019;8(Supplement 2):129-45.	2
1035	Vanmechelen E, Vanderstichele H. Towards an earlier diagnosis of Alzheimer's disease. Journal of biotechnology. 1998;66(2-3):229-31.	2
1036	Veerabhadrapa B, Delaby C, Hirtz C, Vialaret J, Alcolea D, Lleo A, et al. Detection of amyloid beta peptides in body fluids for the diagnosis of alzheimer's disease: Where do we stand? Critical Reviews in Clinical Laboratory Sciences. 2020;57(2):99-113.	2
1037	Velayudhan L, Killick R, Hye A, Kinsey A, Guntert A, Lynham S, et al. Plasma transthyretin as a candidate marker for Alzheimer's disease. Journal of Alzheimer's Disease. 2012;28(2):369-75.	7
1038	Velickaite V, Giedraitis V, Strom K, Alafuzoff I, Zetterberg H, Lannfelt L, et al. Cognitive function in very old men does not correlate to biomarkers of Alzheimer's disease. BMC Geriatrics. 2017;17(1):208.	7
1039	Verbeek MM, Pijnenburg YA, Schoonenboom NS, Kremer BPH, Scheltens P, Grossman M, et al. Cerebrospinal fluid tau levels in frontotemporal dementia [4] (multiple letters). Annals of Neurology. 2005;58(4):656-7.	2
1040	Verbeek MM, Sjogren JM. The use of indexes in the interpretation of cerebrospinal fluid analyses. Neurobiology of Aging. 2010;31(9):1654; discussion 5.	2
1041	Vergallo A, Giampietri L, Pagni C, Giorgi FS, Nicoletti V, Miccoli M, et al. Association Between CSF Beta-Amyloid and Apathy in Early-Stage Alzheimer Disease. Journal of Geriatric Psychiatry and Neurology. 2019;32(3):164-9.	7
1042	Verheijen JH, Huisman LG, van Lent N, Neumann U, Paganetti P, Hack CE, et al. Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay. Clinical Chemistry. 2006;52(6):1168-74.	7

연번	서지정보	배제 사유
1043	Verwey NA, Kester MI, van der Flier WM, Veerhuis R, Berkhof H, Twaalfhoven H, et al. Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects. <i>Journal of Alzheimer's Disease</i> . 2010;20(2):445-52.	7
1044	Verwey NA, Van Der Flier WM, Blennow K, Clark C, Sokolow S, De Deyn PP, et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. <i>Annals of Clinical Biochemistry</i> . 2009;46(3):235-40.	7
1045	Verwey NA, Veerhuis R, Twaalfhoven HA, Wouters D, Hoozemans JJ, Bollen YJ, et al. Quantification of amyloid-beta 40 in cerebrospinal fluid. <i>Journal of Immunological Methods</i> . 2009;348(1-2):57-66.	6
1046	Villa C, Lavitrano M, Salvatore E, Combi R. Molecular and imaging biomarkers in Alzheimer's disease: A focus on recent insights. <i>Journal of Personalized Medicine</i> . 2020;10(3):1-32.	2
1047	Vincent B. Protective roles of melatonin against the amyloid-dependent development of Alzheimer's disease: A critical review. <i>Pharmacological Research</i> . 2018;134:223-37.	2
1048	Vishnu VY, Modi M, Gairola J, Kumar A, Mohanty M, Goyal MK, et al. Clinical, molecular imaging and biomarker concordance in the diagnosis of Alzheimer's disease and vascular dementia. <i>Australasian Medical Journal</i> . 2017;10(4):262-8.	7
1049	Vishnu VY, Modi M, Sharma S, Mohanty M, Goyal MK, Lal V, et al. Role of plasma clusterin in Alzheimer's disease—a pilot study in a tertiary hospital in Northern India. <i>PLoS ONE</i> . 2016;11 (11) (no pagination)(e0166369).	6
1050	Vlachos GS, Paraskevas GP, Naoumis D, Kapaki E. Cerebrospinal fluid beta-amyloid 1-42 correlates with rate of progression in Alzheimer's disease. <i>Journal of Neural Transmission</i> . 2012;119(7):799-804.	7
1051	Vlassenko AG, McCue L, Jasielec MS, Su Y, Gordon BA, Xiong C, et al. Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease. <i>Annals of Neurology</i> . 2016;80(3):379-87.	7
1052	Vogelgsang J, Shahpasand-Kroner H, Vogelgsang R, Streit F, Vukovich R, Wiltfang J. Multiplex immunoassay measurement of amyloid- β_{42} to amyloid- β_{40} ratio in plasma discriminates between dementia due to Alzheimer's disease and dementia not due to Alzheimer's disease. <i>Experimental Brain Research</i> . 2018;236(5):1241-50.	6
1053	Vogelgsang J, Vukovich R, Wedekind D, Wiltfang J. Higher Level of Mismatch in APOE epsilon4 Carriers for Amyloid-Beta Peptide Alzheimer's Disease Biomarkers in Cerebrospinal Fluid. <i>ASN Neuro</i> . 2019;11(no pagination).	7
1054	Vojdani A, Vojdani E, Saidara E, Kharrazian D. Reaction of Amyloid-beta Peptide Antibody with Different Infectious Agents Involved in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> . 2018;63(2):847-60.	7
1055	Vom Berg J, Prokop S, Miller KR, Obst J, Kalin RE, Lopategui-Cabezas I, et al. Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. <i>Nature Medicine</i> . 2012;18(12):1812-9.	1
1056	von Euler Chelpin, M., L. Soderberg, J. Falting, C. Moller, M. Giorgetti, R. Constantinescu, et al. Alpha-Synuclein Protofibrils in Cerebrospinal Fluid: A Potential Biomarker for Parkinson's Disease. <i>Journal of Parkinson's disease</i> ., 2020. 30.	7
1057	Vos S, van Rossum I, Burns L, Knol D, Scheltens P, Soininen H, et al. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. <i>Neurobiology of Aging</i> . 2012;33(10):2272-81.	7
1058	Vos SJ, Visser PJ, Verhey F, Aalten P, Knol D, Ramakers I, et al. Variability of CSF Alzheimer's disease biomarkers: implications for clinical practice. <i>PLoS ONE [Electronic Resource]</i> . 2014;9(6):e100784.	7
1059	Voyle N, Abi-Saab D, Klein G, Hofmann C, Delmar P, Pross N, et al. THE EFFECT OF LOW DOSES OF GANTENERUMAB ON AMYLOID AND TAU BIOMARKERS IN CEREBROSPINAL FLUID (CSF) IN THE MARGUERITE ROAD STUDY. <i>Alzheimer's & dementia</i> . 2018;14(7):P240.	7
1060	Vranova HP, Henykova E, Kaiserova M, Mensikova K, Vastik M, Mares J, et al. Tau protein, beta-amyloid1-42 and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia. <i>Journal of the Neurological Sciences</i> . 2014;343(1-2):120-4.	7

연번	서지정보	배제 사유
1061	Wada-Isoe K, Kitayama M, Nakaso K, Nakashima K. Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study. <i>Journal of the Neurological Sciences</i> . 2007;260(1-2):33-7.	7
1062	Wagshal D, Sankaranarayanan S, Guss V, Hall T, Berisha F, Lobach I, et al. Divergent CSF tau alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy. <i>Journal of neurology, neurosurgery, and psychiatry</i> . 2015;86(3):244-50.	7
1063	Wan H, Day M, Hurko O, Rutkowski JL. Biomarkers for alzheimer's disease: Translational medicine approaches in development of disease modifying therapeutics. <i>American Pharmaceutical Review</i> . 2008;11(6).	2
1064	Wan Y, Kanemaru K, Yamanouchi H. Simultaneous assay of CSF levels of tau and Abeta1-42 to the diagnosis of Alzheimer's disease. <i>Chinese Journal of Neuroscience</i> . 2003;19(1):41-4.	8
1065	Wang B, Xu J, Li Y, Wang W, Li T, Du P, et al. Correlation analysis between APOE gene polymorphism and Alzheimer's disease. <i>International Journal of Clinical and Experimental Medicine</i> . 2018;11(4):3672-8.	7
1066	Wang C, Liu D, Wang Z. Gold nanoparticle based dot-blot immunoassay for sensitively detecting Alzheimer's disease related beta-amyloid peptide. <i>Chemical Communications</i> . 2012;48(67):8392-4.	7
1067	Wang D, Di X, Fu L, Li Y, Han X, Wu H, et al. Analysis of serum beta-amyloid peptides, alpha2-macroglobulin, complement factor H, and clusterin levels in APP/PS1 transgenic mice during progression of Alzheimer's disease. <i>NeuroReport</i> . 2016;27(15):1114-9.	1
1068	Wang H, Dey KK, Chen PC, Li Y, Niu M, Cho JH, et al. Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer's disease. <i>Molecular Neurodegeneration</i> . 2020;15 (1) (no pagination)(43).	7
1069	Wang H, Wang R, Lakshmana MK, Nefzi A. Substituted dithiazole piperazine benzamides as novel amyloid beta peptide reducing agents. <i>Bioorganic and Medicinal Chemistry Letters</i> . 2014;24(18):4384-8.	7
1070	Wang HY, Pei Z, Lee KC, Lopez-Brignoni E, Nikolov B, Crowley CA, et al. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients. <i>Journal of Prevention of Alzheimer's Disease</i> . 2020;7(4):256-64.	7
1071	Wang K, Chen Q, Wu N, Li Y, Zhang R, Wang J, et al. Berberine Ameliorates Spatial Learning Memory Impairment and Modulates Cholinergic Anti-Inflammatory Pathway in Diabetic Rats. <i>Frontiers in Pharmacology</i> . 2019;10:1003.	1
1072	Wang L, Fagan AM, Shah AR, Beg MF, Csernansky JG, Morris JC, et al. Cerebrospinal fluid proteins predict longitudinal hippocampal degeneration in early-stage dementia of the Alzheimer type. <i>Alzheimer Disease & Associated Disorders</i> . 2012;26(4):314-21.	7
1073	Wang L, Zhang M, Wang Q, Jiang X, Li K, Liu J. APOE epsilon4 allele is associated with elevated levels of CSF VILIP-1 in preclinical alzheimer's disease. <i>Neuropsychiatric Disease and Treatment</i> . 2020;16:923-31.	6
1074	Wang MJ, Yi S, Han JY, Park SY, Jang JW, Chun IK, et al. Oligomeric forms of amyloid-beta protein in plasma as a potential blood-based biomarker for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> . 2017;9 (1) (no pagination)(98).	7
1075	Wang S, Wang R, Chen L, Bennett DA, Dickson DW, Wang DS. Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer's brain. <i>Journal of Neurochemistry</i> . 2010;115(1):47-57.	7
1076	Wang SH. Level of related factors in cerebrospinal fluid for evaluating Alzheimer disease patients' condition. [Chinese]. <i>Chinese Journal of Clinical Rehabilitation</i> . 2005;9(9):48-9+69.	3
1077	Wang W, Bodles-Brakhop AM, Barger SW. A role for P-glycoprotein in clearance of alzheimer amyloid beta-peptide from the brain. <i>Current Alzheimer Research</i> . 2016;13(6):615-20.	1
1078	Wang X, Zhu M, Hjorth E, Cortes-Toro V, Eyjolfssdottir H, Graff C, et al. Resolution of inflammation is altered in Alzheimer's disease. <i>Alzheimer's & Dementia</i> . 2015;11(1):40-50.e1-2.	7
1079	Wang Z, Xiong L, Wan W, Duan L, Bai X, Zu H. Intranasal BMP9 ameliorates alzheimer disease-like pathology and cognitive deficits in APP/PS1 transgenic mice. <i>Frontiers in Molecular Neuroscience</i> . 2017;10 (no pagination)(32).	1

연번	서지정보	배제 사유
1080	Wang-Dietrich L, Funke SA, Kuhbach K, Wang K, Besmehn A, Willbold S, et al. The amyloid-beta oligomer count in cerebrospinal fluid is a biomarker for Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> . 2013;34(4):985-94.	7
1081	Waragai M, Adame A, Trinh I, Sekiyama K, Takamatsu Y, Une K, et al. Possible Involvement of Adiponectin, the Anti-Diabetes Molecule, in the Pathogenesis of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> . 2016;52(4):1453-9.	7
1082	Watanabe Y, Shimizu Y, Urakami K, Matsushima E, Nakashima K. Vertical ophthalmoplegia in a demented patient with striatopallidodentate calcification. <i>Psychiatry & Clinical Neurosciences</i> . 2003;57(4):447-50.	7
1083	Watson MA, Scott MG. Clinical utility of biochemical analysis of cerebrospinal fluid. <i>Clinical Chemistry</i> . 1995;41(3):343-60.	2
1084	Watt AD, Perez KA, Rembach AR, Masters CL, Villemagne VL, Barnham KJ. Variability in blood-based amyloid-beta assays: The need for consensus on pre-analytical processing. <i>Journal of Alzheimer's Disease</i> . 2012;30(2):323-36.	2
1085	Wattamwar PR, Mathuranath PS. An overview of biomarkers in Alzheimer's disease. <i>Annals of Indian Academy of Neurology</i> . 2010;13(SUPPL. 2):S116-S23.	2
1086	Wei F, Song J, Zhang C, Lin J, Xue R, Shan LD, et al. Chronic stress impairs the aquaporin-4-mediated glymphatic transport through glucocorticoid signaling. <i>Psychopharmacology</i> . 2019;236(4):1367-84.	1
1087	Wei K, Tran T, Chu K, Borzage MT, Braskie MN, Harrington MG, et al. White matter hypointensities and hyperintensities have equivalent correlations with age and CSF beta-amyloid in the nondemented elderly. <i>Brain and Behavior</i> . 2019;9 (12) (no pagination)(e01457).	7
1088	Wei TY, Fu Y, Chang KH, Lin KJ, Lu YJ, Cheng CM. Point-of-Care Devices Using Disease Biomarkers To Diagnose Neurodegenerative Disorders. <i>Trends in Biotechnology</i> . 2018;36(3):290-303.	2
1089	Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, et al. The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. <i>Alzheimer's and Dementia</i> . 2017;13(5):561-71.	2
1090	Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, et al. The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. <i>Alzheimer's and Dementia</i> . 2013;9(5):e111-e94.	2
1091	Wellington H, Paterson RW, Portelius E, Tornqvist U, Magdalinou N, Fox NC, et al. Increased CSF neurogranin concentration is specific to Alzheimer disease. <i>Neurology</i> . 2016;86(9):829-35.	7
1092	Wellington H, Paterson RW, Suarez-Gonzalez A, Poole T, Frost C, Sjobom U, et al. CSF neurogranin or tau distinguish typical and atypical Alzheimer disease. <i>Annals of Clinical and Translational Neurology</i> . 2018;5(2):162-71.	7
1093	Wen YR, Yang JH, Wang X, Yao ZB. Induced dural lymphangiogenesis facilitates soluble amyloid-beta clearance from brain in a transgenic mouse model of Alzheimer's disease. <i>Neural Regeneration Research</i> . 2018;13(4):709-16.	1
1094	Wen, G.Y. Alzheimer's disease and risk factors. <i>Journal of Food and Drug Analysis</i> , 1998. 6(2): p. 465-476.	7
1095	Wennstrom M, Hall S, Nagga K, Londos E, Minthon L, Hansson O. Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients. <i>Alzheimer's Research and Therapy</i> . 2015;7 (1) (no pagination)(63).	7
1096	Wennstrom M, Londos E, Minthon L, Nielsen HM. Altered CSF orexin and alpha-synuclein levels in dementia patients. <i>Journal of Alzheimer's Disease</i> . 2012;29(1):125-32.	7
1097	Wennstrom M, Surova Y, Hall S, Nilsson C, Minthon L, Hansson O, et al. The inflammatory marker YKL-40 is elevated in cerebrospinal fluid from patients with Alzheimer's but not Parkinson's disease or dementia with Lewy bodies. <i>PLoS ONE</i> . 2015;10 (8) (no pagination)(e0135458).	7
1098	Weston PSJ, Paterson RW, Dickson J, Barnes A, Bomanji JB, Kayani I, et al. Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value over Cerebrospinal Fluid? <i>Journal of Alzheimer's Disease</i> . 2016;54(4):1297-302.	7

연번	서지정보	배제 사유
1099	Weston PSJ, Paterson RW, Modat M, Burgos N, Cardoso MJ, Magdalinou N, et al. Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> . 2015;1(4):440-6.	7
1100	Westwood S, Baird AL, Anand SN, Nevado-Holgado AJ, Kormilitzin A, Shi L, et al. Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. <i>Journal of Alzheimer's Disease</i> . 2020;74(1):213-25.	1
1101	Westwood S, Baird AL, Hye A, Ashton NJ, Nevado-Holgado AJ, Anand SN, et al. Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [¹⁸ F]-Flutemetamol PET Scan Result. <i>Frontiers in aging neuroscience</i> . 2018;10:409.	7
1102	Westwood S, Liu B, Baird AL, Anand S, Nevado-Holgado AJ, Newby D, et al. The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer's pathology. <i>Alzheimer's Research and Therapy</i> . 2017;9 (1) (no pagination)(31).	2
1103	Whelan CD, Mattsson N, Nagle MW, Vijayaraghavan S, Hyde C, Janelidze S, et al. Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer's disease. <i>Acta Neuropathologica Communications</i> . 2019;7(1):169.	7
1104	Willemse EAJ, van Maurik IS, Tijms BM, Bouwman FH, Franke A, Hubeek I, et al. Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> . 2018;10:563-72.	7
1105	Williams SM, Schulz P, Sierks MR. Oligomeric alpha-synuclein and beta-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases. <i>European Journal of Neuroscience</i> . 2016;43(1):3-16.	7
1106	Willis BA, Sundell K, Lachno DR, Ferguson-Sells LR, Case MG, Holdridge K, et al. Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> . 2018;4:652-60.	7
1107	Wiltfang J, Bibl M, Maler M, Klafki MW, Esselmann H, Kornhuber J, et al. Neurochemical diagnostic of dementia - Quo vadis?. [German]. <i>Nervenheilkunde</i> . 2007;26(10):861-6.	3
1108	Wiltfang J, Esselmann H, Bibl M, Hull M, Hampel H, Kessler H, et al. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. <i>Journal of Neurochemistry</i> . 2007;101(4):1053-9.	7
1109	Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S, et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. <i>Journal of Neurochemistry</i> . 2002;81(3):481-96.	7
1110	Wiltfang J, Esselmann H, Cupers P, Neumann M, Kretschmar H, Beyermann M, et al. Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells. <i>Journal of Biological Chemistry</i> . 2001;276(46):42645-57.	7
1111	Wiltfang J, Esselmann H, Smirnov A, Bibl M, Cepek L, Steinacker P, et al. Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. <i>Annals of Neurology</i> . 2003;54(2):263-7.	7
1112	Wiltfang J, Lewczuk P, Riederer P, Grunblatt E, Hock C, Scheltens P, et al. Consensus paper of the WFSBP task force on biological markers of dementia: The role of CSF and blood analysis in the early and differential diagnosis of dementia. [Portuguese]. <i>Revista de Psiquiatria Clinica</i> . 2009;36(SUPPL. 1):1-16.	3
1113	Wisniewski T, Golabek A, Matsubara E, Ghiso J, Frangione B. Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid. <i>Biochemical & Biophysical Research Communications</i> . 1993;192(2):359-65.	7
1114	Wolozin B, Bednar MM. Interventions for heart disease and their effects on Alzheimer's disease. <i>Neurological Research</i> . 2006;28(6):630-6.	2
1115	Woolacott IOC, Nicholas JM, Heller C, Foiani MS, Moore KM, Russell LL, et al. Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype. <i>Dementia & Geriatric Cognitive Disorders</i> . 2020;49(1):56-76.	7

연번	서지정보	배제 사유
1116	Woollacott IOC, Nicholas JM, Heslegrave A, Heller C, Foiani MS, Dick KM, et al. Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup. <i>Alzheimer's Research and Therapy</i> . 2018;10 (1) (no pagination)(79).	7
1117	Wu G, Miller RA, Connolly B, Marcus J, Renger J, Savage MJ. Pyroglutamate-modified amyloid-beta protein demonstrates similar properties in an Alzheimer's disease familial mutant knock-in mouse and Alzheimer's disease brain. <i>Neurodegenerative Diseases</i> . 2014;14(2):53-66.	7
1118	Wu G, Sankaranarayanan S, Hsieh SH, Simon AJ, Savage MJ. Decrease in brain soluble amyloid precursor protein beta (sAPPbeta) in Alzheimer's disease cortex. <i>Journal of Neuroscience Research</i> . 2011;89(6):822-32.	7
1119	Wu G, Sankaranarayanan S, Wong J, Tugusheva K, Michener MS, Shi X, et al. Characterization of plasma beta-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease. <i>Journal of Neuroscience Research</i> . 2012;90(12):2247-58.	7
1120	Wu KY, Hsiao IT, Chen CH, Liu CY, Hsu JL, Huang SY, et al. Plasma Aβ analysis using magnetically-labeled immunoassays and PET ¹⁸ F-florbetapir binding in non-demented patients with major depressive disorder. <i>Scientific Reports</i> . 2018;8(1):2739.	5
1121	Wu Z, Zhang M, Zhang Z, Dong W, Wang Q, Ren J. Ratio of beta-amyloid protein (Abeta) and tau predicts the postoperative cognitive dysfunction on patients undergoing total hip/knee replacement surgery. <i>Experimental and Therapeutic Medicine</i> . 2018;15(1):878-84.	5
1122	Xia N, Liu L, Harrington MG, Wang J, Zhou F. Regenerable and simultaneous surface plasmon resonance detection of abeta(1-40) and abeta(1-42) peptides in cerebrospinal fluids with signal amplification by streptavidin conjugated to an N-terminus-specific antibody. <i>Analytical Chemistry</i> . 2010;82(24):10151-7.	7
1123	Xie J, Gabelle A, Dorey A, Garnier-Crussard A, Perret-Liaudet A, Delphin-Combe F, et al. Initial memory deficit profiles in patients with a cerebrospinal fluid Alzheimer's disease signature. <i>Journal of Alzheimer's Disease</i> . 2014;41(4):1109-16.	7
1124	Xie Z, McAuliffe S, Swain CA, Ward SA, Crosby CA, Zheng H, et al. Cerebrospinal fluid abeta to tau ratio and postoperative cognitive change. <i>Annals of Surgery</i> . 2013;258(2):364-9.	7
1125	Xie Z, Swain CA, Ward SAP, Zheng H, Dong Y, Sunder N, et al. Preoperative cerebrospinal fluid beta-Amyloid/Tau ratio and postoperative delirium. <i>Annals of Clinical and Translational Neurology</i> . 2014;1(5):319-28.	7
1126	Yaka E, Egrilmez MY, Keskinoglu P, Cavdar Z, Genc S, Genc K, et al. Biological markers in cerebrospinal fluid (CSF) and evaluation of in vitro effect of CSF on PC12 cell line viability in Alzheimer's disease. <i>Cell Biochemistry & Function</i> . 2009;27(6):395-401.	7
1127	Yaka E, Yuksel Egrilmez M, Keskinoglu P, Cavdar Z, Genc S, Genc K, et al. Biochemical markers in cerebrospinal fluid (CSF) and evaluation of the effect of CSF on PC12 cell line viability in Alzheimer's disease. [Turkish]. <i>Turk Geriatri Dergisi</i> . 2006;9(1):1-7.	3
1128	Yamauchi K, Tozuka M, Nakabayashi T, Sugano M, Hidaka H, Kondo Y, et al. Higher avidity binding of apolipoprotein (E-AII) complex than of apolipoprotein E monomer to beta-amyloid. <i>Journal of Neuroscience Research</i> . 1999;58(2):301-7.	7
1129	Yan, S.D., D. Stern, M.D. Kane, Y.M. Kuo, H.C. Lampert, and A.E. Roher. RAGE- α beta interactions in the pathophysiology of Alzheimer's disease. <i>Restorative Neurology and Neuroscience</i> , 1998. 12(2-3): p. 167-173.	7
1130	Yanagisawa K, Ihara Y, Miyatake T. Secretory pathway of beta/A4 amyloid protein precursor in familial Alzheimer's disease with Val717 to Ile mutation. <i>Neuroscience Letters</i> . 1992;144(1-2):43-5.	7
1131	Yang T, Dang Y, Ostaszewski B, Mengel D, Steffen V, Rabe C, et al. Target engagement in an alzheimer trial: Crenezumab lowers amyloid beta oligomers in cerebrospinal fluid. <i>Annals of Neurology</i> . 2019;86(2):215-24.	7
1132	Yang T, Hong S, O'Malley T, Sperling RA, Walsh DM, Selkoe DJ. New ELISAs with high specificity for soluble oligomers of amyloid beta-protein detect natural Abeta oligomers in human brain but not CSF. <i>Alzheimer's & Dementia</i> . 2013;9(2):99-112.	7
1133	Yang T, O'Malley TT, Kanmert D, Jerecic J, Zieske LR, Zetterberg H, et al. A highly sensitive novel immunoassay specifically detects low levels of soluble Abeta oligomers in human cerebrospinal fluid. <i>Alzheimer's Research and Therapy</i> . 2015;7 (1) (no pagination)(7).	7

연번	서지정보	배제 사유
1134	Yano K, Hirayama S, Misawa N, Furuta A, Ueno T, Motoi Y, et al. Soluble LR11 competes with amyloid beta in binding to cerebrospinal fluid-high-density lipoprotein. <i>Clinica Chimica Acta</i> . 2019;489:29-34.	7
1135	Yasuda M. Low cerebrospinal fluid concentrations of peptide histidine valine and somatostatin-28 in Alzheimer's disease: Altered processing of prepro-vasoactive intestinal peptide and prepro-somatostatin. <i>Neuropeptides</i> . 1995;29(6):325-30.	7
1136	Ye LQ, Li XY, Zhang YB, Cheng HR, Ma Y, Chen DF, et al. The discriminative capacity of CSF beta-amyloid 42 and Tau in neurodegenerative diseases in the Chinese population. <i>Journal of the Neurological Sciences</i> . 2020;412 (no pagination)(116756).	7
1137	Yi YX, Jian ZJ. [Cerebrospinal fluid levels of beta-amyloid protein 1-42 in Alzheimer disease]. <i>Bulletin of Hunan Medical University</i> . 2002;27(2):171-2.	3
1138	Yin C, Ackermann S, Ma Z, Mohanta SK, Zhang C, Li Y, et al. ApoE attenuates unresolvable inflammation by complex formation with activated C1q. <i>Nature Medicine</i> . 2019;25(3):496-506.	6
1139	Yu QS, Reale M, Kamal MA, Holloway HW, Luo W, Sambamurti K, et al. Synthesis of the alzheimer drug posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, α -synuclein synthesis, interleukin-1 β release, and cholinergic action. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> . 2013;12(2):117-28.	7
1140	Yu Y, Sun X, Tang D, Li C, Zhang L, Nie D, et al. Gelsolin bound β -amyloid peptides(1-40/1-42): electrochemical evaluation of levels of soluble peptide associated with Alzheimer's disease. <i>Biosensors and Bioelectronics</i> . 2015;68:115-21.	1
1141	Yuan Q, Liu X, Xian YF, Tang Y, Zou J, Zhang X, et al. Origins of Beta Amyloid Differ Between Vascular Amyloid Deposition and Parenchymal Amyloid Plaques in the Spinal Cord of a Mouse Model of Alzheimer's Disease. <i>Molecular Neurobiology</i> . 2020;57(1):278-89.	1
1142	Yue F, Lu C, Ai Y, Chan P, Zhang Z. Age-associated changes of cerebrospinal fluid amyloid-beta and tau in cynomolgus monkeys. <i>Neurobiology of Aging</i> . 2014;35(7):1656-9.	7
1143	Yun SM, Cho SJ, Jo C, Park MH, Han C, Koh YH. Elevation of plasma soluble amyloid precursor protein beta in Alzheimer's disease. <i>Archives of Gerontology & Geriatrics</i> . 2020;87:103995.	6
1144	Zabeo M, De Rino F, Rispoli F, Somalvico F, Longhi E, Franceschi M. Tau, p-Tau and beta amyloid 1-42 concentrations in Alzheimer and frontotemporal dementia patients. [Italian]. <i>Rivista Italiana della Medicina di Laboratorio</i> . 2008;4(4):259-63.	3
1145	Zecca C, Brescia V, Piccininni M, Capozzo R, Barone R, Barulli MR, et al. Comparative evaluation of two immunoassays for cerebrospinal fluid beta-Amyloid ₁₋₄₂ measurement. <i>Clinica Chimica Acta</i> . 2019;493:107-11.	7
1146	Zenzmaier C, Marksteiner J, Kiefer A, Berger P, Humpel C. Dkk-3 is elevated in CSF and plasma of Alzheimer's disease patients. <i>Journal of Neurochemistry</i> . 2009;110(2):653-61.	7
1147	Zetterberg H, Andreasen N, Blennow K. Increased cerebrospinal fluid levels of transforming growth factor-beta1 in Alzheimer's disease. <i>Neuroscience Letters</i> . 2004;367(2):194-6.	7
1148	Zetterberg H, Blennow K. Blood Biomarkers: Democratizing Alzheimer's Diagnostics. <i>Neuron</i> . 2020;106(6):881-3.	2
1149	Zetterberg H, Blennow K. Plasma A β in Alzheimer's disease-up or down? <i>Lancet Neurology</i> . 2006;5(8):638-9.	2
1150	Zetterberg H. Is There a Value of Neurofilament Light as a Biomarker for Neurodegeneration in Parkinson's Disease? <i>Movement Disorders</i> . 2020;35(7):1111-2.	2
1151	Zhang N, Zhang L, Li Y, Gordon ML, Cai L, Wang Y, et al. Urine AD7c-NTP predicts amyloid deposition and symptom of agitation in patients with Alzheimer's disease and mild cognitive impairment. <i>Journal of Alzheimer's Disease</i> . 2017;60(1):87-95.	7
1152	Zhang S, Zhao J, Zhang Y, Cai F, Wang L, Song W. Upregulation of MIF as a defense mechanism and a biomarker of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> . 2019;11 (1) (no pagination)(54).	1

연번	서지정보	배제 사유
1153	Zhang WJ, Antonios G, Rabano A, Bayer TA, Schneider A, Rizzoli SO. Super-Resolution Microscopy of Cerebrospinal Fluid Biomarkers as a Tool for Alzheimer's Disease Diagnostics. <i>Journal of Alzheimer's Disease</i> . 2015;46(4):1007-20.	7
1154	Zhong J, Guo C, Hou W, Shen N, Miao C. Effects of MFHAS1 on cognitive impairment and dendritic pathology in the hippocampus of septic rats. <i>Life Sciences</i> . 2019;235 (no pagination)(116822).	1
1155	Zhong L, Xu Y, Zhuo R, Wang T, Wang K, Huang R, et al. Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer's disease model. <i>Nature Communications</i> . 2019;10 (1) (no pagination)(1365).	1
1156	Zhong Z, Ewers M, Teipel S, Burger K, Wallin A, Blennow K, et al. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. <i>Archives of General Psychiatry</i> . 2007;64(6):718-26.	7
1157	Zhou M, Duong DM, Johnson ECB, Dai J, Lah JJ, Levey AI, et al. Mass Spectrometry-Based Quantification of Tau in Human Cerebrospinal Fluid Using a Complementary Tryptic Peptide Standard. <i>Journal of Proteome Research</i> . 2019;18(6):2422-32.	6
1158	Zhou M, Haque RU, Dammer EB, Duong DM, Ping L, Johnson ECB, et al. Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer's disease. <i>Clinical Proteomics</i> . 2020;17 (1) (no pagination)(19).	6
1159	Zhou Y, Zhang H, Liu L, Li C, Chang Z, Zhu X, et al. Fabrication of an antibody-aptamer sandwich assay for electrochemical evaluation of levels of beta-amyloid oligomers. <i>Scientific Reports</i> . 2016;6:35186.	7
1160	Zhou Y, Zhao Y, Xie H, Wang Y, Liu L, Yan X. Alteration in amyloid beta42, phosphorylated tau protein, interleukin 6, and acetylcholine during diabetes-accelerated memory dysfunction in diabetic rats: Correlation of amyloid beta42 with changes in glucose metabolism. <i>Behavioral and Brain Functions</i> . 2015;11 (1) (no pagination)(24).	1
1161	Zhu S, He J, Zhang R, Kong L, Tempier A, Kong J, et al. Therapeutic effects of quetiapine on memory deficit and brain beta-amyloid plaque pathology in a transgenic mouse model of Alzheimer's disease. <i>Current Alzheimer Research</i> . 2013;10(3):270-8.	1
1162	Zhu X, Xu F, Hoos MD, Lee H, Benveniste H, Van Nostrand WE. Reduced levels of cerebrospinal fluid/plasma abeta40 as an early biomarker for cerebral amyloid angiopathy in RTg-DI rats. <i>International Journal of Molecular Sciences</i> . 2020;21 (1) (no pagination)(303).	1
1163	Zimetti F, Caffarra P, Ronda N, Favari E, Adorni MP, Zanotti I, et al. Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> . 2017;55(1):315-20.	7
1164	Zlokovic BV, Martel CL, Matsubara E, McComb JG, Zheng G, McCluskey RT, et al. Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> . 1996;93(9):4229-34.	7
1165	Zou J, Yao Z, Zhang G, Wang H, Xu J, Yew DT, et al. Vaccination of Alzheimer's model mice with adenovirus vector containing quadrivalent foldable Abeta(1-15) reduces Abeta burden and behavioral impairment without Abeta-specific T cell response. <i>Journal of the Neurological Sciences</i> . 2008;272(1-2):87-98.	7
1166	Zou K, Liu J, Watanabe A, Hiraga S, Liu S, Tanabe C, et al. Aβ ₄₃ is the earliest-depositing Abeta species in APP transgenic mouse brain and is converted to Aβ ₄₁ by two active domains of ACE. <i>American Journal of Pathology</i> . 2013;182(6):2322-31.	1
1167	Zurbig P, Jahn H. Use of proteomic methods in the analysis of human body fluids in Alzheimer research. <i>Electrophoresis</i> . 2012;33(24):3617-30.	2